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Abstract 
Homeostasis in humans is maintained via an integrated regulation of gene expression, for which the first and 
crucial step is the control of their transcription rate. Ligand-activated nuclear receptors (NRs) are key 
transcription factors (TFs) that translate both nutritional and hormonal signals into changes in gene expression. 
Structurally, these TFs have a ligand-binding domain (LBD), the structural features of which affect the 
transactivation events that lead to change in target gene expression. The link to DNA is formed via the DNA-
binding domain (DBD) that recognizes specific DNA-binding elements, called response elements (REs). 
Prediction of NR target genes relies on the identification of putative NR REs in the regulatory regions of genes. 
The main objective of the present study was to implement bioinformatics in silico methods into the 
characterization of structural features that underlie the functional differences seen in the NRs peroxisome 
proliferator-activated receptors (PPARs) α, β/δ, γ and the vitamin D receptor (VDR) and the identification of 
target genes of these receptors. The results emphasize the role of the most C-terminal helix of the LBD in the 
differences in co-activator (CoA) association and following transactivation. The stable fixing of this helix is 
possible in PPARs, as determined by their structural features, and enables ligand-independent CoA association. 
In contrast, VDR depends on its ligand to change to an active conformation. On the level of target genes, the 
family of insulin-like growth factor binding protein (IGFBP) genes was studied in detail in terms of 
responsiveness to PPARs and VDR. A meta-analysis of PPAR target genes addressed target gene features more 
broadly, including a detailed analysis of eight established PPAR targets. The binding site composition of the 
target genes of both receptors displayed an abundance of high affinity sites and a general trend towards 
enrichment of such sites in the regulatory areas. It was also evident that these NRs can function distally several 
thousands of base pairs from the transcription start site (TSS), both up- and downstream. Conservation trends 
assessed based on 38 known direct human PPAR targets provided insights into the turnover of binding sites and 
development of de novo binding sites that suggest that binding site composition is flexible. The detection of 
novel target genes was evaluated on human chromosome (chr) 19 genes and their mouse orthologs. In total six 
representatives from this panel were all shown to respond to PPAR ligands. 
In conclusion, the studies presented in this doctoral thesis increased our understanding of the structure-function 
relationship of NR transactivation and typical features of binding site composition of target genes. 
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1α,25(OH)2D3 1α,25-dihydroxyvitamin D3 
Acyl-CoA acetyl-Coenzyme A 
ACOX1 acyl-CoA oxidase 1 
ADRP adipocyte differentiation related protein 
AF-1 activation function 1 
AF-2 activation function 2 
ANF atrial natriuretic factor  
ANGPLT4 angiopoietin-like 4 
APO apolipoprotein 
AR androgen receptor 
ARPO acidic riboprotein 0 
CAR constitutive androstane receptor  
CBP creb binding protein 
CD36 CD36 antigen 
CITCO 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-  
 carbaldehyde-O-3,4-dichlorobenzyl) oxime  
ChIP  chromatin immunoprecipitation 
Chr  chromosome 
CoA co-activator  
CoR co-repressor  
COUP-TF  chicken ovalbumin upstream promoter transcription factor 
COX  cyclooxygenase 
CPT carnitine palmitoyl transferase  
CYP  cytochrome P450  
DAX DSS-AHC critical region on the X chromosome 1, gene 1 
DBD DNA-binding domain  
DMSO dimethylsulfoxide 
 
 DOTAP N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium 
 methylsulphate 
DR direct repeat  
ENCODE Encyclopedia of DNA Elements 
ER everted repeat 
ERα, ERβ estrogen receptor α, β  
ERR estrogen-related receptor 
FADS fatty acid desaturase 
FBS fetal bovine serum 
FXR farnesoid X receptor 
G0S2 G0/G1 switch gene 
GCNF germ cell nuclear factor 
GK glycerol kinase 
GO gene ontology 
GST  glutathione S-transferase  
GR glucocorticoid receptor 
GW501516  2-methyl-4-((4-methyl-2-(4-trifluoromethylphenyl) 
  1,3thiazol-5-yl)-methylsulfanyl)phenoxy-acetic acid 
GW7647  2-(4-(2-(1-cyclohexanebutylcyclohexylureido)ethyl) 
  phenylthio)-2-methylpropionicacid 
HAT   histone acetyl transferase 
HDAC   histone deacetylase 
HDL   high density lipoprotein 
HepG2   human hepatoma derived cell line 
HEK293   human embryonic kidney epithelial cell line 
HNF4 hepatocyte nuclear factor-4 
IGF insulin-like growth factor 
IGFBP insulin-like growth factor binding protein 
 
 IL interleukin 
Insig insulin signaling 
IR inverted repeat 
LASS1 longevity assurance homolog 1 
L783483  [3-chloro-4-[3-[7-propyl-3-(trifluoromethylenzo[d]isoxazol-6-  
 yloxy]propylsulfonyl]phenyl]-acetic acid  
LBD  ligand-binding domain  
LBP ligand-binding pocket  
LDL low density lipoprotein 
LIPE hormone sensitive lipase 
LPL lipoprotein lipase 
LRH-1  liver receptor homolog 1 
LRP lipoprotein receptor-related protein 
LXR liver X receptor 
MCF-7 human breast adenocarcinoma cell line 
MR mineralocorticoid receptor 
NCoR  NR co-repressor 
NGFIB nerve growth factor inducible 
NF-1  nuclear factor-1 
NOR1 neuron-derived orphan receptor 1 
NR nuclear receptor 
NURR1 nuclear receptor-related 1 
p300 E1A-binding protein 
PAK p-21 activated kinase 
PC-3 human prostate adenocarcinoma cell line 
PDB Protein Data Bank 
PEI polyethylenimine  
PEPCK phosphoenolpyruvate carboxykinase 
 
 PG prostaglandin 
PGC-1α peroxisome proliferators-activated receptor γ coactivator 1α 
PIC preinitiation complex 
PNR photoreceptor-specific nuclear receptor 
PPAR  peroxisome proliferator-activated receptor  
p-PolII phosphorylated RNA polymerase II 
PPRE PPAR response element 
PR progesterone receptor 
PXR pregnane X receptor 
RAC3  receptor-associated coactivator 3 
RAR retinoic acid receptor 
Rb retinoblastoma protein 
RE  response element  
ROR retinoid orphan receptor  
Rosiglitazone  5-[4-[(N-methyl-N-(2pyridyl)amino)ethoxy]benzyl] 
 thiazolidine-2,4-dione  
RXR  retinoid X receptor  
RVR rev-ERBA 
SaOS-2 human bone osteosarcoma cell line 
SF-1 steroidogenic factor 1 
SHP small heterodimer partner 
SLC solute carrier family 
SOM self-organizing map 
SR-B1 scavenger receptor B1 
SRC-1  steroid receptor coactivator 1  
SSAT spermidine/spermine N1-acetyltransferase 
SULT  sulfotransferase 
TF transcription factor 
 
 TGF tumor growth factor 
Th T helper cell 
TIF2  transcription intermediary factor 2 
TIMM translocase of inner mitochondrial membrane 
TLX tailless homolog (Drosophila) 
TNFα tumor necrosis factor α 
TSS  transcription start site 
TR thyroid hormone receptor 
TR2 nuclear hormone receptor TR2 
TR4 nuclear hormone receptor TR4 
UCP uncoupling protein 
UGT UDP-glycosyltransferase 
VDR  1α,25(OH)2D3 receptor 
VDRE  1α,25(OH)2D3 response element  
WM weight matrix 
WY14643   [4-chloro-6-(2,3-dimethylphenylamino)pyrimidin- 
  2- ylsulfanyl] acetic acid
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1. Introduction 
Biological systems show tremendous complexity at the level of structural organization and capacity 
to modulate their behavior in response to environmental changes. To achieve this, molecules with 
specific properties have evolved to store and transmit information, as well as carry out specialized 
functions (reactions, modifications, interactions). These molecules put together, determine what 
processes the system, such as a cell, a tissue, or an organ can carry out. At the same time, the lack of 
individual molecules or the change in concentrations of molecules in relation to each other can 
fundamentally alter the functioning of the system. Therefore, homeostasis is an important requisite 
for stable biological systems. 
This stability requirement extends also to information storage and retrieval. In living systems 
information is stored in units called genes, that together can be used for the synthesis of about one 
order of magnitude more of the functional molecules of cells, the proteins they encode. As an 
example, humans have over 20,000 genes. Physically, genes exist as nucleic acids, most often as 
DNA molecules, and the information can be accessed via a process called transcription. Complexity 
has also evolved at the transcriptional level. The proteins responsible for the regulation and accessing 
of genetic information have also evolved to function together, in regulatory modules, or multi-protein 
complexes that possess many different activities. Their combined function is needed in response to 
environmental challenges. Therefore, homeostasis in humans involves and is maintained, via an 
integrated transcriptional control of multiple genes. 
Recent research has brought vast advances in the characterization of whole sets of genes and proteins 
in different organisms. Luckily, in parallel advanced computational methods have been developed to 
access and analyze this data. Bioinformatics is a field of research that has developed the tools for 
comparing large molecular datasets, both DNA and protein, databases for storage of this data in a 
meaningful way and adapted statistical methods to analyze complex datasets and their biological 
relationships. The research in this field is tightly linked with the biological application of the 
methods, aiming to improve the computational models to suit the specific biological questions. 
The functional properties of proteins are connected to their structural elements. The discovery of 
these relationships is the aim of structural informatics, where computational methods for visualization 
of structures and modeling of interactions can lead to the discovery of molecular mechanisms 
underlying their functionality. The challenge lies in the dynamics of the structures. For example, 
binding of a molecule, such as an activating ligand, to a family of TFs, called NRs, induces 
conformational changes in the whole molecule leading to altered interaction surfaces. At the level of 
DNA, higher organisms show a tendency of increased proportion of non-coding DNA. This region 
contains many of the regulatory elements that guide the first phase of accessing the gene information, 
transcription. These switches often correspond to binding sites of TFs. Subsequently a major sub-
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discipline of bioinformatics research has focused on the development of methods that can faithfully 
identify these sites. However, locating the functional regulatory elements has proven challenging in 
mammalian genomes, owing to the large search space of gigabytes of potential binding sequence 
compared to binding site lengths of 5 to15 bp. This means that in any given genome a large number 
of fits to the binding site sequence will occur. Since the number of TFs is limited in any cell, this 
leads to the situation that not all sites are used. Therefore one challenge has been to determine, which 
sites are functionally used in the set determined by the whole genome. 
Ligand-activated NRs are key TFs that translate both nutritional and hormonal signals into changes in 
gene expression. Understanding the processes that they regulate as well as how they act is important 
for building a general understanding of how our body responds to nutrition, stress and thyroid and 
steroid hormones. Specific understanding will help to address possible treatment and prevention of 
disease states that origin from disturbance of this homeostatic control. As an example, the nutritional 
challenges today are very different from those in earlier times when food was scarce. It is important 
to acknowledge that our daily lifestyle affects the homeostatic control and may over time lead to the 
development of diseases, such as heart disease and type II diabetes. 
This thesis aims to extend the research on NR regulomes, the characterization of the set of regulated 
genes and the functional properties affecting the regulatory process, with the application of 
bioinformatics methods, such as in silico binding site screening and structural analysis. 
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2. Review of Literature 
 
2.1 Regulation of gene expression 
Genes are DNA sequences that contain the information needed to make the functional units of the 
cell, its proteins, and comprise the information, the hereditary units, passed on every generation. 
Since the description of the DNA double helix by Watson and Crick in the early 1950s (Watson and 
Crick, 1953), the whole complexity of genomic events, the ways how our cells access and use this 
information, has started to become revealed. This flow of information is depicted in Fig. 1. We now 
acknowledge that DNA does not exist as a separate molecule in the cell. Instead it is wrapped around 
a protein core forming chromatin and also interacts with regulatory proteins.  
 
genome
chromosomes
genes
Genes contain 
instructions to 
make proteins
DNA
proteins
Proteins act alone 
or in complexes 
to perform many 
cellular functions
cell
 
Fig. 1. Information flow in the cell. The genetic information is stored in the nucleus of each cell in the form of 
chromosomes. The chromosomes are long DNA molecules that contain genes, the instructions to make the functional 
molecules of cells, their proteins. The DNA sequence determines the amino acid sequence of proteins that finally fold to 
their final 3D-shape. The structural elements of proteins enable them to act alone or in complexes to perform many 
cellular functions (adapted from U.S. Department of Energy Human Genome Program, http://www.ornl.gov/hgmls). 
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Each cell type is defined by the proteins it produces. This means that each cell has a way to decide 
and determine, which genes get transcribed from DNA to RNA, and subsequently translated from 
RNA to protein. In a changing environment, however, it is necessary that the whole set of 
transcriptional events, starting from the level of which genes should be used, is dynamic. Moreover, 
cellular responses to environmental stimuli need to be coordinated and accurate. In effect, changes in 
the proteins produced are needed, which is achieved at the level of gene transcriptional regulation. 
2.1.1 Development of the field of bioinformatics parallels the steps towards understanding the 
regulation of gene expression on a whole genome level 
Information about DNA and protein sequences and structure started to build up in the 1950s. 
Databanks were established for the collection of structure and sequence data and in 1977 the first 
complete sequence of an organism, the bacteriophage φ X174, was published (Sanger et al., 1977). 
With the arrival of the sequencing technique, more sequences rapidly accumulated from related 
organisms. This soon created a need for both storage and sequence comparison methods, which 
inspired the development of a new field, bioinformatics. The first algorithm for sequence comparison, 
the Needleman-Wunsch algorithm, had already been published in 1970 (Needleman and Wunsch, 
1970), but it took more than ten years before more algorithms started to be published: Smith and 
Waterman published their algorithm for sequence comparison in 1981(Smith and Waterman, 1981) 
and the FASTA algorithm was published in 1985 (Lipman and Pearson, 1985). Large central database 
organizations were also created at that time. The European Molecular Biology Laboratory (EMBL) is 
housing since 1981 the EMBL Data Library. In 1988 the National Center for Biotechnology 
Information (NCBI) was created in USA, which is responsible for similar sequence data repositories, 
such as Genbank. The third large DNA database was started in 1986 in Japan, called DDBJ. Today 
there is large variety of databases containing nucleic acid sequence data organized around specific 
qualities. These include the NCBI-housed refereed sequence database Refseq, the repbase repository 
for repetitive sequences and other types of databases concerning gene-disease associations, such as 
OMIM. More importantly, the end of 1980s also witnessed the commencement of the Human 
Genome Initiative. The human genome sequencing project was formally started in 1990, coinciding 
with the development of perhaps the most popular sequence comparison algorithm used today, 
BLAST (Altschul et al., 1990). During the 1990s several lower organism genomes were published, 
including bacterial E. coli and the nematode C. elegans genomes (Blattner et al., 1997; Waterston and 
Sulston, 1995). The decade of genome sequencing culminated in the publishing of the draft sequences 
of the human genome in 2001 by the public sequencing consortium and the private company Celera 
(McPherson et al., 2001; Venter et al., 2001). 
The sequencing alone was a huge accomplishment, but with the sequence data at hand, new 
challenges emerged with bioinformatics playing a profound part to support both data storage and 
analysis. As a discipline that builds upon biosciences, mathematics, information science and statistics, 
the impact of bioinformatics is best seen as the application of these fields in ways that provide 
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insights into the vast, diverse and complex biological data making it more understandable and in 
trying to discern unifying principles. As an example, a vast number of unknown genes and proteins 
had been mapped from the genome. Deciphering their functional roles was something that algorithms 
for detecting sequence similarities or identifying functional domains of proteins, could help with 
(Birney et al., 2001). Database structures allowing functional classifications at various levels (such as 
Gene Ontology (GO) database) were created to unify data under common models to help understand 
the complex biological pathways and processes (an overview of the different databases currently 
existing is given in (Galperin, 2007)). Simultaneously, high-throughput molecular biology methods, 
such as microarrays, developed for the measurement of entire set of transcripts from cells (Ramsay, 
1998), motivated the development of advanced data-analytical methods (Gollub and Sherlock, 2006).  
Together, the availability of sequence data and genome wide transcriptional analysis have made it 
possible to move from describing the genomic molecular parts list into the analysis of its dynamics 
and regulation. After the completion of the human genome sequence, the next large genomics task 
was launched in 2003 by the National Human Genome Research Institute (USA). The Encyclopedia 
Of DNA Elements (ENCODE) project was started to discover the remaining functional sequence 
elements of the human genome (in addition to gene sequences) through a collaborative effort of 
computational and laboratory-based scientists (ENCODE Project Consortium, 2004). 
2.1.2 Human genome in comparison to genomes of other species 
The human genome, the final version published in 2003 (International Human Genome Sequencing 
Consortium, 2004), consists of approximately three billion base pairs (3.08 Gb) of DNA, out of 
which only 1.2% is coding for proteins (Table 1). A large fraction of the genome consist of repetitive 
sequences, interspersed elements already occupy 45% of the genome and may have a less significant 
functional role. The remaining sequence is used for regulation of gene expression and genome 
organization. In total, humans have approximately 20,000 to 25,000 genes (latest release of the 
European database Ensembl contains 22,205 genes). These can be classified according to their role to 
different biological processes. This labeling of genes by functional classification is the function of the 
GO database. The largest category of known genes consists of genes encoding proteins that regulate 
and maintain the DNA information, TFs and other DNA-binding proteins (Table 2). This is followed 
by the category signal transduction. This data emphasizes the importance placed in understanding the 
communication between environmental signals and gene transcription. Surprisingly, still three years 
after the completion of the human genome sequence, a full consensus around the complete set of 
coding genes does not exist. Only very few of the human genes are thought to be missing from the 
computational predictions, but the exact genomic structure is estimated to be correct for only 50% of 
the predicted genes, due to the large number of alternative splicing sites in the human genes (Guigo et 
al., 2006). 
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Table 1. Overview of the human genome 
Size of the genome (Gb) 3.08 
Haploid chromosome number 23 
Fraction of coding sequence (%) 1.2 
Number of genes 20,000-25,000 
Average gene size (kB) 27 
Most gene rich chromosome (genes/MB) Chr 19 (23) 
Least gene rich chromosome Chr 13, Chr Y (5) 
     Table 2. GO-categories involved in gene regulation and signaling in humans 
GO-category % of genes 
Nucleic acid binding (total) 13.5 
Transcription factor 6.0 
Nucleic acid enzyme 7.5 
Signal transduction (total) 12.2 
Signaling molecule 1.2 
Receptor 5.0 
Kinase 2.8 
Regulatory molecule 3.2 
 
The best-characterized eukaryotic genome to date still is the yeast genome (Goffeau et al., 1996). 
Compared to this simple eukaryote (genome size 12 MB), the genome in humans has expanded 
profoundly (3 GB). Additionally, the complexity of its regulation and maintenance has increased as 
well. Yeast has in average one regulatory protein per 20 genes, while humans have one for every ten 
genes (Levine and Tjian, 2003). To date, the regulation of gene expression in yeast has been 
successfully characterized in a relatively detailed manner with respect to participating molecules and 
regulatory sequences.  It has also been possible to create lists of target genes for each regulatory 
molecule, termed regulomes. In comparison, only the initial steps towards the human regulome have 
been made. The ENCODE project has started to map the regulatory DNA of selected chromosomal 
locations of the human genome down to a base pair resolution. The pilot phase is focused on a 
selected 30 MB fragment of the genome, representing approximately 1% of the whole sequence. This 
is already almost three times larger than the whole yeast genome. 
Soon after the human genome was finished, the mouse and rat draft genomes became available 
(Gibbs et al., 2004; Waterston et al., 2002), followed by a number of different species including our 
closest relatives (measured by sequence similarity) in the family of great apes (Chimpanzee 
Sequencing and Analyzing Consortium, 2005). The bioinformatics analysis utilizing these other 
mammalian and vertebrate genomes, comparative genomics, has added extra dimensionality to the 
understanding of how mammalian genomes evolved as well as how the human genome differs in 
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form and function from the others (Table 3). On the level of genes and proteins humans are very 
similar to other mammals. Changes in the genomes happen via a spectrum of events, ranging from the 
very large down to the single base pair level (the smaller changes will be discussed later). The largest 
changes occurred mainly via rearrangements of chromosomes. This is evident from the comparisons 
of gene order in the different mammalian species: typically, large segments of chromosomes retain 
gene order. Due to these large rearrangements, however, it can be seen that regions of conserved gene 
order have ended up on different chromosomes in today’s mammalian genomes. These corresponding 
segments in the other genome are described as being syntenic. In general, these rearrangements are 
rare events in genomes, one every ten million years, with the exception of the genomes of rodents, 
dog, cow and some of the New World apes that show very high rates of rearrangements relative to 
other mammals (Murphy et al., 2001). 
 
Table 3. Characteristics of selected vertebrate genomes studied to date (adopted from (Murphy et 
al., 2001)) 
 
Species  Common name  Haploid chr number Genome size (GB) 
Primates     
Pan troglodytes Chimpanzee 24 3.1 
Gorilla gorilla Gorilla  24 NA 
Pongo pygmaeus Orangutan  24 NA 
Cercopithecus 
aethiops 
African green monkey  30 NA 
Cebus capucinus Capuchin monkey  27 NA 
Papio hamadryas Baboon 21 NA 
Macaca mulata Rhesus monkey 21 3.1 
Lagomorpha     
Oryctolagus cuniculus Rabbit 22 3.5 
Rodentia     
Mus musculus  Mouse 20 2.5 
Rattus norvegicus Rat 21 2.8 
Carnivora     
Canis familiaris Dog  38 2.4 
Felis catus Cat  19 3.0 
Cetartiodactyla     
Bos Taurus Cow  30 3.0 
Sus scrofa Pig  19 2.8 
Galliformes     
Gallus gallus  Chicken 37 
 
1.3 
Atheriniformes     
Danio rerio Zebrafish 25 1.7 
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Comparisons of the human and the chimpanzee genome have allowed the assessment of key 
differences between humans and their closest relatives. The genome-wide divergence of human and 
chimpanzee is 1.06%, so for the most part the comparisons between these species revealed 
similarities. Compared to other mammalian genomes, together the hominid genomes show a rapid 
evolution in a subset of genes involved in immunity, such as those responsible in antimicrobial 
activity, olfactory genes and genes functioning in reproduction. In contrast, processes including 
intracellular signaling, metabolism and especially genes expressed in the brain show low rates of 
evolution. However, compared to mice, accelerated evolution in hominids involves also genes with 
brain-related functions. Interestingly, the comparative analysis of human and chimpanzee also 
revealed instances, where the human disease-causing allele is the wild type allele in chimpanzee. For 
example, proline is the wild type amino acid in position 12 of the NR PPARγ, in humans this 
variation has been linked with increased risk of type II diabetes (Chimpanzee Sequencing and 
Analyzing Consortium, 2005). 
The mouse genome, which diverged from the human genome 75 million years ago, is most often used 
in sequence comparison to detect functional conservation, especially conservation of regulatory 
sequence elements. Relatively large proportion of genes can be matched between these species: 
approximately 80% of mouse genes have an ortholog, a gene encoding a protein with similar 
structure and function, in the human genome (Bulyk, 2003). The main motivation of utilizing the 
mouse genome for sequence comparisons instead of closest relatives to humans, such as the 
chimpanzee genome, is the sufficient evolutionary distance, in other words the sequence had enough 
evolutionary time for random mutations to separate well-conserved functional regions outside coding 
area. More recently, comparisons between related species has been suggested as an alternative 
approach to study lineage-specific conservation. This phylogenetic footprinting or shadowing aims to 
identify essential elements by identifying differences in closely related species. A collection of 
related species, such as several primate genomes, are compared together, which enables localization 
of collective variable regions and conserved regions. The utility of this approach was studied by 
Boffelli and colleagues with the example of intron-exon boundaries of several genes and to detect the 
regulatory regions of a human-specific gene, apolipoprotein (a) (Boffelli et al., 2003).  
It is interesting to try and relate the sequence differences to the phenotypic differences observed 
between species. However, the comparative analysis has shown that no direct relationships exist 
between sequence diversity and phenotypic diversity. Humans differ phenotypically much more from 
chimpanzee than two closely related mouse species, however, dogs show very little sequence 
divergence but have highly different phenotypes. It is possible that a number of small changes 
correspond the variation observed. Never the less, it is also intriguing to suggest that part of the 
differences in the end come from transcriptional regulation. 
2.1.3 DNA architecture 
DNA exists in the cells wrapped around a core of histone proteins (a core octamer formed from two 
copies of histones H2A, H2B, 3 and 4 and histone H1 covering the linker bases) with approximately 
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200 bp intervals. In this form, DNA can be condensed to the very extreme form of metaphase 
chromosomes during cell division or exist in various intermediate states that by physical means can 
restrict or allow the accessibility to certain regions of the genome. Between cell divisions two main 
forms can be distinguished: accessible open chromatin, or euchromatin, and inaccessible densely 
packed heterochromatin. The functional properties of histones can be regulated to affect the local 
chromatin status. A common way to modify the function of proteins is via covalent modifications. 
This also applies to the histone core proteins of the nucleosome, for which several modifications have 
been described (Grant, 2001). The acetylation of both histones H3 and H4 are well-known labels of 
active chromatin, whereas methylation of histone H3 at the lysine residue at position 9 is one 
example of a modification that leads to inactivation and favors heterochromatin formation. Both 
acetylation and methylation act by either adding hydrophobicity to the histone tail or by smothering 
it’s positive charge thus alleviating the strong interaction between positive charge on lysines and the 
negatively charged DNA wrapped around it. Alleviating the interaction favors access of regulatory 
proteins and subsequent recruitment of other complexes that can, for example, shift nucleosome 
positions to permit further access to regulatory DNA elements. In contrast, the methylation of histone 
H3 lysine 9 creates a binding site for heterochromatin forming proteins leading to silencing of 
transcription.  
In total, human genetic information is spread over 23 pairs of linear DNA molecules (chromosomes) 
that vary in length from 47 to 247 MB, all contained in the nucleus of the cell. It has been proposed 
that the spatial location in the nucleus reflects also chromatin status, with inactive chromatin mainly 
occupying nuclear periphery (Swedlow and Lamond, 2001). In support of this hypothesis, the 
inactive X chromosome in females, also known as the Barr body, exists in heterochromatin form in 
the nuclear periphery. It is also known that the gene density varies greatly between chromosomes. A 
study comparing the gene-poor chr 18 and the gene-rich chr 19 showed that chr 18 was located near 
nuclear periphery, while after inhibition of transcription the preferential localization disappeared 
(Croft et al., 1999). The localization may be explained by recruitment of heterochromatin-specific 
proteins to inactive sites, which direct the localization pattern. 
There is evidence that chromatin is organized in loops that get attached to the nuclear matrix 
(approximately 100 kB in length) and these chromatin units are the functional domains, within which 
regulatory elements can come into contact with the genes in that domain by DNA looping. Simonis 
and colleagues (Simonis et al., 2006) demonstrated recently that active and inactive genes are 
connected via long-range interactions. Preferentially, active genes are interacting together, similarly 
inactive ones cluster to the same region. The locations of individual genes are also likely determined 
by the types of proteins binding to their regulatory sequences, the binding of TFs directing the genes 
to active regions. Furthermore, Spilianakis and co-workers showed evidence of an interchromosomal 
regulation, where even DNA elements existing on different chromosomes could regulate genes that 
were physically attached to the same nuclear region (Spilianakis et al., 2005).  
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2.2. Impact of bioinformatics on the understanding of the key 
elements of gene regulation: Regulatory proteins and DNA sequence 
elements 
The regulation of gene expression involves a large set of nuclear proteins that includes the chromatin 
modifying proteins, together with TFs, co-regulators and the basal transcriptional machinery (Levine 
and Tjian, 2003). A central role in the process, the way how environmental stimuli, or other signals 
from the cell are translated into changes in gene expression, is mediated by the activation and binding 
of DNA sequence selective TFs to the regulatory regions of a gene. This recognition event often leads 
to the recruitment of multi-protein complexes to these sites. Included with these macromolecular 
assemblies are co-regulator proteins that in turn recruit other multi-factor complexes that carry out 
tasks, such as chromatin re-modeling, or connecting the TF to the basal transcriptional machinery. 
The basal transcriptional machinery consists of several proteins that bind next to the TSS of genes 
and enable RNA polymerase II-mediated gene transcription to occur. In summary, regulation of gene 
expression involves a series of intermolecular interactions that starts from a specific DNA-protein 
contact at each TF binding site and extends to protein-protein interactions enabled by structural 
modifications. This finally leads to a change in the number of departures of the RNA polymerase 
from the TSS of a gene (i.e. the transcription rate). Importantly, this change is simultaneously taking 
place for the entire set of genes that can be recognized by the TF in a given tissue. 
The task to define the set of genes regulated by each TF, its regulome, involves the understanding and 
characterization of the following aspects of the process: Firstly, the initiating DNA-protein 
interaction involves a recognition of a specific DNA sequence, which can be defined for each TF. 
Secondly, the following intermolecular interactions encompass a large selection of regulatory 
proteins, where specificity and preferential interactions may dictate the overall dynamics of the 
process, affecting the time scale, during which a change in chromatin status and the assembly of 
transcriptional machinery are observed for a given TF. Finally, the overall result is the change in 
transcriptional rate of each target gene that will lead to a change in the respective mRNA levels. As a 
consequence, two bioinformatics challenges can be identified in the characterization of regulomes 1) 
understanding at the protein level the functional properties of participating molecules by modeling as 
well as visualizing intermolecular interactions and 2) identifying on a genomic scale the 
transcriptional targets by binding site detection algorithms and microarray methods. 
2.2.1 Bioinformatic challenges at the protein level 
Multiple databases have been created that collect protein sequences, perform classification and 
similarity searches with final documentation of the findings. In addition, protein crystal structures 
have been systematically stored into the Protein Data Bank (PDB). As more and more structures 
become available, structural comparisons and prediction of protein structures by modeling has 
inspired the development of dedicated software in the field of bioinformatics. This has resulted in 
advances in the understanding of the relationship between protein structures and their functional 
properties. The process of protein crystallization requires time and effort and is not readily adaptable 
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to the high-throughput scales of other techniques, such as microarrays. Subsequently, the prediction 
of functional properties by modeling the structure using structural neighbors can be an attractive 
alternative (Tramontano, 2006).  
Computer-aided visualization of the determined protein structures, or models, permits the 
identification of functional parts of the protein, such as different domains, catalytic parts, modifiable 
side chains and protein-protein interaction surfaces. Many proteins bind small molecules (such as 
substrates, ligands and prostetic groups). Examination of their binding mode is of special interest in 
pharmaceutical industry for the development of drug molecules that may serve as activators or 
inhibitors of these protein structures. It can be also of use in the understanding of the activation 
mechanisms perpetrated by TFs, in particular the subgroup of ligand-activated TFs, such as the NRs. 
Ligand-binding induces structural changes in these molecules that are evident from the examination 
of bound/unbound crystal structures. These changes translate to a modification of protein-protein 
interaction surfaces, which in turn explain transactivation mechanisms of different family members 
(Robinson-Rechavi et al., 2003). Activation by ligand is only one way of affecting the structural 
properties of a TF. Identification of covalent modification, such as phosphorylation, acetylation or the 
more recently characterized sumoylation of TFs, leads to a better understanding of the functional 
consequences that these modifications will have (for example, those described in the NF-κB TF 
signaling pathway (Perkins, 2006)). Phosphorylation is a very widespread modification, especially of 
those TFs that are activated by signaling cascades initiated at the cell surface by various ligand-
specific receptors, such as cytokine signaling via the Jak/STAT pathway (reviewed in (Imada and 
Leonard, 2000)). 
The nature and the selectivity of the protein-DNA interaction are of special interest in understanding 
gene regulation. The PDB now contains the structures of several DNA-binding protein classes. These 
can be divided into eight different structural/functional groups (Luscombe et al., 2000): the helix-
turn-helix, zinc co-ordinating, zipper-type, other α-helix, β-sheet, β-hairpin/ribbon, enzyme-type 
DNA-binding proteins and others (Fig. 2). Homeodomain TFs are an example of the group of helix-
turn-helix proteins. Zipper-type proteins include TFs, such as Fos, Jun and Max. However, in 
eukaryotes the single largest group of TFs is the zinc co-ordinating group. These proteins utilize a 
metal ion in their DNA-binding domain (DBD). The role of the metal ion is believed to create 
structural stability in domains that are not sufficiently large for a stable hydrophobic core. The metal 
ion itself is held in place by interactions with discretely positioned amino acid residues, either 
cysteines or histidines. TFs, such as NRs, the zinc-finger proteins and the tumor suppressor protein 
p53 belong to this group. Additionally, two groups of proteins utilize β-sheets in DNA-binding. The 
β-sheet proteins include, for example, the TATA-box-binding protein (a component of the basal 
transcriptional machinery). Finally, the group named as ‘‘other’’ includes the STAT family of TFs 
and Rel TFs. The details of the DNA-binding mode of the different classes of TFs are extensively 
reviewed in the literature (Luscombe et al., 2000). However, given the structural diversity of TFs, no 
simple rule exists on how the amino acid sequence relates to the DNA sequence it binds. Family-
specific rules for DNA base recognition can be generated, though, by examining the structures. 
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Moreover, via modeling of the binding of different DNA sequences to those TFs that have a solved 
crystal structure (or closely related crystal structure) available, relatively accurate predictions of 
binding strength can be made (Morozov et al., 2005).  
 
Helix-turn-helix Zinc-coordinating Zipper-type
Other α-helix
β-hairpin/ribbon Other
Enzyme
β-sheet proteins
 
Fig. 2. Families of DNA binding proteins. The structural elements to recognize DNA have evolved diversity. 
Representatives from each class of DNA binding proteins are shown with the reference PDB code in brackets. Adopted 
from (Luscombe et al., 2000). 
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The group other α-helix contains the histone proteins alongside with some TFs. Recently, the DNA-
interaction of histone molecules was modeled in order to predict histone locations on DNA sequences 
of different base pair composition (Segal et al., 2006). Such predictions could be useful in predicting 
the physical accessibility of individual DNA regulatory elements in vivo. As a result this model 
successfully predicted histone-poor regions (such as those with high CG-content). Moreover, a 
tolerable overall fit was obtained between the model and experimental verification over longer 
sequences around transcribed genes. 
 
2.2.2 Bioinformatics challenge on DNA level 
By experimental means, or by structural modeling techniques, it is possible to address the question, 
what kind of DNA sequences are recognized by each TF. The recognition sequences vary in length 
between 5 and 15 bp and due to the sheer size of the mammalian genome in effect have a multitude of 
occurrences within the 3 billion base pair sequence. Methods, such as gelshift (or electrophoretic 
mobility shift assay), SELEX, or more recently developed array based assays can be used to 
screen/compare binding of different DNA elements. It is important to note that in vitro determined 
binding does not necessarily represent binding strength in vivo, where the presence of other binding 
factors may alter stability. Secondary interactions between TFs can enable even weak affinity sites to 
be functional in the proper context and the exact contribution of, such effects is difficult to address 
experimentally (Bulyk, 2003; Hallikas et al., 2006).  
Since the completion of the sequencing of the human genome, it has become possible to search for 
defined binding motifs from entire genomes. For this purpose, bioinformatics research has developed 
different ways, in which to represent the binding site motif in search algorithms that will predict 
possible binding sites. The most often used approach is the weight matrix (WM) approach, where 
known, experimentally defined binding sites collected from publications are aligned and used to form 
a matrix that represents the frequencies of the four DNA bases (A, G, C, or T) at each location in the 
binding site (Stormo, 2000). A threshold is then determined for the matrix that will identify putative 
binding sites most similar to those already known. The ease of the use of matrix-based methods and 
their ready availability from databases has made them popular. However, the results themselves are 
not in direct relationship to binding strength and the performance (and quality) of the matrix is also 
dependent on the availability of sufficient number of known binding sites. 
Recently, alternative methods that exploit experimental binding data sets were developed (Hallikas et 
al., 2006). These scoring matrices perform well in the detection of near consensus RE variants and 
also approximate to a certain extent their relative binding strengths. A study by Morozov and 
colleagues compared these methods to the structural informatics approach, a computer simulation of 
the binding of different DNA sequences to the TF molecule (possible only where a crystal structure 
of the TF DNA-binding domain exists) (Morozov et al., 2005). In this work, they showed that as the 
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number of variations increases, the combinatorial effects, not predictable when considering single 
nucleotide positions, also start to emerge. 
The availability of a number of complete genomes has motivated the development of binding site 
prediction tools that exploit sequence alignments between several species to detect potential 
functional regions in the genome of interest, with the hypothesis that evolutionary pressure maintains 
elements and that this implies functionality. Mammalian regulatory regions often involve a set of TF 
binding sites clustered together, called enhancer regions. It is thought that several such TF modules 
can exist per gene and they can be located distally relative to the TSS. The functionality of the 
module is often dependent on the presence of several TFs and therefore a larger than 5 to 15 bp 
window conserved between species is searched for, assuming that conservation is evidence for 
functional importance. Visel and co-workers reported a database search tool, called 
EnhancerBrowser, for such conserved regions between different genomes using whole genome 
alignment methods (Visel et al., 2007). Moreover, it has been proposed that inside such modules co-
operative binding is also possible, leading to the stabilization of TFs to weak binding sites. This can 
be a desired feature, rather than creating a platform for any of the participating TFs to bind (an OR-
type switch), the requirement of stabilization creates an exclusive AND-type switch, where activation 
occurs only in the presence of all factors.  
For the conservation of functionality it may not be necessary that the exact order of TF binding sites 
is conserved (which is assumed in global alignment approaches). Hallikas and colleagues reported 
conserved enhancer regions defined by the preservation of the same TF binding site composition, 
irrespective of the surrounding sequence in total, in their database of human to mouse sequence 
alignments that was created by the software Enhancer Element Locator (EEL) (Hallikas et al., 2006). 
The stabilization hypothesis is a key element in their enhancer locator, a requirement that restricts the 
distribution of TF binding sites forming the module. The concept of binding site clustering had been 
explored before in Drosophila (Ludwig et al., 2000). Based on the comparison of two closely related 
fly species, D. melanogaster and D. pseudoobscura, Berman et al. proposed a very similar enhancer 
identification software relying on TF clustering (Berman et al., 2004). Based on the fly studies 
conservation of the similar TF modules was not apparent, rather locations, in addition to patterns of 
TF sites, were distinct. The clustering approach alone, however, leads to a higher number of false 
positive sites, when applied to more complex mammalian genomes (Hallikas et al., 2006). 
A study by Ludwig and co-workers compared enhancers of distal and closer relative of D. 
melanogaster (Ludwig et al., 2005). Substituting the enhancer from a distant relative species D. 
pseudoobscura, resulted in an identical pattern production driven by the expression of the gene eve. 
This is surprising since, the enhancer is completely conserved in only three of the 18 binding sites 
and two are lacking completely. On the other hand, the enhancer from the closer relative D. erecta, 
failed to preserve eve gene expression. This suggests that in contrast to amino acid sequence of 
proteins, enhancers show a more flexible architecture that allows modification, including turnover of 
binding sites. Different rules of molecular evolution thus apply to regulatory sequences. Furthermore, 
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the differences between D. melanogaster and D. erecta enhancers may reflect differences in TF 
concentrations that activate the enhancer.  
De novo binding sites can readily evolve (Stone and Wray, 2001). This rapid turnover of binding sites 
was demonstrated with a computer simulation of factors controlling evolution of binding sites. The 
waiting time, measured within a neutral evolution model involving random mutations, was shown 
highly dependent on sequence length (exponential scaling) and more moderately to be dependent on 
the length of regulatory area (linear scaling). With a population size of one million, a novel 
hexameric binding site was shown to evolve in every 2,250 generations, which in terms of evolution 
is microscale. The preservation of this new binding site, its fixation, was also estimated. Taking the 
fruit fly as an example, for a generation time of five weeks, it would only take 75 years to establish a 
new binding site. Given that species like D. melanogaster and D. pseudoobscura diverged 40 to 60 
million years ago, the previous findings of Ludwig and colleagues, that the enhancers, while retaining 
functionality, have diverged considerably, is not that surprising. Even the simultaneous appearance of 
two binding sites within 200 bp region was calculated to take only 55,000 years, which is a small 
time interval in terms of evolution. 
Instead of searching for functional binding sites or modules, the outcome of regulation is another 
starting point to define regulomes. This requires determining mRNA levels from cells under two 
conditions, comparing the activation of a TF to the normal state, and the subsequent analysis of the 
complex dataset. The dynamic nature of the regulation means that in order to capture all events, a 
time series experiment is needed. This typically results in different types of response according to 
which the responding genes can be clustered using sophisticated analysis tools. The clusters 
themselves can then serve as input for algorithms to discover similarities and differences in the 
regulatory elements (Huber and Bulyk, 2006). Unfortunately, this approach alone does not 
distinguish indirect target genes that depend on the activation of some of the direct targets but 
themselves lack binding sites for the TF in question. As a solution, recently developed microarray-
based immunoprecipitation techniques enable the experimental detection of bound TFs to the non-
repetitive sequence component of the genome (Horak and Snyder, 2002). However, in multi-cellular 
organisms, such as humans, no single cell type in the adult is expressing the whole set of genes. As a 
consequence, the full regulome for a TF needs to be assembled from an overlap of a set of different 
tissues. Holstege and Clevers compared these bioinformatics and experimental approaches (Holstege 
and Clevers, 2006). Clearly, the understanding of regulation on a genome-wide scale has advanced by 
the development of more efficient methods in both fields, yet further challenges need to be overcome 
before a complete description of regulatory regions can be compiled.  
The modular enhancer type activation model suggests that regulation of transcription is often 
dependent on the presence of a set of TFs co-operatively playing a role in the regulation. In effect, the 
process to build a regulome for a certain TF, in the end, translates into a process of describing 
interconnected regulomes. This requires the collection of extensive datasets that describe binding site 
preferences, location preferences and expression profiles for thousands of TFs. Taken together, the 
integration of various types of evidence, both experimental and computational, will be required in the 
Kuopio Univ. Publ. C. Nat. and Environ. Sci. 207: 1-112 (2007)   31 
Merja Matilainen:    Identification and characterization of target genes of the nuclear receptors VDR and PPARs:  
                                    implementing in silico methods into the analysis of nuclear receptor regulomes 
characterization of regulomes. This continues to motivate the tight interaction between computational 
biology and wet-lab molecular biology. 
 
2.3 NRs PPARα, γ, β/δ and VDR  
NRs form a TF family of 48 members in humans. Some of the family members are responsive to 
nanomolar range concentration of activating ligands, another group senses their ligands at 
micromolar range, whereas for the remaining receptors, a natural ligand has not been characterized 
(Chawla et al., 2001b). The ligand-centered view (Table 4) suggests that ligand responsive NRs bind 
small hydrophobic compounds ranging from bulky xenobiotic compounds via different steroid 
structures to more simple fatty acid derivatives. Being lipophilic, the ligands can readily enter cells 
through membranes and reach their receptor inside the cell. Many NRs are located inside the nucleus 
and only some NRs reside in the cytoplasma. 
Alternatively, evolutionary relationships (at the primary amino acid sequence level) reveal a different 
picture of the family (Fig. 3) (Bertrand et al., 2004), which is more focused on differences that 
translate into the structural and functional variations. One example is different dimerization modes, 
since a large subgroup of NRs forms dimeric complexes with RXRs (indicated with a star). Recently, 
the comparison of the expression levels and distribution of all the NRs in mice provided yet another 
way of classification that may better reflect shared function and physiology of the family members 
(Fig. 3) (Bookout et al., 2006). This study demonstrated that groups of NRs play central roles in the 
long-term regulation of cellular control processes, such as inflammation, cell growth and 
differentiation, nutrient storage and use, development and reproduction. 
The human VDR was cloned in 1988 (Baker et al., 1988). This NR is classically associated with the 
regulation of calcium homeostasis and bone formation but is also known to be involved in a number 
of other physiological processes, especially its role in cell growth and inflammation has been 
extensively studied (Hansen et al., 2001; Levine and Tjian, 2003). In the early 1990s, NRs sensing 
fatty acids, called PPARs, were cloned from different species. The first member, PPARα, was found 
responsive to peroxisome proliferators, hence the name and indeed the activation of this receptors 
leads to an increase in the number of peroxisomes in the liver of rodents (Issemann and Green, 1990). 
In humans, this effect is lacking and beneficial roles have been shown in several studies examining 
epidemiologic data from clinical use of PPARα ligands in the treatment of disease (Tenkanen et al., 
1995; Robins et al., 2003). Peroxisomes play a role in the oxidation of fatty acids that also occurs in 
the mitochondria. Several genes in these oxidative pathways and in pathways of fat transport, 
distribution and storage have later been characterized as PPAR target genes. Shortly after the first 
member was discovered, the isotypes, PPARβ/δ and PPARγ, were cloned (Dreyer et al., 1992; 
Kliewer et al., 1994). Both VDR and PPARs have attracted the attention of pharmacological research, 
VDR for its role for treatment of hyper-proliferative diseases and PPARs as key regulators of energy 
metabolism (especially fat but also influencing glucose levels). Several drugs, such as 
thiazolidinediones (TZDs), that are currently used to treat type II diabetes, or fibrates that are used for 
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the treatment of dyslipidemia are in fact activators for these receptors. As drug targets, these 
receptors are of interest for structure/function characterization and the widespread physiological roles 
make them good targets for regulomics research. 
 
Table 4. Classification of NRs based on ligand binding 
 
Subfamily Name Nomenclature Ligand* 
AR NR3C4 dihydrotestosterone 
ERα, β NR3A1, A2 17β-estradiol 
GR NR3C1 cortisol 
MR NR3C2 aldosterone 
PR NR3C3 progesterone 
RARα, β, γ NR1B1, B2, B3 all-trans retinoic acid 
TRα, β NR1A1, A2 3,5,3’-triiodothyronine 
Receptors 
with high 
affinity for 
ligands 
VDR NR1I1 1α,25-dihydroxyvitamin D3
CAR NR1I3 androstanol, xenobiotics 
ERRα, β, γ NR3B1, B2,B3 anti-estrogens 
FXR NR1H4 bile acids 
HNF-4α, γ NR2A1, A2 fatty acids 
LRH-1 NR5A2 phospholipids 
LXRα, β NR1H2, H3 oxysterols 
PPARα, γ, β/δ NR1C1, C2, C3 fatty acids and their derivatives 
PXR NR1I2 pregnanedione, xenobiotics 
RORα, β, γ NR1F1, F2, F3 fatty acids, cholesterol, retinoids 
RXRα, β, γ NR2B1, B2, B3 retinoids, fatty acids 
Sensors with 
low affinity 
for ligands 
SF-1 NR5A1 phospholipids 
COUP-TFα, β, γ NR2F1, F2, F6 
DAX NR0B1 
GCNF NR6A1 
NGFIB, NURR1, 
NOR1 
NR4A1, A2, NR4A3 
PNR NR2E3 
RVRα, β NR1D1, D2 
SHP NR0B2 
TLX NR2E1 
Orphans 
TR2, TR4 NR2C1, C2 
unknown 
 
*classification based on synthetic or natural compounds co-crystallized with NRs, physiological effect for all sensor NRs not 
established 
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Fig. 3. Alternative NR classifications. The classification of NRs based on sequence similarity (amino acid level) is 
shown on the left (Robinson-Rechavi et al., 2003). This classification in part reflects functional similarities. As an 
example, a star indicates groups of receptors that form heterodimers with RXRs. On the right, the NR ring of physiology 
classifies the receptors according to anatomical expression patterns to reflect shared physiological roles of the receptors 
(Bookout et al., 2006). 
 
2.4 Structural aspects of NR function 
2.4.1 Functional domains 
The functional properties of NRs depend on their structural elements. The majority of the NRs 
contain the following domains that have similar functions in each receptor (Mangelsdorf et al., 1995). 
The N-terminus of most NRs hosts the activation function 1 (AF-1) domain that has been 
characterized as one possible contact point for co-regulator proteins and often contains residues that, 
when phosphorylated, affect the activity of the receptor. Following the AF-1 domain is the DBD that 
consists of two zinc-finger motifs, one of which fits the major groove of DNA and the other that is 
positioned above and perpendicular to it (Fig. 4). The variability in this domain translates into 
variability in the DNA-binding sites of NRs. Two receptors (DAX-1 and SHP-1) lack this DBD and 
function mainly as dominant negative repressors of other NRs. 
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Fig. 4. NR DNA binding. The schematic diagram of the DNA-binding of NRs shows the location of the zinc-fingers in 
the primary amino acid sequence (Aranda and Pascual, 2001). The contact of the NR with DNA is shown with the 
example of the TR-RXR heterodimer crystal structure (PDB entry 2nll), where the AGGTCA recognition motif is 
indicated for one hexamer. 
 
The DBD is connected to the LBD by a flexible hinge region, which in some cases may contain a 
nuclear localization signal, or participate in co-regulator interactions. If viewed in three dimensions, 
the LBD of NRs is a three layered α-helical sandwich structure that has a ligand-binding cavity at the 
bottom of the domain (Folkertsma et al., 2005). For some NRs, for which no ligand has been 
characterized, amino acid side chains in fact fill this cavity. On the other extreme, other NRs are able 
to fit a variety of ligands of different size, volume and shape. Their cavity size can reach over 1000 
Å3 in size, PPARs even have a cavity of 1400 Å3 in size. The LBD should also not be considered to 
be static as in a few highlighted cases, the LBD has been shown to fit ligands by undergoing 
structural changes that accommodate the new ligand (evaluated for VDR ligands in Molnár et al., 
2006). 
The last and most C-terminal α-helix of NRs is also known as the activation function 2 (AF-2), or 
helix 12 (H12) and its positioning has a crucial role in the transition between inactive and active state 
of the receptor. A negatively charged glutamate residue located on H12 needs to be fixed at a defined 
distance from a positively charged residue in H3. This fits the CoA molecule peptide (description of 
CoAs follows below) in size and charge and thus enables a tight intermolecular interaction to occur 
between the receptor in its active state and the CoA molecule (Li et al., 2003b). This important helix 
is highlighted in the crystal structure of the PPAR-RXR heterodimer LBDs shown in Fig. 5. 
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Fig 5. Interaction surfaces of the NR LBD. The LBD of NRs plays a role in three important interactions. Firstly, most 
receptors can bind a ligand. The ligand-binding cavity is at the lower end of the receptor. Secondly, the receptor is able to 
contact CoAs (and corepressors (CoRs). The CoA interaction surface is facing forward, the critical structural part for this 
interaction, H12, is indicated in the figure on the left and other helices forming this surface are indicated n the figure on 
the right. Finally, many NRs can form dimers, a subgroup forms these dimers together with RXRs. The structure of the 
PPAR-RXR heterodimer (PDB entry 1fm9) illustrates these interaction surfaces of NRs. 
 
Structurally, the VDR differs from most other NRs by having a truncated N-terminus that lacks the 
AF-1 domain. Compared to the PPARs, VDR also has a smaller ligand-binding cavity (697 Å3), but 
binds its natural ligand with much higher affinity (Kd = 1-2 x 10-10 M). This classifies the VDR 
amongst the endocrine receptors, such as progesterone receptor (PR). However, the other 
classifications, shown in Fig. 3, based on sequence similarities, or expression profiles, classifies the 
receptor together with receptors, such as constitutive androstane receptor (CAR) and pregnane X 
receptor (PXR), classically known for their function in xenobiotic metabolism. VDR, CAR and PXR 
also have overlap in DNA-binding site recognition. To date, six crystal structures of VDR exist in the 
PDB that differ in terms of bound ligand (reference codes 1db1, 1ie8, 1ie9, 1s0z, 1s19 and 1txi). The 
VDR structure has the general NR topology and consists of 13 α-helices and a three-stranded β-sheet, 
its closest structural homolog is that of RARγ (Rochel et al. 2000; Renaud et al., 1995). The crucial 
H12 is in the active conformation in these ligand-bound holo-VDR structures and contacts the ligand 
as well as additional stabilizing residues (T415, L417, V418, L419, F422, D232, V234, S235, I238, 
Q239, A267, I268, H397, Y401 and S235). 
Two structurally different protein isoforms exist for PPARγ, γ1 and γ2,  that differ in the length of the 
N-terminal AF-1 domain (Mukherjee et al., 1997). In total, six alternatively spliced transcript 
isoforms have been isolated in humans (Chen et al., 2006). It appears that the regulation of the 
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isoforms differs. However, there is insufficient knowledge about their functional differences. 
PPARγ2 is predominantly expressed in adipose tissue and was activated in a similar way as PPARγ1. 
Both PPARα and PPARγ AF-1 domains can be phosphorylated (by phosphorylation pathways, such 
as the MAPK signaling cascade). Interestingly this can lead to opposite effects: activity increases 
have been reported for both receptors with several signaling cascades, whereas the phosphorylation of 
serine 112 in PPARγ was shown to decrease ligand-binding (Juge-Aubry et al., 1999; Shao et al., 
1998). The latter effect suggests that intra-molecular communication exists between the different 
domains, an observation that will later be further evaluated in connection with how ligand-binding 
changes receptor functionality. 
A much larger set of PPAR crystal structures is available for examination from the PDB. This set 
contains two unliganded structures (2gwx of PPARβ/δ and 1prg of PPARγ). Ligand-bound receptors 
together with a CoA-derived peptide include one PPARα structure (1k7l) and six PPARγ structures 
(2prg, 1wm0, 1k74, 1fm6, 1fm9 and 1RDT). One structure is crystallized together with an antagonist 
and a CoR-derived peptide, the PPARα structure 1kkq. The structure 1PRG was one of the first 
structures to be published: similar to VDR, 13 α-helices are visible; the β-strand, however, is small 
and four-stranded. The top part of the LBD has a rigid structure that enables the existence of a large 
ligand-binding pocket (rosiglitazone occupies approximately 40% of the cavity). A direct contact 
between the ligand and H12 is also observed (Nolte et al., 1998). 
2.4.2 Ligands 
The interest in the therapeutic use of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), the natural ligand 
for the VDR, has motivated the development of several analogs that maintain the beneficial roles of 
the natural ligand, 1α,25(OH)2D3, in controlling inflammation or cell proliferation, but lack the 
calcemic side effects (hypercalcemia and hypercalciuria) (Bikle, 1992; Binderup et al., 1991; van den 
Bemd et al., 2000). 1α,25(OH)2D3 analogs  in clinical use are reviewed by Brown and colleagues 
(Brown, 2001). Structurally 1α,25(OH)2D3 analogs resemble the natural ligand (Fig. 6). 
PPARs are activated by ligand concentrations in the micromolar range (Forman et al., 1996; Xu et al., 
1999). These ligands differ significantly in their structure. To illustrate this, some of the different 
ligands for PPARs are shown in Fig. 6. Their potential for therapeutic use in metabolic disease is 
reviewed in (Berger et al., 2005). The possibility that different ligand structures may induce different 
CoA association profiles with more cell type-specific responses, is actively explored (a similar trend 
was seen in the development of 1α,25(OH)2D3 analogs). PPARα binds a diverse set of ligands. 
Among the most potent endogenous ligands are arachidonic acid derivates, such as leukotriene B4, or 
prostaglandins (PGs) D1 and D2, whereas the pharmacological activation of the receptor goes via 
fibrates, such as fenofibrate or bezafibrate (Devchand et al., 1996; Forman et al., 1997). However, the 
endogenous activation of the receptor may mainly occur with high levels of free fatty acids that occur 
under fasting conditions (Kersten et al., 1999). The best-known PPARγ ligands, such as rosiglitazone, 
belong to the family of TZDs. Natural activation has been demonstrated by various fatty acids, 
arachidonic acid derivatives and their metabolites, but the inductions are weak. There is some 
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preference for polyunsaturated fatty acids (Huang et al., 1999; Nagy et al., 1998). Initially, PPARβ/δ 
was less intensively studied. Systematic screens have identified saturated and unsaturated fats as 
ligands, but only after the development of the synthetic ligand GW501516 and observations of its 
positive effect on cholesterol transport in rhesus monkeys more attention has turned to this subtype 
(Oliver et al., 2001). Recently, the use of PPAR ligands has expanded from treatment of metabolic 
diseases and is being evaluated for the treatment of inflammation, hyperproliferation and cancer 
(Friedmann et al., 2005; Panigrahy et al., 2005). 
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Fig. 6. VDR and PPAR ligands. The natural ligand for VDR, 1α,25(OH)2D3, has a typical cholesterol backbone. A 
selection of VDR analogues with specific modifications to this structure are shown on the right (Posner, 2002). The larger 
ligand-binding pocket of PPARs is able to bind a diversity of ligands. The structures of the synthetic PPAR ligands 
GW7647 (PPARα), rosiglitazone (PPARγ) and GW501516 (PPARβ/δ) shown reflects this structural diversity. From 
natural PPAR activators, palmitic acid, leukotriene B4 and eicosapentanoic acid are shown. 
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2.4.3 NR dimerization interfaces and DNA-binding 
The DBDs of NRs contain zinc atoms classifying them into the zinc co-ordinating group of DNA-
binding proteins. The NR DNA-binding sites, also known as REs, are composed of hexameric 
binding motifs, for which an ideal (or consensus) sequence can be described. In detail, structural 
analysis shows that one α-helix located at the C-terminal of the first zinc finger, known as the 
recognition helix or P box, contacts the hexameric core binding motif in the major groove of DNA 
(Fig. 4) (Luisi et al., 1991). Predominantly within the group of orphan receptors, there are NRs that 
bind as monomers with specific flanking nucleotide preferences to RGKTCA-type sequences (R = A 
or G, K = G or T). Some orphans and in addition steroid receptors, such as androgen receptor (AR), 
recognize two hexameric motifs as homodimers. In this form, steroid receptors recognize an inverted 
repeat (IR) orientation with 1 or 3 nucleotide spacing. Additionally, the steroid receptors form an 
exception to the RGKTCA-rule, with a preference for RGAACA-like motifs. The remainder of 
receptors that include many of those sensing micro- and macronutrients and xenobiotics form 
heterodimers preferentially with RXRs α, β, or γ. Most heterodimers recognize two hexameric motifs 
of RGKTCA-type motifs in a direct repeat orientation, but also everted repeats (ERs) have been 
identified (Fig. 7). Conversely, the RXR-farnesoid X receptor (FXR) heterodimer is the only one 
known to recognize IRs. Each heterodimer has individual preferences to the nucleotide composition 
(including consensus sequence variations tolerated), spacing and orientation, however, overlaps exist 
(Rastinejad et al., 1995).  
 
RGKTCA RGKTCA
TGAMCY RGKTCA
RGKTCA TGAMCY
(N)n
(N)n
(N)n
Direct repeat (DR)
Everted repeat (ER)
Inverted repeat (IR)
 
Fig. 7. Schematic diagram of different hexamer orientations of NR binding sites. Orientation and spacing are crucial 
determinants of NR binding site specificity. The DR motif has two hexamers formed of AGGTCA motifs in parallel 
orientation, whereas in ER and IR one of the hexamers has this motif in the reverse orientation. 
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The dimerization interfaces of homo- and heterodimers involve both the DBD and the LBD residues. 
The DBD interface follows the zinc-fingers in structure, whereas a hydrophobic region at the N-
terminus of H10/11 dominates the LBD dimerization interface. In some cases, the dimerization with 
liganded RXR is sufficient to form a transcriptionally active complex. This effect, referred to as 
phantom ligand effect, classifies some heterodimers as permissive dimers. The effect that the binding 
of a substrate/ligand on one domain has on the properties of other domains, is referred to as allosteric 
regulation. Shulman and co-workers reported a statistical method to discover the energetically 
coupled residues within NR protein structures (Shulman et al., 2004). Interestingly, they were able to 
show critical residues for this allosteric network that regulate the specificity of ligand regulation. 
Metabolic versus endocrine ligands for VDR were shown to be differentially dependent on specific 
amino acid residues. In addition, their study offered a structural explanation for the phantom ligand 
effect of permissive heterodimers. The effect of dimerization with liganded RXRs was shown to 
mediate intermolecular changes via key residues that permit an activated state of the partner receptor 
without the presence of its ligand. 
PPARs belong to the group of NRs that regulate transcription as heterodimers with RXRs (via DR1-
type REs). The receptors bind the REs with PPARs occupying the 5’-hexamer, which deviates from 
the binding mode of most other NR-RXR heterodimers. The dimerization is also atypical concerning 
symmetry: the PPAR-RXR dimer is asymmetrical and residues from H10 and some from H7 and H9 
contribute to the dimerization interface. In addition to DR1-type REs, binding of PPAR-RXR 
heterodimers to IR3- and DR2-type REs has been reported (Hsu et al., 1998; Keller et al., 1995).  
VDR, like the PPARs, forms heterodimers with RXRs and the dimer binds a dual hexameric 
RGKTCA motif (also variation to this consensus motif are recognized). As with most RXR 
heterodimers, the RXR molecule occupies the 5'-hexameric site. Compared to the PPARs, VDR is 
more flexible concerning spacing and orientation of the two hexameric sites. Classical 1α,25(OH)2D3 
REs (VDREs) are DR3-type REs, however, the VDR-RXR heterodimer can also bind DR4-type REs 
and a number of ERs. Based on in vitro studies, ER6- to ER11-type REs can function as VDREs, 
however, so far only natural ER6-, ER8- and ER9-type elements have been described (Schräder et al., 
1995, Tavera-Mendoza et al., 2006 ; Thompson et al., 2002). VDR is also able to form homodimers 
capable of binding to DR6-type REs (Polly et al., 1996). It is rather unclear, however, to what extent 
these homodimers contribute to gene transactivation since the preferred dimerization partners for 
VDR, the RXRs, are ubiquitously expressed. 
 
2.5 Transactivation mediated by NRs 
2.5.1 Direct protein-protein interactions 
Conceptually, there are two types of co-regulator proteins that come in direct contact with the NRs, 
CoAs and CoRs. CoAs, such as the p160 family members SRC-1, TIF-2 or RAC3, bind the receptor 
in its active state, when the position of H12 and the two charged residues allow it. CoAs in turn bind 
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and recruit histone acetyl transferases (HATs) that relax the chromatin state locally by adding acetyl 
groups to the tails of histone molecules. The interaction motif of many CoAs consists of a conserved 
LXXLL motif (L = leucine and X = any amino acid). The leucines fit the hydrophobic pocket 
between the charge clamp residues, further stabilizing the interaction provided by flanking charged 
residues (Heery et al., 1997). This kind of interaction mode has been described also for the PPARγ 
CoA 1α (PGC-1α) CoA, though it may also utilize a slightly different interaction surface (Wu et al., 
2003). The CREB-binding protein (CBP) and E1A-binding protein (p300) are highly related proteins 
that also possess the capability to interact with activated NRs (they also interact with a variety of 
TFs) and furthermore they may also interact with the p160 proteins. p300/CBP contains a domain 
with HAT-activity on its own and additionally can recruit other HATs, such as p300/CBP-associated 
factor (Demarest et al., 2002). Currently, proteins that possess other functionalities besides histone 
acetylation are considered as NR CoAs.  A large number of approximately 200 CoA proteins have 
been described, with roles in methylation, transcriptional elongation and ubiquitination (Lonard and 
O'Malley, 2006). The concept of multi-subunit CoA complexes has emerged, where the collection of 
functions that carry out the modifications required for gene transactivation, are mediated by different 
proteins in the complex. 
Induction of transcription requires the formation of a preinitiation complex (PIC), which includes the 
TFIIA to TFIIF complexes and RNA polymerase II itself (Berk, 1999). The complex initiates from the 
binding of the TATA-box-binding protein, followed by the TFII proteins A and B and the polymerase. 
A large multi-subunit mediator complex bridges the distance between the TF and the PIC and 
stimulates the phosphorylation of the largest subunit of the polymerase, initiating elongation 
(Woychik and Hampsey, 2002). TRAP220, a member of the DRIP/TRAP family is found as a 
component of the mediator protein complex and can bind NRs in the active state, utilizing the same 
binding mode as the p160 proteins. The initiation of this protein interaction, leads to transcriptional 
activity on a gene’s promoter. 
CoRs bind inactive NR by utilizing, in part, the same binding interface as CoAs thus making their 
binding mutually exclusive. When bound to NRs, they recruit enzymes with histone deacetylase 
activity (HDACs) that reverse the covalent modifications caused by the HATs and thus reverse the 
effects of the latter enzymes. In effect, DNA and histones become more attracted. The best-
characterized CoRs are NCoR1 and SMRT. These CoRs have a similar but longer receptor 
interaction domain than CoAs with the sequence LXXI/H/IXXXI/L (I = isoleucine, H = histidine and 
X = any residue). As with CoAs, an expansion in the set of known CoRs has occurred. These include 
the proteins small ubiquitous nuclear CoR, SHARP (interacts with SMRT), nuclear receptor 
interacting protein 1, Alien and scaffold attachment factor B1 that do not share sequence homology to 
the NCoRs (Debril et al., 2005; Dressel et al., 1999; Lee et al., 1998; Shi et al., 2001; Zamir et al., 
1997). 
In summary, these interactions enable NRs to come into contact with chromatin state modifiers via 
sequential recruitment of various protein complexes and to bridge to the basal transcriptional 
machinery via the mediator complex.  
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2.5.2 Regulation of transcription rates 
The final outcome, in terms of a target gene’s mRNA transcription rate, can occur in both directions. 
So far, gene activation is better understood than gene repression, even though both have been 
observed to occur with approximately equal numbers for different NR ligands. The activation of gene 
transcription for ligand-activated receptors is described as a two-step process, where the switch from 
chromatin loosening HAT recruitment is thought to precede the recruitment of the mediator complex 
that bridges the NR to the RNA polymerase II at the TSS. To understand the sequence of events 
taking place on a target gene promoter, the well-known VDR target gene cytochrome P450 (CYP) 24 
was analyzed by Väisänen and colleagues using chromatin immunoprecipitation (ChIP) assays 
covering a region of 10 kB upstream from the TSS (Väisänen et al., 2004). On this promoter a clear 
change from inactive chromatin to active chromatin (manifested by acetylated histone H4 
appearance) was observed upon VDR recruitment to the promoter and at later times points mediator 
proteins and phosphorylated RNA polymerase II (p-PolII) were detected. However, at actively 
transcribed gene promoters the histone modification step may be not necessary due to a pre-existing 
permissive chromatin status indicated by high histone acetylation level (Sinkkonen et al., 2005). 
For repression no general model exists, but instead different models have been described on a single 
gene level. In the case of the gene apolipoprotein (APO) C3, a replacement model was proposed, 
where the NR hepatocyte nuclear factor α (HNF-4α), participating in the maintenance of the basal 
transcriptional level of the gene, is substituted for the ligand-bound PPARs. This leads to a decrease 
in the transcription level due to differences in the level of transactivation mediated by these NRs. 
Overlapping binding sites and subsequent competition may also lead to repression, as was observed 
for the rat bone sialoprotein gene promoter, where the TATA box-binding protein has an overlapping 
binding site with the VDR (Kim et al., 1996). When occupied by VDR, gene transcription is 
prevented. A similar overlapping binding site is found in the rat osteocalcin gene, where an AP-1 
binding site co-locates with a VDRE (Demay et al., 1992). Gene repression involving AP-1 binding 
sites was recently described as an essential element for late down-regulation effect mediated by the 
estrogen receptor α (ERα) (Carroll et al., 2006). 
2.5.3 Dynamics of gene regulation by NRs 
Métivier and co-workers have addressed the dynamics of NR-mediated transactivation so far in 
highest detail in their study (Métivier et al., 2003). This study focused on ERα recruitment to the pS2 
gene promoter, where an elegant time series ChIP analysis was performed to evaluate the sequential 
recruitment of the different protein complexes. The results revealed a steady cyclical pattern of ERα 
recruitment to the promoter that was subsequently followed by proteasome-mediated receptor 
degradation. An initial cycle of ERα recruitment, which resulted in no mRNA production, involved 
the recruitment of nucleosome organization modeling SWI/SNF complex. This was followed by 
further histone modifications achieved via the recruitment of p160 or p300/CBP during each 
following cycle. The TRAP220-mediator complex followed the acetylation state modifiers and a 
subsequent phosphorylation of RNA polymerase II was observed. At the end of each cycle, ERα was 
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directed to proteosomal degradation via AAA ATPase proteins independent of 20S or APIS1, a 
subunit of the 20S proteasome complex. This clearance was followed by histone deacetylation prior 
to the initiation of following cycles. 
 
2.6 The role of PPARs and VDR on a genome wide scale 
A global analysis of the anatomical and circadian NR expression patterns was recently carried out in 
adult male mouse tissues derived from two inbred strains (Bookout et al., 2006). In this study, shared 
NR gene expression patterns were hypothesized to reflect related function and common regulation. 
This analysis classified the NR family in two large subgroups: NRs that function in 1) reproduction 
and the central nervous system and 2) nutrient metabolism and immunity (Fig. 3). In some ways these 
results reflected other classification patterns. In this study, VDR clustered together with PXR, CAR, 
its two closest evolutionary relatives, and FXR, into the xenobiotic and bile acid metabolism cluster. 
The highest expression of VDR is seen in tissues that play a role in calcium homeostasis, small 
intestine, kidneys and bone, fitting with its classical role in bone formation, manifested in the 
deficiency disease rickets. The dominancy of this feature in its function was perhaps surprising, as the 
role of the receptor has been characterized in various other processes. However, supporting a more 
ubiquitous role, lower expression levels were detected in nearly all mouse tissues explored. 
Gene expression of the three PPAR subtype genes were also reported in various tissues: PPARβ/δ 
can be found nearly in every tissue tested, whereas PPARα was expressed at highest levels in liver, 
heart, kidney, muscle, intestine and brown fat, all characterized by a high level of fatty acid 
catabolism. PPARγ was found in highest levels in adipocytes, in accordance with its important role in 
adipocyte differentiation. Furthermore, PPARα and β/δ were clustered together with five orphan NRs 
and RXRα in a metabolism cluster, while PPARγ separated to the immunity cluster, together with the 
glucocorticoid receptor (GR) and the liver X receptor (LXR) α. The physiology of each receptor is 
further explored below in connection to the physiological processes, in which their role has been 
established. The physiological role of TFs is manifested through their target genes and accordingly, 
examples of known target genes are mentioned for those processes characterized in this detail. 
Additionally, some physiological effects that have been characterized from in vivo models (typically 
mouse models) are also discussed. 
2.6.1 Characterized physiology and known target genes of the VDR 
Calcium homeostasis 
In vertebrates, maintenance of bone integrity is dependent on the regulated absorption and 
distribution of bone forming minerals. In small intestine and kidney, VDR target genes include those 
involved in the absorption of calcium. This metal ion is one of the major components of bone 
(together with phosphate) and requires facilitated absorption from the intestine. The target genes in 
these tissues facilitate intracellular transport, for example, calbindin D-9K and calbindin D-28K and 
transfer across membranes, such as the calcium pump PMCA (Bouillon et al., 2003). In bones, two 
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types of cells participate in bone remodeling: VDR expressing osteoblasts that form bone and bone-
resorbing osteoclasts, which do not contain VDR. Among the genes regulated in osteoblasts are well-
known VDR target genes, osteocalcin, associated with the mineralized matrix of bone and 
osteopontin. While the latter has an established role in bone where it binds tightly hydroxyapatite and 
enables osteoclast adhesion (Reinholt et al., 1990), it has also been shown to be a constitutive 
component of elastic fibers in skin and aorta (Baccarani-Contri et al., 1995) and bind to CD44 of T-
lymphocytes modulating immune reactions (Weber et al., 1996). Role of VDR in immune reactions is 
further discussed later. Additionally, effects on osteoclasts are mediated indirectly via the regulation 
of secreted proteins in osteoblasts, such as the osteoclast differentiation factor that activates 
osteoclasts. 
Cellular proliferation and differentiation 
The first evidence of beneficial effects of VDR in hyper-proliferative disease came in the early 1980s, 
as it was discovered that nanomolar doses of 1α,25(OH)2D3 arrested the proliferation of murine 
myeloid leukemia cells and induced their differentiation into macrophages (Abe et al., 1981). Since 
then the role of VDR and the potential use of VDR analogs has been studied in various cancer models 
and in the modulation of cellular differentiation. Amongst other techniques, the following microarray 
studies have explored expression changes in response to 1α,25(OH)2D3 (Moll et al., 2006; Pálmer et 
al., 2003; Swami et al., 2003; Wang et al., 2005). 
The genes responsible for the regulation of cell cycle progression are obvious candidates to mediate 
the anti-proliferative effects of this hormone in cells. The cell cycle is tightly controlled and special 
checkpoints for the progression to the next step exist to prevent premature or undesired progression in 
cell division. On the molecular level, the different checkpoints translate into the sequential activation 
of cyclin-dependent kinases (CDKs). The critical cyclin-kinase complex for the initiation of cell 
division is the CDK4/6 complex that binds cyclin D. The activation of the kinase complex leads to 
the phosphorylation and inactivation of the retinoblastoma protein (Rb). This in turn releases the TF 
E2F from the embrace of its inhibitor, Rb and initiates the transcription of genes needed for the 
progression into cell division (M phase). For the inhibition of the activity of the CDK4/6 complex, 
there exists the specific INK4 family of CDK-inhibitors. This family comprises of the proteins 
p16INK4A, p15INK4B, p18INK4C and p19INK4D. In addition, members of the CIP/KIP family of CDKIs are 
able to inhibit all CDK complexes. This family comprises the proteins p21CIP1/WAF1, p27KIP1 and 
p57KIP2. Both p21CIP1/WAF1 and p27KIP1 gene expression levels have been reported to increase by 
1α,25(OH)2D3 treatment (Liu et al., 1996; Wang et al., 1996). The former study also reported a 
VDRE within the human p21CIP1/WAF1 promoter. More recently this phenomenon was studied more 
intensely with ChIP promoter screening for VDR binding sites. Together, these studies demonstrate 
that the up-regulation of the p21CIP1/WAF1 gene is directly mediated by the VDR and involves several 
binding sites and synergy with p53, another TF that is involved in cell cycle regulation (Saramäki et 
al., 2006). In addition, the induction of p21CIP1/WAF1 is also reported to occur via the IGFBP-3 gene, 
another direct target of VDR (Peng et al., 2004). This suggests both primary and secondary roles for 
1α,25(OH)2D3 and its receptor, VDR, in the regulation of this gene. In addition, the expression levels 
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of several other CDKIs, cyclins and CDKs, are regulated by VDR (Jensen et al., 2001). Moreover, 
VDR has been shown to directly regulate a gene that encodes for a protein that is involved in cellular 
DNA repair mechanisms, GADD45 (Jiang et al., 2003). This protects from UVB-induced DNA 
damage that is critical, especially for skin that is the most exposed tissue to this type of 
electromagnetic radiation (De Haes et al., 2005). Skin is also able to synthesize 1α,25(OH)2D3, when 
exposed to UV-light, and is therefore our body’s main way of producing this hormone. 
In addition to cell cycle checkpoint genes, VDR has a role in the regulation of proto-oncogenes and 
tumor suppressor genes. For example, the oncogenic TF c-fos gene transcription (Mathiasen et al., 
1993) has been reported to be rapidly up-regulated in several cell lines and among tumor suppressor 
proteins, the regulation of E-cadherin has been shown to be transcriptional regulated by 
1α,25(OH)2D3 (Pálmer et al., 2001). Further, the modulation of growth factor signaling, such as that 
of the tumor growth factor (TGF) β and insulin-like growth factor (IGF)-I signaling, plays a role in 
the anti-proliferative/pro-differentiation effects of the VDR. For instance, a VDRE has been 
identified from the TGFβ2 gene promoter (Wu et al., 1999) and regulation of TGFβ receptor-1 has 
been observed with several microarrays (Pálmer et al., 2003). Several members of the gene family 
that encode the IGFBP proteins, including the IGFBP-3 gene, whose promoter contains a VDRE 
(Peng et al., 2004), have been reported to be regulated by 1α,25(OH)2D3 (Drivdahl et al., 1995). 
These proteins can bind and sequester the circulating IGFs making its growth-promoting stimulus 
inaccessible to cells (Baxter, 1994). On the other hand, membrane bound IGFBPs have a lowered 
affinity for IGFs and function to present the growth factor to its receptor (Kelley et al., 1996). Such 
an effect was observed for IGFBP-5 in bone fractures, where it functioned to locally increase the 
concentration of IGF-1 promoting bone reformation (Mohan et al., 1995). 
Immune reactions 
Several cells of the immune system, such as monocytes, antigen presenting macrophages, dendritic 
cells and activated T-lymphocytes, express the VDR. An interaction between VDR and AP-1 
signaling was suggested as one underlying mechanism for the immunosuppressive action of VDR 
that leads to suppression of inflammatory cytokine expression (Alroy et al., 1995). VDR was shown 
to block an interaction of the TFs Fos, Jun and NF-AT (Towers et al., 1999). Due to their 
immunosuppressive ability, VDR ligands have been found beneficial in several autoimmune diseases, 
such as multiple sclerosis where an autoimmune reaction is triggered against self-antigens in the 
brain, rheumatoid arthritis where inflammation is triggered in the joints, in inflammatory bowel 
disease where the gastrointestinal tract is affected, and in type I diabetes where the pancreatic insulin 
producing cells, β-cells, are affected (the immunological functions of the 1α,25(OH)2D3 endocrine 
systems are reviewed in (Hayes et al., 2003)). In all these diseases evidence for the beneficial effects 
of 1α,25(OH)2D3 has accumulated. 
 
Multiple sclerosis develops when an immune response is triggered by the inappropriate recognition of 
self-epitopes on myelinated nerve fibers. This leads to the recruitment of T cells and macrophages 
into the central nervous system resulting finally in demyelination of nerves that leads to the 
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symptoms of the disease. The differentiation of T helper 1 (Th1)-type cells is controlled by antigen 
stimulation and cytokines, particularly interleukins (IL) -12 and -23. This cytokine signaling 
translates to Th1-specific gene expression profile via the TF T-bet (Szabo et al., 2000). VDR has 
been shown to inhibit IL-12 production directly leading to the suppression of Th1-response 
(D’Ambrosio et al., 1998). The Th2 population, functioning in defense against parasites and 
hypersensitivity reactions, is not affected. Mattner and colleagues addressed this in a mouse model 
immunized with self-antigen peptide and treated with 1α,25(OH)2D3. Inflammatory infiltration and 
demyelination of brain and spinal cord were reduced (Mattner et al., 2000). Effects mediated via 
inhibition of IL-12 signaling have also been proposed to underline the beneficial effects of VDR in 
type I diabetes (Gregori et al., 2002). Among other signaling pathways, the up-regulation of TGFβ 
and IL-4 have been proposed to contribute to the effect (Cantorna et al., 1998). In the treatment of 
rheumatoid arthritis, convincing clinical evidence exists to support the beneficial, anti-inflammatory 
effects of 1α,25(OH)2D3 (Andjelkovic et al., 1999). This disease is one of the most common chronic 
inflammatory diseases and results in tissue damage of the joints involving the matrix modeling 
proteases. In addition, prostaglandin signaling plays a role in the immune system and inflammatory 
processes associated with rheumatoid arthritis. Interestingly, IL-1ß-stimulated prostaglandin E2 
synthesis is completely inhibited by 1α,25(OH)2D3 treatment and also metalloproteinases are 
regulated (Tetlow et al., 1999). 
 
Antigen-presenting cells, in particular dendritic cells, are also affected by the immunosuppressive 
activity of 1α,25(OH)2D3. These cells play a central role in regulating immune response to self and 
foreign antigens. During the normal immune response, T cell response and specificity are conferred 
through the clonal restricted T cell receptor, which recognizes major histocompatibility complex class 
I and class II molecule complexed with peptides. However, the potency of this activation also 
depends on the maturation status of the dendritic cells, in particular the display of costimulatory 
surface proteins (Banchereau, Steinman, 1998). Important evidence of 1α,25(OH)2D3 effect on 
antigen presentation comes from VDR knockout mouse studies, where dendritic cells from VDR-
deficient mice showed a significantly higher level of maturation markers such as class II MHC, 
CD40, CD80 and CD86 on cell surface. In the presence of GM-CSF and IL-4, 1α,25(OH)2D3 
completely inhibited DC differentiation manifested by the low-level expression of IL-12 and 
maturation markers (Griffin et al., 2001). This effect has lead to the use of 1α,25(OH)2D3 or its 
analogs in graft rejection therapies. Furthermore, recent evidence also suggests that 1α,25(OH)2D3 
treatment leads to the induction of tolerogenic dendritic cells, which protect the allograft rejection 
(Adorini et al., 2003). 
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2.6.2 Characterized physiology and target genes of PPARs 
2.6.2.1 PPARα 
Fatty acid oxidation 
The role of PPARα is best established in fatty acid oxidation, which takes place predominately in the 
liver. An extensive list of direct targets, for which binding sites have been identified exists for mouse 
PPARα, however, not all have a characterized PPRE in the human gene (reviewed in detail in 
(Mandard et al., 2004)). The use of fatty acids in energy production requires the uptake of free fatty 
acids and fatty acids carried by lipoproteins from the circulation into liver cells. The fatty-acid 
transport protein-1 gene is a known PPARα target in mouse and the CD36 gene (APO receptor) has 
been described as a target in both species (Frohnert et al., 1999; Sato et al., 2002). The hepatic fatty 
acid binding protein, responsible for the intracellular trafficking of fatty acids in liver cells has a 
characterized binding site in the mouse gene (Poirier et al., 2001). Its role may be in enhancing the 
signaling role of fatty acids, by mediating their traffic into the nucleus, where they may activate 
PPARs in a feed-forward fashion to increase the transcriptional levels of genes that participate in the 
subsequent steps of fat metabolism. 
Prior to the translocation of fatty acids to the mitochondria, they need to be activated by the enzyme 
encoded by the gene long-chain fatty acyl-CoA synthetase, for which a PPRE was described in the rat 
promoter (Schoonjans et al., 1995). The cascade of human PPAR targets continues with the 
mitochondrial translocase genes carnitine palmitoyl acetyltransferase (CPT) 1α, CPT1β in the outer 
membrane and CPT2 in the inner membrane (Barrero et al., 2003; Mascaro et al., 1998; Napal et al., 
2005). The enzymes functioning inside the mitochondria in the first steps of β-oxidation, such as the 
respective acyl-CoA-dehydrogenase genes for the different length of fatty acids, were described in 
mice as direct PPAR target genes (Gulick et al., 1994) and have also been shown regulated in humans 
by microarrays (Vanden Heuvel et al., 2003). The first identified direct PPARα target gene, acyl-CoA 
oxidase (ACOX1), encodes the enzyme catalyzing the first step of peroxisomal β-oxidation (Tugwood 
et al., 1992). The orthologous human gene was also later characterized as being a PPAR target 
(Varanasi et al., 1996). Besides mitochondria and peroxisomes, the smooth endoplasmic reticulum 
also participates in fatty acid oxidation, but at a minor level. This is the site of ω-oxidation and the 
enzymes catalyzing these reactions, belonging to the 4A/F group of CYP enzyme, were characterized 
as direct target genes PPARs in rodents (Johnson et al., 1996). 
Other metabolic pathways regulated in the liver 
When fatty acids serve as the only energy source for a prolonged time, the liver starts 
gluconeogenesis in an attempt to maintain blood glucose levels and later, to synthesize ketone bodies, 
that go on to serve the energy needs of the brain. PPARs also participate in the regulation of genes in 
the gluconeogenesis and ketone synthesis pathways. If these conditions persist, amino acids become 
the main energy source of liver cells and this shift is also regulated. Liver is also the main site of 
biotransformation reactions that inactivate xenobiotics and some endogenous compounds. The role of 
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PPARα in the regulation of genes participating in these reactions has been well reviewed in the 
literature and will not be discussed here (Mandard et al., 2004). 
Regulation of lipoprotein levels 
The clinically most interesting aspect of gene regulation by PPARα is the regulation of lipoprotein 
metabolism. In this pathway, most of the genes are also known to be direct targets of PPARs in 
humans. The fibrate drugs that activate PPARα have been shown to increase high density 
lipoproteins (HDL) level in plasma and decrease the triglyceride levels. Additionally, in physiological 
fasting conditions, the transport of fatty acids to the liver by the carrier proteins is enhanced. The 
genes APOA1 and APOA2, the two major components of HDLs, are direct targets in humans (Vu-Dac 
et al., 1994; Vu-Dac et al., 1995). The HDL surface proteins, encoded by the genes, phospholipid 
transfer protein (PLTP) and the gene encoding the receptor for HDL in liver tissue, the scavenger 
receptor-class B type I (SR-BI), were found to be direct targets of PPARs (Malerød et al., 2003; Tu 
and Albers, 2001). In connection with triglyceride levels, the down regulation of the APOC3 has been 
described to be PPAR-dependent (Hertz et al., 1995). APOC3 functions to suppress the lipoprotein 
lipase (LPL) gene. This suppression ultimately leads to elevated triglyceride levels. Furthermore, 
levels of LPL protein have been shown to be up-regulated by PPARs, further substantiating the effect 
(Li et al., 2002). In addition, the human APOA5 gene, which is involved in the maintenance of normal 
triglyceride levels, is a direct PPAR target (Prieur et al., 2003). 
Other pathways 
In other tissues, a role for PPARα has been described in the regulation of uncoupling proteins 
(UCPs). The thermoregulatory UCP1 gene, in brown adipose tissue (in mice, adult humans lack 
brown adipose tissue), UCP2 that participates in insulin production in pancreatic β-cells and UCP3, 
expressed mainly in skeletal muscles (Armstrong and Towle, 2001; Barberá et al., 2001; Brun et al., 
1999) have all been described as PPAR target genes. Additionally, a role in bile acid absorption for 
PPARα  was recently described by regulating the ileal fatty acid binding protein (FABP6) and the 
transporter solute carrier family (SLC) 10, member A2 (Landrier et al., 2005). 
2.6.2.2 PPARγ 
To appreciate the role of PPARγ, it is important to understand the metabolic crosstalk between the fat 
storing (adipose) and the main fat burning (liver and muscle) tissues, because directly linked to this 
tissue network is also the control of blood glucose levels (Evans et al., 2004). Insulin is best known 
for its role in the regulation of blood glucose levels, however it also regulates triglyceride catabolism 
via the inhibition of the hormone sensitive lipase (LIPE) gene, a known PPAR target, already 
suggesting a link between the regulation of the two energy sources (Holm, 2003). The key 
observation that links the regulation of lipid levels (mediated by PPARs) and insulin sensitivity is that 
lipid levels in tissues in fact have an effect on glucose homeostasis. The effect has given rise to the 
lipotoxicity hypothesis, which states that abnormal accumulation of triglycerides and fatty acyl-CoA 
in both muscle and liver cells can result in insulin resistance (Shulman, 2000). Thus the storage of 
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fatty acids in fat tissue, promoted by PPARγ, prevents lipotoxicity from developing. This effect, 
together with regulation of signal molecules secreted from the fat tissue, such as adiponectin and 
leptin (both having wide spread effects on whole body energy metabolism), can underline the positive 
effect of PPARγ ligands in the use of the treatment of diabetes (Kallen and Lazar, 1996; Maeda et al., 
2001). In addition, PPARγ  has been reported to play a role in atherosclerosis, where likewise the 
abnormal deposition of fat, in this case as cholesterol, into blood vessels causes the disease. PPARγ 
has been characterized to mediate the processing of cholesterol back into transport on HDL particles, 
explored more in detail below. 
Differentiation of adipocytes and fat storage 
The longer isoform of PPARγ, PPARγ2 (28 additional amino acid at the N-terminus), has been 
characterized as the master regulator of the formation of fat cells and their normal function in the 
adult. Much of the discussion related to the role of fat tissue in glucose homeostasis deals with this 
isoform. Evidence for its pivotal role in the process comes from various observations: 1) the 
expression levels of the PPARγ2 are increased during differentiation of fat cells, 2) non-adipogenic 
cells can be differentiated into fat cells by PPARγ2 overexpression and 3) PPARγ2 knockout mice 
(that also lack the PPARγ1 isoform of the protein as well) fail to develop fat tissue (Barak et al., 
1999; Rosen et al., 1999; Tontonoz et al., 1994). The differentiation process was studied in a 
microarray experiment performed on human adipocytes, where PPARγ was knocked-down using an 
antisense oligo knock-down system (Perera et al., 2006). A total of 278 genes were found to be 
dependent on PPARγ for the maintenance of their normal expression (regulation absent in knock-
down), out of which 77% were genes for which the expression levels differed between adipocytes and 
pre-adipocytes. The biological processes characteristic of fat cells appear to be enriched on the list of 
PPAR targets derived from this study. These include the process of lipid storage into fat from 
circulation mediated by PPAR target genes, such as LIPE, perilipin (Holm, 2003) and CD36. 
Activation of these metabolic pathways shifts the triglyceride excess from the muscle, the liver and 
the circulation, into adipose tissue. This results in improvements to insulin sensitivity. In addition, 
other signaling pathways via tumor necrosis factor α (TNFα) and resistin that promote insulin 
resistance were inhibited by PPARγ ligands (Hallakou et al., 1998). 
Lipid processing and signaling by macrophages 
The PPARγ1 isoform has a wider tissue distribution. Its role has been recently demonstrated in steps 
leading to atherosclerosis, specifically in its contribution to macrophage transition into foam cells. 
The immune system and inflammation reactions play a critical role in the development of this disease 
and PPARγ agonists have been found to regulate their effect in a way, which improves the symptoms 
of the disease. The development of atherosclerosis starts with the infiltration of monocytes through 
endothelium into the intima layer of blood vessels where they engulf oxidized low-density lipoprotein 
(LDL) particles and transform into foam cells. These cells secrete cytokines that promote 
inflammation and smooth muscle cell proliferation. The uptake of ox-LDL is mediated by the PPAR 
target gene CD36. In addition, PPARγ increases the expression of the transporter gene ABCA1 
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(although this effect has been reported to be indirect mediated by the induction of the direct target 
LXRα), which mediates cholesterol efflux from cells (Chawla et al., 2001a). To study the genes 
involved Hodgkinson and co-workers performed a microarray study on human macrophages that had 
been treated with both synthetic ligands (ciglitazone and rosiglitazone) and endogenous PPARγ (15δ-
PGJ2) ligands, with a 24 h exposure time (the panel of ligands also included the PPARα ligand 
WY14643 and a combination of rosiglitazone with the antagonist BADGE). From this, genes 
involved in lipid processing were reported (Hodgkinson and Ye, 2003). Therefore, the authors 
proposed a model, where the sequence of events stimulated by PPARγ involves the uptake of pro-
atherogenic oxLDL, which gets processed and exported to HDL. This leads to an anti-atherogenic 
effect overall, as lipid trafficking via HDL alleviates their accumulation in blood vessels. 
Furthermore, the down-regulation of TNFα and other cytokine genes, the products of which promote 
inflammation contributes to the beneficial effects observed. Thus, similar to processes regulated in fat 
tissue, processing and signaling events in adipocyte tissue are under the regulation of PPARγ1 in 
macrophages. It is worth noting that the PPARα ligand stimulated the same genes, though with 
slightly different inductions suggesting that the PPAR isotypes may share this role that so far is 
mainly characterized for PPARγ, though the high ligand concentration used for PPARα (100 μM) 
may have also activated the other PPAR subtypes. 
2.6.2.3 PPARβ/δ 
Energy expenditure 
The interest towards PPARβ/δ has grown only recently, as its beneficial effects on lipid profiles were 
discovered (reviewed in (Barish et al., 2006)). A mouse model overexpressing this subtype was found 
to induce a muscle-type switching phenotype that increases endurance, which also gave them the 
nickname ‘‘marathon mice’’ (Wang et al., 2004). In adipose tissue, PPARβ/δ was found to increase 
thermogenesis (via UCPs) and fatty acid oxidation (shared target genes with PPARα). The PPARγ 
target genes responsible for lipogenesis and lipid storage were found to be unresponsive to PPARβ/δ  
(Wang et al., 2003a). The lean phenotype of the mice was in accordance with this. In addition, levels 
of HDL and triglycerides were increased in blood circulation (similar to the effect observed with 
PPARα ligands) and glucose production in liver was decreased due to a shift to the pentose 
phosphate pathway. Recently, beneficial effects were reported in human subjects (Sprecher et al., 
2006). 
Differentiation and wound healing in skin 
Additionally, the role of PPARβ/δ in skin and wound healing has been explored (Wahli, 2002). 
Schmuth and colleagues showed in a microarray study that PPARβ/δ stimulates differentiation via 
the induction of keratinocyte differentiation related genes, such as involucrin, desmoplakin and 
cystatin A (Schmuth et al., 2004).  Simultaneously, genes involved in lipid accumulation, such as 
adipocyte differentiation related protein (ADRP) that plays a role in intracellular lipid droplet 
formation (PPRE reported in (Targett-Adams et al., 2005)) and angiopoietin-like 4 (ANGPTL4) 
(intronic PPRE reported in (Kersten et al., 2000)) were upregulated (these genes are shared targets 
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with PPARα and PPARγ). The pro-differentiation effect is also observed in the wound healing 
process, as characterized with knock-out mice. PPARβ/δ is up-regulated in inflammation and 
stimulates differentiation of the keratinocytes and protects them from apoptosis. 
The discovery of the role of PPARs in humans on whole organism level is not straightforward, as is 
evident from the investigations of the role of the VDR as well. In fact, a lot of valuable data 
concerning the physiology of PPARs has been derived from rodent models/experiments, as discussed 
above. However, a couple of experiments to compare the role of the orthologs have suggested that not 
all observations in rodents translate to the human system: Vanden Heuvel and colleagues 
characterized the genes responsive to PPARα ligand (WY14643, 6 h exposure) from human and rat 
liver cell lines (HepG2 and FaO respectively) and found only a marginal 2.5% overlap in the genes 
regulated by this ligand (Vanden Heuvel et al., 2003). Moreover, the mouse model, in which the 
mouse PPARα was replaced by the human ortholog, also revealed that the human receptor, in fact, 
regulated different target genes when expressed in mouse than its mouse ortholog (Cheung et al., 
2004). On the other hand, several publications addressing individual target genes report observing the 
regulation in both species, but with different fold inductions. However, the possibility that regulation 
may integrate multiple signals in different species and not manifest in an identical physiological 
effect, should be appreciated. 
Furthermore, the DBDs of the three PPAR subtypes in human are highly conserved (over 80% 
identical residues) and their LBDs fairly similar as well (approximately 70% identity). The similarity 
of the PPAR subtypes would suggest that, in fact, some target genes and regulatory pathways may 
indeed be under the regulation of more than one subtype but have just been described more in detail 
for one PPAR subtype so far. This effect was observed by Tachibana and co-workers in a cellular 
model system (HepG2 liver cell line) using a tet-off expression system, where the regulation of the 
expression of each subtype could be controlled (Tachibana et al., 2005). Several over-expression 
conditions were tested with ligand treatments (24 h) on subtype level and this resulted in several 
shared target genes showing up in the microarray results. Each PPAR was found to induce fatty acid 
oxidation in these cells. PPARα was found most effective, fitting well its characterized role, but the 
results also provided evidence for widespread sharing of target genes, when expression levels are 
manipulated. This suggests that to some extent also overlap in target genes is to be expected, where 
selectivity may depend on expression levels and ligand concentrations used. However, since the 
physiological roles of the receptors have been shown to differ in several studies, this divergence in 
vivo, from a structural perspective, could be postulated to reflect their structural differences, leading 
to differential recruitment of co-factors, for example. Indeed, unliganded PPARβ/δ has been shown to 
associate with CoRs with higher affinity than the other subtypes, also when bound to DNA (Shi et al., 
2002) and the effects mediated by this subtype in muscle cells have been tightly linked with the 
association with PGC-1α CoA after ligand-binding (Hondares et al., 2007).  
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2.6.3 Overlap in VDR and PPAR signaling 
Although PPARs are better known for their role in lipid level regulation, they are also known to 
influence cell proliferation and differentiation, processes that were discussed in connection to VDR 
previously (as exemplified by the keratinocyte and adipocyte differentiation discussion above). 
Therefore, it is not surprising that shared target genes exist. For example the gene G0/G1 switch gene 
2 (G0S2) that results in growth arrest is a shared target of VDR and PPARs (Pálmer et al., 2001) 
(Zandbergen et al., 2005). PPARs have also been connected to the regulation of the INK4 family 
members, p16 was reported as a direct target recently (Gizard et al., 2005). On the other hand, VDR 
has recently been connected to regulation of adipocyte function. Insulin-induced gene-1 (Insig-1) and 
its homolog the Insig-2 gene encode closely related proteins of the endoplasmic reticulum that block 
proteolytic activation of sterol regulatory element binding proteins, which are membrane-bound TFs 
that activate synthesis of cholesterol and fatty acids. These proteins are known to restrict lipogenesis 
in mature adipocytes and block differentiation of pre-adipocytes. Interestingly, the Insig-1 gene is 
regulated by PPARγ, whilst Insig-2 gene regulation by VDR was recently reported (Kast-Woelbern et 
al., 2004; Lee et al., 2005b). Both genes are induced during adipocyte differentiation and seem to 
restrict the size of this cell type (Li et al., 2003a). This is of significance, because smaller adipocytes 
display higher insulin-sensitivity, indicating that both NRs could influence insulin-sensitivity. 
There is also a connection between osteoporosis and atherosclerosis (reviewed in detail in 
(Hamerman, 2005)). Several matrix proteins are shared between bone and arterial vessel wall, 
including osteopontin. Activation of PPARγ is able to re-direct the differentiation of mesenchymal 
progenitor cells from osteoblast precursors to adipocyte precursors, which reduces bone formation. 
Combined with the down-regulation of the osteoprotegerin gene, that inhibits osteoclastogenesis, 
these effects could lead to calcification of vessel walls seen in atherosclerosis. Under current 
knowledge, however, this link cannot be fully established, but these important signaling pathways 
may converge. The role of VDR in arterial smooth muscle cells was studied recently by Wu-Wong 
and collaborators (Wu-Wong et al., 2006a). In a separate study, this group also performed an 
evaluation of 1α,25(OH)2D3 analogues in the vessel calcification process (Wu-Wong et al., 2006b). 
Further understanding of VDR and PPAR signaling can thus lead to improved therapies against both 
of these diseases, whose incidence increase with age. 
 
2.7 Methods for the in silico prediction of NR binding sites and 
target genes 
For in silico analysis of NR binding sites, a couple of dedicated tools exist. Nubiscan is a WM-based 
tool that allows users to input their own search matrix individually for both hexameric motifs (in the 
case of dimeric binding NRs) (Podvinec et al., 2002). In addition, ready matrices exist for most 
receptors. Distinct from the WM approach employed above and distinct from approaches dedicated 
on specific NR recognition motifs, the NHR Scan tool allows the user to search simultaneously for all 
kinds of orientations and spacing, with variations allowed based on a fused list of all known NR 
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binding sites (Sandelin and Wasserman, 2005). The idea to make an all-inclusive search derives from 
the similarity of the DBDs of NRs but leaves it for the users own expertise to select from the result 
list the ones recognized by the NR of interest. In addition to these dedicated tools, several other 
search tools that use TF databases, such as TRANSFAC or JASPAR (ConSite) contain WMs for the 
better characterized NRs (Galperin, 2007). 
The WM-approach to discover target genes was used for a genome-wide search of PPREs (Lemay 
and Hwang, 2006). A co-localizing motif was found frequently but the authors were unable to 
determine what could bind it. A different approach to benefit from a collection of known binding 
sites of the ERα and β was used by Lin and co-workers (Lin et al., 2004). They also included the 
surrounding sequence of functional binding sites with the assumption that these neighboring DNA 
elements may contain co-localizing motifs useful for the detection of functional binding sites. Other 
whole genome datasets were based on a further experimental evaluation of binding preferences to 
consensus variants, among others, Bourdeau and collaborators focused their search on high affinity 
ERα/β binding sites (Bourdeau et al., 2004) and Wang and co-authors scanned the genome for single 
(and zero) nucleotide consensus deviants for the VDR DR3- and ER6-type REs, for which 
experimental binding data was first provided (Wang et al., 2005). 
Each of the whole genome datasets published for NR binding sites placed special importance on one 
or two parameters defining functional binding sites, namely binding strength of consensus variants, 
conservation, or contribution of the surrounding sequence. Often, the search window was defined to 
narrow down the list of predicted elements to those in the vicinity of the TSS of the respective gene. 
Promoter analysis done in earlier times (prior to the release of the whole genome) started with 
cloning of promoter fragments upstream of the TSS and scanning functional regions by mutational 
analysis. In total, this has yielded a vast list of published proximal elements. With the sequence data 
at hand, though, evidence against a positional bias is increasing. Additionally, more distal upstream 
NR binding sites have been described and, in addition, functional sites within the transcribed region, 
particularly within the introns of genes have been found. The possibility of DNA loops within 
chromatin units serves as an explanation of how such distal sites can come into contact with the TSS. 
Based on a comparative genomic analysis, this is a feature that applies to NRs. A study by Xie and 
colleagues analyzed multiple species to discover conserved TF binding sites and, interestingly, for 
certain TFs a positional bias for the proximal promoter was indeed found (Xie et al., 2005). However, 
there were also exceptions to the rule, such as NR DNA-binding motifs that were found with equal 
distribution throughout the analyzed +/-5 kB around the TSS, suggesting that location is not a 
functional constraint for NR binding sites. Each of the variables, such as requirements for binding 
strength, location, conservation and surrounding sequence, places different limits on the effectiveness 
of NR RE identification by in silico methods, but a consensus for their most efficient application is 
lacking. 
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3. Aims of the Study 
 
PPARs belong to the low ligand affinity NR group. Some structure-function relationships in the 
activation of these receptors involve major areas of uncertainty. In addition, the characterization and 
prediction of their target genes and those of other NRs including VDR has not been studied in 
sufficient detail (in terms of binding site composition) to result in reliable in silico models to 
characterize their regulomes, as explained in the literature review. 
 
Therefore the specific aims of this study were: 
 
1. To investigate the mechanism of ligand-independent CoA interaction of human PPARs. 
 
2. To characterize direct VDR and PPAR target genes of the IGFBP gene family to investigate 
possible overlap in their signaling. 
 
3. To develop reliable in silico binding site prediction methods for the identification of VDREs 
and PPREs based on the characterization of IGFBP genes. 
 
4. To correlate in silico binding site composition predictions with mRNA regulation. 
 
5. To evaluate the utility of various parameters of binding site composition for target gene 
prediction, including location relative to TSS, conservation between species, number of 
putative REs and their binding strength and test this on a genomic scale. 
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4. Materials and methods 
 
4.1 Materials 
4.1.1 Ligands 
In the following sections the roman numerals refer to the four studies forming the thesis (see page 6 
for numbering). NR ligands used in the studies are shown in Table 5. Stock solution of 1α,25(OH)2D3 
was in 2-propanol and further dilution were made in EtOH. Other compounds were stored and diluted 
in DMSO. The translation inhibitor cycloheximide was dissolved in EtOH and used in a final 
concentration of 10 μM.  
 
Table 5. NR ligands used in the studies 
Compound NR Source Used in 
1α,25(OH)2D3 VDR Dr. L. Binderup, LEO Pharma, Ballerup, Denmark I, II 
CITCO CAR Biomol, Copenhagen, Denmark I 
WY168281 PPARα Dr. P. Honkakoski, University of Kuopio, Finland I 
GW7647 PPARα Alexis Biochemicals, San Diego, CA, USA III, IV 
Rosiglitazone PPARγ Dr. M.W. Madsen, LEO Pharma, Ballerup, Denmark I, III, IV 
L783483 PPARβ/δ Dr. M.W. Madsen, LEO Pharma, Ballerup, Denmark I 
GW501516 PPARβ/δ Alexis Biochemicals, San Diego, CA, USA 
 
III, IV 
4.1.2 Cell lines 
Cell lines used and their growth conditions are described below (Table 6). Medium was 
supplemented with 2 mM L-glutamine, 0.1 mg/ml streptomycin and 100 U/ml penicillin. Cells were 
grown in humidified 95% air / 5% CO2 incubator. When split for experiment, the cells were grown 
overnight in phenol-red free DMEM supplemented with 5% charcoal-stripped fetal bovine serum 
(FBS). FBS was stripped of lipopihilic compounds by stirring it with 5% (w/v) activated charcoal 
(Sigma-Aldrich) for 3 h at room temperature (RT). Charcoal was then removed by centrifugation and 
sterile filtration. 
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Table 6. Growth conditions for the cell lines used in the studies 
Cell line Medium FBS (%) Used in 
MCF-7 α-MEM 5 I, II 
HEK293 DMEM 10 I, III, IV 
PC-3 DMEM 10 II 
SaOS-2 DMEM 10 II 
HepG2 DMEM 10 III, IV 
 
4.1.3 DNA constructs 
Protein expression constructs 
Previously sub-cloned protein expression vectors of the full-length cDNAs for human CAR (Baes et 
al., 1994), human VDR (Carlberg et al., 1993), human RXRα (Levin et al., 1992), human PPARα 
(Sher et al., 1993), human PPARγ (Schmidt et al., 1992) and human PPARβ/δ (Tontonoz et al., 1994) 
were used for mutagenesis, T7 RNA polymerase-driven in vitro transcription/translation and the 
overexpression of the respective proteins in mammalian cells. 
The NR interaction domains of mouse SRC-1 (amino acids 597 to 791) (Onate et al., 1995), human 
RAC3 (amino acids 673 to 1106) (Li et al., 1997) and human TIF-2 (amino acids 646 to 926) (Voegel 
et al., 1996) were previously subcloned into the BamHI/HindIII cloning site of the GST fusion vector 
pGEX/KGK (Amersham Biosciences, Buckinghamshire, UK). The GST fusion proteins were used in 
supershift assays. 
Reporter gene constructs 
The core sequences of the REs or RE-containing regions are indicated in the original articles. These 
were fused to the thymidine kinase (tk) promoter driving the firefly luciferase gene (LUC) in a pGL3-
derived Luciferase Reporter Vector (Promega, Madison, WI, USA). The XbaI-restriction site at 
nucleotide position 1742 had been removed from the original vector by mutagenesis. The individual 
REs were cloned as two-copy constructs of the RE into the remaining XbaI cloning site. For the 
cloning of RE-containing regions PCR primers with SacI (forward primer) and XbaI (reverse primer) 
cutting sites were used in the PCR reaction with genomic DNA as a template. After restriction 
enzyme digestion the inserts were cloned between the SacI and XbaI sites of the vector. All 
constructs were verified by sequencing. 
Site-directed mutagenesis 
Mutations produced to expression vectors are indicated in the original articles. The protein expression 
construct for PPARγ was used as a template for site-directed mutagenesis to result in specific amino 
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acids changes in the protein produced (used in I). Reporter gene constructs of RE-containing regions 
were used as a template for site-directed mutagenesis to result in nucleotide substitutions in the RE 
sequence (II, III, IV). The QuickChangeTM Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, 
USA) was used as described by the manufacturer together with oligonucleotides containing the 
mutated sequence (MWG BioTech AG, Ebersberg, Germany). Each point mutation was confirmed by 
sequencing. 
 
4.2 Methods 
4.2.1 In vitro methods 
4.2.1.1 Transfection and luciferase reporter gene assay 
Cells were seeded into six-well plates and grown overnight in cell line-specific medium (Table 5) 
supplemented with 5% (w/v) charcoal-treated FBS. Transfection methods used in the studies 
employed either N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulphate (DOTAP, 
Roth, Karlsruhe, Germany) (I, II) or polyethylenimine (PEI) (Laffitte et al.) (III, IV) to form 
liposomes. In the DOTAP method per each well 10 μg of DOTAP was incubated for 15 min at RT 
with 1 µg of the reporter plasmid and 1 µg of the pSG5-based reporter expression vector in a total 
volume of 100 µl. In the PEI method the incubation of DNA with the transfectant was preceded by a 
15 min incubation of the DNA plasmids (1 µg each) with 50 µl of 150 mM NaCl and a simultaneous 
incubation of 10 μg of PEI (Sigma-Aldrich, St. Louis, MO, USA) with 50 µl of 150 mM NaCl. 
Subsequently, the two solutions were combined and incubated another 15 min at RT. In both 
methods, phenol red-free Dulbecco’s modified Eagle’s medium (DMEM) was added to a final 
volume of 1 ml. Medium of the cells was replaced and the transfection medium added. After 4 h 
ligands were added in the indicated concentrations in phenol red-free DMEM supplemented with 5% 
FBS. 
On the next day, 16 h after ligand addition, cells were washed once with ice-cold PBS (140 mM 
NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4•2H2O) and lysed with 200 µl of reporter 
gene assay lysis buffer (Roche, Mannheim, Germany) per well. The cells were incubated for 15 min 
at RT at a rocking platform. The lysate was collected and the cell material pelleted with a 5 min 
centrifugation at 20,000 g at RT. To determine the total protein concentration, 10 µl of the lysate was 
taken and combined with 200 µl of Protein Assay buffer (Biorad, München, Germany) and 
absorbance measured at 595 nm. For luciferase activity measurement 150 µl of the lysate was 
combined with 100 µl of luciferase substrate (Luciferase Reporter Gene Assay buffer, Canberra-
Packard, Groningen, Netherlands) and measured with the Highpass filter. A 96-well plate reader 
luminometer was used for both measurements (Anthos Labtec Instruments, Wals/Salzburg, Austria). 
The luciferase activities were normalized against total protein concentration. 
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4.2.1.2 In vitro transcription and translation 
To produce nuclear receptor proteins for gelshift and supershift assays a coupled in vitro 
transcription/translation reaction was performed using their cDNA expression vectors described in 
the materials (Craig et al., 1992). Rabbit reticulocyte lysate was used as recommended by the supplier 
(Promega). 
25 µl rabbit reticulocyte lysate, nuclease treated 
1 µl amino acid mix (1 mM) 
1 µl RNasin (40 U/µl, Fermentas, Vilnius, Lithuania) 
10 µl rNTPs (5 mM) 
3 µl MgCl2 (50 mM) 
5 µl template DNA (0.4 mg/ml) 
1 µl T7 RNA polymerase (20 U/µl, Fermentas) 
4 µl H2O 
The reaction was incubated for 90 min at 30ºC. Protein amounts were quantified by test translation in 
the presence of [S35]-methionine for each protein batch produced. The concentrations of the receptor 
proteins were adjusted to approximately 4 ng/μl (10 ng is approximately 0.2 pmol) taking into 
account the number of methionine residues per protein. 
4.2.1.3 Bacterial overexpession of proteins 
For supershift assays GST-fusion proteins of SRC-1, RAC3 and TIF-2, were produced with the E. 
coli BL21(DE3)pLysS strain (Stratagene) containing the expression vector for each protein. The 
bacterial culture was stimulated with 0.25 mM isopropyl-β-D-thio-galactopyranosine for 3 h at 37ºC 
once it had reached an OD600 of 0.4 to 0.6. The GST-proteins were purified and immobilized on 
glutathione-sepharose 4B beads (Amersham-Pharmacia) according to the manufacturer’s protocol. 
Elution was performed in the presence of glutathione and proteins concentrated using Millipore 
UFV5BGC00 centrifugation filter-tubes (Millipore Corporation, Espoo, Finland). The amount of 
GST-protein required for the assays was determined empirically. 
4.2.1.4 Gelshift and supershift assays 
For gelshift and supershift assays the following reaction was incubated for 15 min at RT: 
5 µl in vitro translated proteins (10 ng) 
2.5 µl KCl (1 M) 
2 µl solvent or ligand 
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4 µl 5 x buffer (50 mM Hepes, pH 7.9; 5 mM DTT; 25% glycerol and 125 ng/µl herring sperm DNA 
(Promega)) 
5.5 µl H2O 
For supershift assays indicated amounts of the co-regulator GST fusion proteins were added to the 
reaction mixture and incubated an additional 15 min at RT. 
After the incubation (both assays), 1 ng of [P32]-labeled double-stranded oligonucleotides (50,000 
cpm) were added and incubated 15 min at RT. Protein-DNA complexes were then resolved by 
electrophoresis through 8% non-denaturating polyacrylamide gels in 0.5 x TBE (45 mM Tris, 45 mM 
boric acid, 1 mM EDTA, pH 8.3)(200 V, 105 min). The gels were dried, exposed on a 
phosphoimager screen overnight and quantified on a Fuji FLA3000 reader using ImageGauge 
software. 
4.2.2 Ex vivo methods 
4.2.2.1 RNA extraction, cDNA synthesis and real-time PCR 
Cells were seeded into 6-well plates and grown overnight to reach a density of 60-70%. The cells 
were stimulated with ligands as indicated in the individual publications. Total RNA was isolated from 
the cells using RNAeasy kit (ZymoResearch, HiSS Diagnostics GmbH, Freiburg, Germany) as 
instructed by the manufacturer. Total RNA amount was quantified (NanoDrop ND-1000, NanoDrop, 
USA) and 1 µg used in the following cDNA synthesis reaction: 
1 µl oligodT18 primer (100 pmol) 
4 µl dNTPs (5 mM) 
2 µl DTT (10 mM) 
8 µl 5 x M-MuLV buffer 
1 µl RNasin (40 U/µl, Fermentas) 
2 µl M-MuLV reverse transcriptase (20 U/µl, Fermentas) 
ad H2O to 40 µl 
The reaction was incubated for 1 h at 37ºC followed by an inactivation for 5 min at 95ºC. The cDNA 
was diluted 1:10 in H2O. 
Real-time quantitative PCR was performed in an IQ-Cycler (BioRad) using the dye SybrGreen 
(Molecular Probes, Leiden, Netherlands). The following reaction was set up: 
2 µl 10 x buffer (HotStart PCR buffer (Fermentas) used in II, III, FastTaq PCR buffer (Roche) used 
in IV) 
2.4 µl 25 mM MgCl2 (replaced with H2O for FastTaq reaction) 
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0.4 µl dNTPs (10 mM) 
1.2 µl SybrGreen (1:2500 dilution from stock) 
0.2 µl HotStart / FastTaq DNA polymerase (5 U/µl) 
4.8 µl H2O 
4 µl template cDNA 
5 µl primer mix (0.8 µM) 
PCR cycling conditions and respective primers are described in the individual papers but for most 
PCRs the following program was used:  
1. Denaturation for 5 min at 95ºC  
2. PCR amplification repeated for 40-45 cycles 
 Denaturation for 30 s at 95ºC 
 Annealing for 30 s at primer-specific annealing temperature 
 Elongation for 40 s at 72ºC 
3. Final elongation 10 min at 72ºC 
4. Denaturation for 1 min at 95ºC 
5. Melt curve analysis with 0.5ºC decrease in 70 temperature steps  
Fold inductions were calculated using the formula 2-(∆∆Ct), where ∆∆Ct is the ∆Ct(treatment)-
∆Ct(solvent),∆Ct is Ct(gene)-Ct(ARP0) and Ct is the cycle at which the threshold is crossed. PCR product 
quality was monitored using a post-PCR melt curve analysis at the end of amplification cycles. 
4.2.2.2 Chromatin immunoprecipitation assay 
Cells were seeded into culture bottles and grown overnight to reach a density of 60-70%. At the start 
of the experiment the medium in the bottles was reduced to 10 ml. The cells were stimulated with 
ligands as indicated in the individual publications (between 0.5 and 4 h). 
Cross-linking of proteins and DNA 
Formaldehyde was added to culture medium to cross-link proteins bound to DNA as follows: 
270 µl formaldehyde (final concentration of 1%), incubating for 5 min at RT (except in II for 10 min) 
1.5 μl glycine (1 M), incubating for 5 min incubation at RT (to stop the cross-linking) 
Both incubations were performed on a rocking platform. The medium was removed and the cells 
washed twice with ice-cold PBS. Subsequently, the cells were scraped into ice-cold PBS and 
centrifuged for 4 min at 700 g at 4ºC. 
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Lysis of cells and sonication 
After centrifugation the cell pellet was resuspended in 1 ml of lysis buffer (1% SDS, 10 mM EDTA, 
50 mM Tris-HCl, pH 8.1) supplemented with a protease inhibitor cocktail (Roche). Lysis was 
performed for 15 min at RT. The lysates were sonicated to result in DNA fragments ranging from 200 
to 1000 bp in length (Diagenode Bioruptor, Liege, Belgium). Cellular debris was removed by 
centrifugation for 10 min at 20,000 g at 4ºC. 
Immunocollection 
The lysates were diluted 1:10. The following incubation was carried out in presence of specific 
antibodies: 
100 µl of undiluted lysate  
5 µl (200 μg/ml) of indicated antibody 
24 µg of sonicated salmon sperm DNA 
900 µl ChIP dilution buffer (0.01% SDS, 1.1% Triton-X 100, 1.2 mM EDTA, 16.1 mM NaCl, 
protease inhibitors, 50 mM Tris-HCl, pH 8.1) 
overnight at 4ºC with rotation 
The antibodies used are described in the individual publications. For input samples, 25 µl of 
undiluted lysate was diluted with 475 µl ChIP dilution buffer and the processing of these samples was 
continued with reverse cross-linking and DNA extraction as described below. 
Collection of immunocomplexes 
The immune complexes were collected with 60 µl of Protein A agarose slurry (Upstate 
Biotechnology, Lake Placid, NY, USA) for 2 h at 4ºC. The beads were pelleted by centrifugation for 
1 min at 100 g at RT and washed for 5 min on a rotating platform with 1 ml the following buffers in 
the following order: 
1. Low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM 
Tris-HCl, pH 8.1) 
2. High salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM 
Tris-HCl, pH 8.1) 
3. LiCl wash buffer (0.25 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM 
EDTA, 10 mM Tris-HCl, pH 8.1). 
Finally, the pellets were washed twice with TE-buffer (1 mM EDTA, 10 mM Tris-HCl, pH 8.1). 
Elution and reversal of cross-linking 
Elution of immunocomplexes was performed twice with 250 µl of elution buffer (1% SDS, 100 mM 
NaHCO3) for 15 min at RT with rotation and the eluents were combined. Cross-linking was reversed 
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by an overnight incubation at 65ºC. NaCl was added to a final concentration of 200 mM into the 
incubation reaction and the incubation was followed by another incubation for 1 h at 45ºC with 
proteinase K (final concentration 40 μg/ml, Invitrogen) (II). Alternatively (used in III and IV) the 
reverse-crosslinking was done in one step with 2 μl of proteinase K (final concentration 80 μg/ml, 
Fermentas) that was active at 65ºC. 
DNA extraction 
The DNA was extracted by adding 500 μl of 25/24/1 phenol/chloroform/isoamyl alcohol followed by 
a centrifugation at 20,000 g at RT. DNA was recovered from the aqueous phase using a DNA 
extraction kit (Qiaex II Gel Extraction, Qiagen) as instructed by the manufacturer in paper II, or with 
precipitation with 0.1 volumes of 3M sodium acetate, pH 5.2 and 2 volumes of ethanol using 1 µl of 
glycogen (20 mg/ml, Fermentas) as carrier (III, IV). The output samples were dissolved into 30 µl 
H2O and the input samples into 200 µl. 
4.2.2.3 PCR of chromatin templates 
PCR conditions for primers are described in the individual papers (II, III, IV). PCR reactions were 
performed as described earlier (see ‘‘RNA extraction and real time PCR’’) in an IQ-Cycler with 
SybrGreen dye and the products resolved on 2% TAE (200 mM Tris-HCl pH 7.5, 100 mM acetate, 5 
mM EDTA) gels. The gels were imaged with Fuji FLA3000 reader using ImageGauge software. The 
melt curve analysis combined with gel imaging allowed the detection of specific primer-dimer-free 
PCR products that were used for calculating from Ct-values the quantitative data relative to controls 
(used in IV). Output samples were first normalized to their inputs and subsequently the fold change 
relative to non-specific IgG background was calculated. The fold inductions were calculated using 2-
(ΔCt), where ΔCt is Ct(specific antibody)- Ct(IgG control antibody) and Ct is the cycle at which the 
threshold is crossed. Relative association levels were calculated using 2-(10-Ct(output-input)). 
4.2.3 In vivo methods 
Eight-week-old male BALB/c x DAB2 mice (National Laboratory Animal Center, Kuopio, Finland) 
were housed in stainless steel metabolic cages under controlled temperature (21–23°C) and light 
conditions (lights on 7 a.m. to 7 p.m.). Mice had free access to water and diet ad libitum (Altromin, 
Lage, Germany) for 14 days prior to initiation of treatment. All experiments were approved by the 
Committee for the Welfare of Laboratory Animals at the University of Kuopio and conducted in 
accordance with the guidelines of the European Community Council directives 86/609/EEC. 
GW501516 was administered in saline by intraperitoneal injection (1 μg/g body weight). After 3 and 
6 h the animals were sacrificed and their livers were removed and shock frozen in liquid nitrogen. 
Liver tissue samples were pre-homogenized in lysing matrix A tubes (Bio 101, Vista, CA) using a 
Fast Prep FP120 machine (Savant Instruments, Holbrook, NY, USA). Samples were processed twice 
for 40 s at setting 6.0 with a 10 min cooling interval on ice. Afterward, the samples were cooled on 
ice for 10 min, spun down for 1 min at 2000 rpm in a bench-top centrifuge and 600 µl of the cleared 
supernatant was transferred to the Mini RNA isolation kit (ZymoResearch) columns for RNA 
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extraction. 
4.2.4 In silico methods 
4.2.4.1 Structural analysis and visualizations of the protein structures 
For visualization and structural analysis of crystal structures from the PDB, the program SwissPDB 
viewer (www.expasy.org/spdbv/) was used. This software allows the visualization of secondary 
structure elements and inter/intramolecular interactions, such as hydrogen bonding. 
4.2.4.2 In silico screening of putative PPREs  
Genomic sequences spanning +/-10 kB around the TSS (III, IV), or until the end of the gene (II), of 
the genes analyzed were extracted from the current database release (NCBI build 35 (II), Ensembl 
release 40 (III, IV) from human genome (II, III, IV) and mouse genomes (IV) (for the genes 
mSULT2A1 and mRETN a full sequence became available in the October 2006 release 41 and was 
used for the analysis). Putative VDREs/PPREs were screened from the sequence files as described in 
the individual publications (II, III, IV). Conservation of putative REs between human and mouse was 
checked (III, IV) using the Vertebrate Multiz Alignment and Conservation track available from 
UCSC genome (NCBI releases: human Feb 2006 hg18, mouse Feb 2006, mm8) (Blanchette et al., 
2004). The PPRE was marked conserved when a putative PPRE was predicted by the search in both 
species at an aligning location. Conservation of surrounding sequence was checked 50 bp upstream 
and downstream of the TSS: two occurrences of a continuous stretch of minimum five matching bp 
were required to label the PPRE to be located within conserved surrounding sequence. The human 
chr 19 and its syntenic mouse regions, used in IV, were extracted from Ensembl release 41 and 
screened for putative PPREs (medium to strong predicted binding strength) +/- 10 kB around each 
TSS. The Ensembl ortholog prediction was used to match the respective human and mouse genes. 
A list of established human PPAR target genes (used in IV) was extracted from literature with the 
following selection criteria: 1) mRNA or protein level changes in human were reported and 2) a 
PPRE was described from the human gene and 3) tested in at least gelshift, reporter gene or ChIP 
assay. 
4.2.4.3 Calculation of predicted binding strength 
Prediction of relative binding strength of PPREs (used in IV) was based on experimental gelshift 
results. Data of single nucleotide variations obtained in study III was used to classify them according 
to reduction in binding strength to three categories (IV, Table S1). Many natural sequences contain 
more than one deviation from consensus. To approximate the combination effect of variations from 
the different categories experiments were carried out with representatives from different 
combinations of these categories. An extended collection of binding strength data of PPRE-like 
sequences was used to calculate the average binding strength in each of the following combinations 
1/0/0, 0/1/0, 2/0/0, 3/0/0, 1/1/0, 0/0/1, 0/2/0, 2/1/0, 3/1/0, 4/0/0 and 1/0/1 of variations from category 
I/II/III respectively. Other combinations resulted in less than 1% average binding and were not 
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considered for the PPRE search. Assignment of each tested sequence to these combination classes 
was made according to IV, Table S1, subtype specifically. 
4.2.4.4 Clustering using self-organizing maps (SOMs) 
SOM is an artificial neural network algorithm that belongs to the unsupervised learning methods. The 
algorithm produces a mapping of high-dimensional data into two-dimensions. Therefore it is useful in 
the visualization and interpretation of large data sets (Kohonen, 1997). The map consists of a regular 
grid of processing units, or ‘‘neurons’’. These are initially assigned some arbitrary values in the data 
space and in the following iterative cycles move towards the actual data points. Three basic steps are 
repeated at the SOM algorithm until it converges: sampling, similarity matching and updating.  
1. Initialization. Choose randomly the initial weight vectors wj(0), j = 1, 2, . . . , l, of the l neurons in 
the lattice. 
- Alternatively, the weight vectors may be chosen randomly from the available input (data) vectors 
x1, . . . , xN. 
2. Sampling. Take a sample vector x(n) from the input space for the iteration n. 
3. Similarity matching. Let i(x) denote the index of best matching (winning) neuron for the sample 
vector x. 
- At iteration n, i(x) is found from the minimum Euclidean distance criterion i(x) = arg min || x(n) - 
wj||, j = 1, 2, . . . , l 
4. Updating. Update the weight vectors of all neurons using the rule wj(n + 1) = wj(n) + 
η(n)hj,i(x)(n)[x(n) - wj(n)], 
- Both the learning parameter η (n) and the neighborhood function hj,i(x)(n) are varied during 
learning.  
5. Continuation. Continue with step 2 until the feature map has converged. 
The SOM algorithm leads to a topological ordering of the feature map in the input space. Regions, in 
which the data are dense, occupy a larger domain in the output space. 
A variation of the SOM, called tree-structured SOM, was used here. In this algorithm several SOMs 
are produced that are organized hierarchically in a pyramid-like fashion in several layers. The number 
of neurons at a larger level is four times the number of the previous level. The main difference in the 
algorithm is that the neighborhood function has been reduced to a fixed form, where always the four 
adjacent neurons of the best matching unit form the neighborhood that gets updated. The lower levels 
of the map give a coarse mapping of the data, with fine structure and clusters emerge as more neurons 
are included in the map. 
4.2.4.5 Sammon’s mapping 
The aim of Sammon’s mapping is similar to that of SOM, to represent points from an n-dimensional 
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space in 2-dimensions. Compared to SOM, some more accurate projection is produced where the 
conservation of the original structure is maximized. This quality means that the mapping is able to 
represent the relative distances of vectors and is useful in determining the shape of clusters and 
relative distances between them. The calculation of the map, however, is more time consuming. This 
can be solved by applying SOM before Sammon’s algorithm, where the SOM has achieved data 
reduction by replacing the original data vectors with fewer representative reference vectors. 
A version of the Visual Data software (Visipoint, Kuopio, Finland), whose core is based a tree-
structured SOM, was used (Koikkalainen, 1994). SOM was applied to cluster binding site 
composition data of target genes with the aim to separate the genes based on number of 
medium/strong binding sites and conservation pattern of all binding sites. This dataset consisted of 
six variables. The first two variables BSH and BSM represented the sum of predicted binding strength 
of n putative medium/strong PPREs found within the 20 kB of the analyzed region, in human and 
mouse respectively. The maximum of the subtype-specific predicted values was chosen for each 
PPRE. BS = bs1 + bs2 +… +bsn, where bsi = max {bsα, bsγ, bsδ}. The remaining four values 
represent conservation patterns. Binary values were used, where 0 denotes absence of conserved 
binding sites and 1 presence of them: CSH = conserved medium/strong binding sites in human, CWH = 
conserved weak binding sites in human, CSM = conserved medium/strong binding sites in mouse, 
CWM = conserved weak binding sites in mouse. Prior to SOM initialization, all variables were scaled 
between 0 and 1. The maximal resolution was set to 256. An initial coarse map at resolution of 4 was 
used in cluster assignment and assessment of their separation was done using Sammon’s mapping. 
The final clustering of the gene data was based on the 256-map and respective Sammons mapping, 
with the cluster numbering referring to original cluster at the low-resolution map. 
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5. Results 
 
5.1 Ligand-independent association of human PPARs with CoAs 
The positioning of the last α-helix of NRs, H12, has a critical role in the association with CoAs and 
the subsequent transactivation events. Comparison of NR crystal structures shows that this part of the 
receptor undergoes largest conformation changes upon activation. In the case of many receptors, such 
changes happen upon ligand binding (as is evident from structural differences between unbound apo-
structures and those crystallized with an activating ligand, or agonist). However, some NRs are 
characterized to have constitutive activity, which can be attributed to an ability to achieve the active 
conformation (and H12 positioning) without a ligand. Consequently, these receptors can associate 
with CoAs in a ligand-independent fashion. 
PPAR ligands are known to directly contribute to the stabilization of the active conformation by a 
direct contact made between the molecules and the H12 of the receptor. However, a structural 
comparison of the positioning of H12 in the apo-structures of PPARγ and β/δ and NRs with known 
constitutive activity (LRH-1 and ERRγ) revealed a surprising similarity in the positioning of the helix 
(I, Fig. 1A). Furthermore, as the apo-PPARγ structure was superimposed with the respective agonist-
bound structure, the critical separation of the charge clamp residues, K329 and E499, was preserved 
in the apo-structure (I, Fig. 1B and C). This structural feature suggested that the CoA interface is 
preserved in the unliganded receptor. 
The closest NR relative to the PPARs, with characterized constitutive activity, is CAR.  
Unfortunately, at the time of this study, a CAR crystal structure was not available for direct structural 
comparisons. However, this receptor, whose constitutive activity we had addressed in earlier studies 
(Frank et al., 2004), was included into a comparative panel to assess the CoA association of PPARs, 
together with VDR, a NR that does not bind these proteins in the absence of ligand. 
Supershift experiments with members of the p160 CoAs SRC-1, TIF-2 and RAC3, demonstrated that 
all PPARs were able to interact in absence of ligand (I, Fig. 2A), with RAC3 showing the most 
prominent interaction. Addition of ligand enhanced the interaction, however the effect was minor.  
The association of PPARγ was compared to that of CAR and VDR with increasing concentrations of 
GST-RAC3 protein (I, Fig. 2B). Without a ligand, CAR associated already with the lowest 
concentrations, whereas VDR did not associate at all. PPARγ had an intermediate profile that 
demonstrated its ability to interact with CoAs without a ligand. Addition of a ligand had no effect on 
CAR, a minor effect on PPARγ and a drastic effect on VDR that enabled its association, even with 
the lowest CoA concentrations tested. The stabilization of an active conformation of PPARs, ligand-
independently, was also apparent from the limited protease digestion assays performed (I, Fig. 2D). 
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Whereas the binding of a specific ligand was necessary for the stabilization of the LBD of the VDR 
(presence of c1-band), this was not needed for CAR and of limited effect concerning PPARγ. 
Next, the basal activity and ligand-inducibility of the chosen NRs, were compared using cell-based 
assays. Two cell lines, the human breast cancer cell line MCF-7 and the human embryonic kidney 
cell line HEK293, were used. The cells were transfected with a luciferase reporter construct bearing 
four copies of the characterized DR1-type RE, derived from the human CPTIβ gene promoter (for 
PPAR binding), two copies of the DR4-type RE from rat pituitary specific 1, Pit-1, promoter (for 
CAR binding), or four copies of the DR3-type VDRE of the rat atrial natriuretic factor (ANF) and 
the respective expression constructs (I, Fig. 3A-D). High activity levels in absence of ligand were 
seen in both cell lines in case of both CAR and PPARs, but not in case of VDR. Addition of ligand 
showed a 36- and 74-fold increase in activity levels with VDR, CAR was stimulated maximally 1.8-
fold and PPAR agonists reached a 3.5-fold maximum (PPARβ/δ agonist). To show that this effect 
was not due to presence of endogenous PPAR agonists in the cells, we overexpressed the CoR 
NCoR1. A significant decrease in activity levels was observed. However, this effect was reversed by 
the addition of strong agonists, such as rosiglitazone in the case of PPARγ. 
In conclusion, ligand-independent association of PPARs with CoAs was shown in vitro with 
supershift and LPD assays and with transfection assays in living cells.  
 
5.2 Structural determinants of H12 stabilization in PPARs 
Structural in silico analysis of the apo- and agonist-bound PPAR structures was used to derive 
candidate amino acids responsible for the ligand-independent CoA association. Mutants were 
subsequently prepared to test their significance in transfection and supershift experiments (I, Figs. 4-
6). Candidate amino acids were assigned to four groups, based on which type of stabilization they 
provide (PPARγ2 numbering is used for the residues). The two first groups contain amino acids 
identified to contribute to H12 stabilization (I, Fig. 4). The first group consists of K329 and E499 that 
stabilize the active conformation both ligand-dependently and -independently. Mutation of either of 
these amino acids abolishes the CoA interaction and the luciferase activity levels of the mutant 
receptors, inside cells, decreases dramatically. The residual activity level was comparable to that of a 
H12 deletion mutant (30% versus 25%). This remaining activity suggests that interactions with other 
types of CoAs that associate with other parts of the receptor, such as the AF-1 domain, are possible 
and contribute to the normal functioning of PPARγ. The second group consists of K347 and D503, 
which interact directly with each other and contact the CoA peptide. These residues were shown to 
affect the ligand-independent association of the NR with CoAs only. 
The third group includes residues involved in the heterodimerization of PPARγ and RXR, in addition 
to their role in the direct stabilization of H12 (I, Fig. 5). The charged amino acids, E352, D424, R425 
and R471, form salt bridge pairs that stabilize the tertiary structure and are strictly conserved in all 
heterodimerizing NRs. Y505 is in turn hydrogen bonded to these residues providing a structural link 
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between the heterodimerization interface and H12 stabilization. The individual mutations of these 
residues reduced basal activities to between 45 and 80% of the wild type receptor value and are all 
ligand-responsive. 
The residues in the last group, H351, Y355, H477 and Y501, contact the ligand (rosiglitazone) and 
additionally form an extensive hydrogen bond network in the absence of agonist (I, Fig. 6). In effect, 
they are responsible for both ligand-dependent and -independent stabilization. The mutants showed 
slightly lower basal activity (80%) and reduction in ligand-binding ability (45%). These mutants 
include the mutation of Y501, the residue responsible for the direct ligand-H12 interaction. However, 
much stronger effects were seen with its hydrogen-bonding partner H477. 
A sequence comparison with PPARα and β/δ shows that all of these residues identified for the 
stabilization of H12 in PPARγ are conserved (I, Fig. 7). Further, phylogenetic trees based on 
sequence alignments of NR H12 residues (8 last residues) demonstrate that H12 of PPARs resembles 
most that of CAR (Fig. 8). In conclusion, the four groups of amino acids described are responsible for 
the ligand-independent stabilization of H12 in PPARs and the phylogeny supports the conclusion that 
the structural and functional features of the H12 of PPARs most resemble those of the constitutively 
active receptor CAR.  
 
5.3 Identification of direct VDR and PPAR target genes within the 
IGFBP gene family 
A number of NRs have been reported to regulate the IGFBP gene family members, suggesting a 
central role for this family in NR driven physiology. In total, this gene family has six members and of 
which two pairs, IGFBP-1 and IGFBP-3 (on human chr 7) and IGFBP-2 and IGFBP-5 (human chr 
2), are direct genomic neighbors to each other, oriented in a tail-to-tail direction. Previous studies 
indicated that the IGFBP-3 gene is a direct VDR target gene and the protein product was shown to 
play a role in mediating the anti-proliferative effects of 1α,25(OH)2D3. Briefly, the physiological role 
of this gene family is in the regulation of the bioavailability of the circulating growth factors IGF-I 
and IGF-II and in the regulation of their effect on membrane signaling (Kelley et al., 1996). 
Additionally, the IGFBP-1 gene has been characterized as a marker for metabolic diseases, fitting 
with the PPAR regulatory domain (Gibson et al., 1996). Less evidence for the regulation of family 
members by PPARs is available, though, one research team has shown evidence for IGFBP-1 gene 
regulation by PPARγ ligands in the ovary (Seto-Young et al., 2005). However, this effect may be 
mediated by the NR PXR (Hilding et al., 2003). Since several IGFBP family members exist and 
multiple isotypes may be expressed in a given tissue, the overall physiological effect could reflect 
regulation of multiple members, rather than just one. Therefore, in the following studies we tested the 
responsiveness of all members of this family to VDR (II) and PPAR (III) ligands. Additionally, we 
expected that some members may be differentially responsive to these NRs, making the gene family 
an interesting test set to try to correlate the mRNA inducibility with binding site composition as 
revealed by in silico search of VDREs and PPREs. 
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5.3.1 Regulation of IGFBPs by VDR 
The two cell lines used in this study (II) were the prostate cancer cell line PC-3 and the osteosarcoma 
cell line SaOS-2. The expression of all family members was confirmed by quantitative, real-time 
PCR from both cell lines (II, Fig. 1A and B) and the relative expression levels showed that IGFBP-4 
and IGFBP-6 were the highest expressed. In PC-3 cells, IGFBP-2 and especially IGFBP-5, had 
relatively low expression, whilst IGFBP-1 and IGFBP-3 had moderate expression levels. While all 
members were also expressed in SaOS-2, the differences were less pronounced. To exclude possible 
secondary effects arising from the induction of these genes on account of primary 1α,25(OH)2D3 
target gene stimulation, the inductions of the family members were tested both in the presence and 
absence of the protein translation inhibitor cycloheximide at 24 h (II, Fig. 1C and D). The induction 
pattern was compared to that of p27, which is known not be a gene that is directly regulated by VDR. 
As seen from both cell lines, IGFBP-1, IGFBP-3 and IGFBP-5 responded in the presence and 
absence of cycloheximide, while inductions of IGFBP-4 and IGFBP-6 (only observed in SaOS-2) 
were abolished by the cycloheximide treatment. Additionally, IGFBP-1, IGFBP-3 and IGFBP-5 were 
the only family members that were inducible with shorter treatments, a typical characteristic of direct 
target genes. In conclusion, we identified three responsive family members that are likely direct 
targets and three non-responsive members. 
In order to search for possible VDREs in the regulatory regions of these IGFBP genes, we analyzed a 
list of known natural VDREs (>15) and obtained on that basis the consensus sequence RGDKYR (R 
= G or A, D = A, G or T, K = G or T, Y = C or T) which we searched for REs in DR3-, DR4- and 
ER6- to ER9-orientations (orientations were based on our previous in vitro studies) from the IGFBP 
gene areas (II, Fig.2). We included 10 kB of promoter sequence and the coding sequence (until end of 
last exon). Additionally, for the gene pairs IGFBP-1 and IGFBP-3 and IGFBP-2 and IGFBP-5, we 
analyzed their intergenic region. Moreover, only candidate VDREs, formed of hexamers with 
maximal two deviations from the optimal RGKTCA core sequence, were included. Additionally 
putative VDREs located in Alu repetitive sequence elements were excluded due to the high likelihood 
that they mostly lye within closed chromatin are inactive (Kondo and Issa, 2003). With these filtering 
conditions, we found several putative VDREs from the promoters of the genes IGFBP-1, IGFBP-3 
and IGFBP-5. The IGFBP-5 gene also had an element in its first intron, in addition two putative 
VDREs were located further in the first intron of IGFBP-2. Furthermore, both intergenic regions 
analyzed contained two putative VDREs. In contrast, IGFBP-4 and IGFBP-6 contained no VDREs 
that passed our criteria. 
Next, we tested whether the putative VDREs (15 in total, out of which one contained a SNP that 
resulted in two alternative forms of that VDRE) were able to bind the receptor in transactivation 
assays. The MCF-7 cell line was used for comparison together with the cell lines PC-3 and SaOS-2. 
Each candidate VDRE was cloned in two copies into a luciferase reporter construct and the 
inductions compared to that of the known rat ANF DR3-type VDRE (II, Fig 3). Overall, higher 
inductions were obtained in the MCF-7 cell line, otherwise similar effects were observed: REs 2, 8 
and 13 (for numbering refer to II, Fig. 2) were comparably or higher induced, relative to the reference 
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VDRE, the SNP variation of RE13 lost responsiveness compared to the more common variant but yet 
was functional and additionally REs 3, 4, 5, 9, 10 and 14 were induced 5- to 13-fold indicating that 
they could also function as VDREs. These VDREs are located in the vicinity of the responsive 
IGFBP family members (II, Fig. 2). However, both IGFBP-2 intronic elements were shown to be 
able to function as VDREs as well. REs 3, 8 and 9 are DR3-type REs, where as REs 10 and 14 are 
DR4-type REs (II, Table 1). Importantly, these results show that ER7- (REs 2, 4, 5) and ER9-type 
(RE13) REs can function as VDREs.  
The binding of VDR-RXR heterodimers to these putative VDRE sequences was also assayed with 
gelshifts (Fig. 4). Again the rat ANF gene DR3-type VDRE served as a reference. The results were in 
accordance with the transactivation assays concerning REs 2, 4, 5, 8, 9, 10 and 13 (both variations). 
Of these, REs 2, 4, 5, 8, 9 and 13 bound stronger than the reference RE. The ER11-type RE created 
from RE13 by the SNP bound 44% relative to the ER9-type variant. Together with the transactivation 
results, this suggests that VDR-RXR indeed has the capacity to bind a large variety of ER-type 
elements. Two REs (3 and 14) that were functional in the transactivation assay bound VDR-RXR 
24% and 11%, respectively, and would therefore be considered too weak to be efficient VDREs 
based on earlier in vitro criteria (Toell et al., 2000). In summary, our in silico search identified a 
number of strong VDREs and overall a good correlation with both methods was obtained concerning 
functionality of the predicted VDREs. Only in case of two REs (11,15), their functionality was only 
evident from one assay (gelshift).  
To assess the functionality of these elements in authentic chromatin contexts, ChIP assays were 
performed (II, Figs. 5A-C). Chromatin was extracted from PC-3 cells treated for 0.5, 1, 2, 3 and 4 h 
with 1α,25(OH)2D3. Input lanes serve as control of similar detection capacity of the primers and IgG 
and p53 antibodies were used as unspecific controls. Even though the in vitro assays already 
suggested that multiple VDREs had been identified that could serve as functional binding sites, 
surprisingly many regions associated with VDR in the ChIP assay as well and only REs 11, 12 and 15 
failed to do so. Several regions (2, 3, 6/7, 8, 9, 10, 13 and 14) bound the receptor in the absence of a 
ligand. Modulation in the binding was seen for regions 2, 8, 9 and 10, with association reaching a 
maximum at 120 min and stronger yet for regions 1, 4 and 5. Further ChIP assays were carried out to 
assess the occupancy of these sites by other regulatory proteins. The binding of RXRα was seen in all 
regions (apart from RE1) that associated with VDR. The CoR SMRT was detected at 8 of 10 regions 
that associated with VDR-RXR in the absence of ligand and reappeared at regions 4, 5, 13 and 14 at 
later timepoints. CoA binding (SRC-1) was seen 0.5-2 h after ligand treatment. However, both co-
regulators had an individual profile for their association to different regions. In contrast, the 
association of the mediator protein and p-PolII was timely coordinated for all regions, occurring 1 to 
2 h after ligand treatment and persisting for approximately 1 h. Taken together, the IGFBP-1/IGFBP-
3 and IGFBP-2/IGFBP-5 gene clusters contain 10 VDR- and RXR-associated regions (2, 3, 4, 5, 6/7, 
8, 9, 10, 13 and 14), which each show an individual, ligand-dependent profile of SMRT, SRC-1, 
TRAP220 and p-PolII binding. 
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Since the two REs located in the intron of IGFBP-2 showed functionality in all of the assays 
described above, this raised the question, whether they are involved in the regulation of the IGFBP-2 
gene that is greater than 17 kB away, or may regulate the even more distal IGFBP-5. The answer to 
this question was provided indirectly by assessing with ChIP assays the VDR association with the 
TSS regions (II, Fig. 5C). VDR interaction was found on the TSS of IGFBP-1, IGFBP-3 and IGFBP-
5 and not on the TSS of IGFBP-2, which confirmed the real-time PCR data that showed that these 
three genes and not IGFBP-2, are VDR regulated. 
In conclusion, the in silico analysis performed well to detect putative VDREs and was in good 
correlation with the real-time PCR analysis assessing the regulation of mRNA levels of the IGFBP 
family members.  
5.3.2 Regulation of the IGFBPs by PPARs 
None of the IGFBPs had been characterized as direct PPAR targets at the time of the study. 
Therefore, we selected as a starting point the IGFBP-1 gene for further analysis, for which already 
some evidence for regulation existed. Using HepG2 cells treated with specific agonists for the three 
subtypes, we showed that the IGFBP-1 mRNA level was induced 2- to 3-fold in an early time-course 
experiment. The effect was also seen in mouse liver tissue obtained from mice treated with the 
PPARβ/δ agonist GW501516 (III, Fig. 1). The induction levels were comparable with the known 
PPAR target gene CPT1α. 
For the purpose of developing an efficient binding site search for PPREs, we evaluated the binding of 
the three subtypes to single nucleotide variations of the consensus PPRE, AGGTCAaAGGTCA (III, 
Fig. S1). This resulted in a categorization of the binding variations into three classes I (able to bind 75 
+/- 15% of consensus RE), II (45 +/- 15%) and III (15 +/- 15%). We used this classification to 
identify tolerated combinations of variations, using gelshift data on 10 published PPREs (III, Table 
S3) and an additional set of PPRE-like sequences (data not shown). Based on this data, we formulated 
an in silico search, where all putative PPREs that deviated maximally by three variations of class I 
combined with one from class II (if these were on the same site and the other hexamer fitted the 
consensus) or less variations (only one variation from class III was allowed and maximally two from 
class II) were identified. 
A 20 kB region, centered around the TSS of the human IGFBP-1 gene, was analyzed in silico, which 
resulted in 5 putative PPREs (III, Figs. 2A). The binding of PPARs to these REs was examined with 
gelshift assays (III, Figs. 2B-D) and this revealed that most of the sites identified were fairly weak 
PPREs (binding 1 to 17% relative to the CPT1 PPRE used as reference), as was expected from the 
number and variation class of consensus variations in their sequences (III, Table 1). In general, the 
binding of PPARγ was stronger to each element than that of PPARα or PPARβ/δ. 
Based on the gelshift data alone it seemed that only very weak associations with PPARs would be 
mediated by the PPREs identified. Next, the HepG2 cell line was used to test, whether this held true 
also for the associations in ChIP (III, Fig.3). An initial panel showing association with all PPARs (III, 
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Fig.3A) revealed that only the two promoter elements (RE1, RE2) associated with the receptor ex 
vivo. The association on RE2 was detected ligand-independently, whereas PPARs appeared on RE1 
only after respective ligand stimulations (2 h). The specific ligands seemed to favor the association of 
their respective subtype on RE2 (except with no change in the PPARβ/δ association level was seen 
with PPARα agonist). In contrast, only a few bands in RE3 and 4 were detected, these are likely 
attributable to non-specific background. No signal was detected from the strongest in vitro PPRE 
containing region 5, or the control region that contained no PPRE. In addition, the association of 
other regulatory proteins was evaluated with a longer time course of PPARα treatment. RE1 was 
shown to associate with a restricted panel of regulatory proteins (PPARα, RXRα and p-PolII), 
whereas RE2 associated with the full set of proteins tested (TRAP220, PGC-1α, RAC3 and NCoR1, 
in addition to the ones mentioned). The association of RXRα, p-PolII, TRAP220 and both CoAs were 
strongest at 120 min, in contrast to the diminished NCoR1 signal at this time point. At time point 0 
min and at some later time points, simultaneous occupancy by both CoAs and CoRs was observed. 
However, based on the co-factor code such a co-existence is possible (Rosenfeld et al., 2006). 
Additionally, the results indicate that ligand-independent CoA association occurs in living cells. The 
structural explanation for this effect was explored in study I. 
The regions that were found associating with PPARs in ChIP (around RE1 and 2) were cloned into 
luciferase expression vectors that were co-transfected with and without the corresponding PPAR 
isotype and RXRα into HepG2 cells and compared with PPRE containing region of the human CPT1 
gene promoter (III, Fig. 4). Both the IGFBP-1 and the CPT1 promoter region constructs 
demonstrated a higher basal activity relative to the empty vector already in the absence of 
overexpressed NRs and this activity was further increased with the introduction of excess PPAR and 
RXRα. Furthermore, mutations of the critical 6th position of the PPAR binding hexamer (changing A 
to G) in the promoter region containing constructs, resulted in a significant loss of activity (both for 
RE1 and RE2). The mutation into the CPT1 construct was introduced at a less critical position (7th 
position, A to T) and had a minor effect on the resulting luciferase activity. Significant ligand-
responses were detected with all PPARs on RE2, whereas only the PPARβ/δ ligand induced RE1. In 
conclusion, RE1 and RE2 both contribute to the activation of the IGFBP-1 promoter, with RE2 
having a more prominent role. 
The successful identification of functional PPREs from the IGFBP-1 gene prompted us to screen the 
regulatory regions of the five other human IGFBP gene family members in a similar fashion. Five 
putative PPREs were identified from the promoter of the gene IGFBP-2, two from the IGFBP-3 gene, 
one from the IGFBP-4 gene, three from the IGFBP-5 gene and seven from the IGFBP-6 gene. Based 
on the in silico result, IGFBP-2, IGFBP-5 and IGFBP-6 seemed therefore likely to be regulated, 
whereas IGFBP-3 and IGFBP-4 did not. This prediction was tested by monitoring the PPAR 
occupancy of the TSS regions of these five genes (and of IGFBP-1 as reference) with ChIP ex vivo 
(III, Fig. 5). Template from HepG2 cells was used, except in case of IGFBP-5 that was not expressed 
in HepG2 cells. Instead, we used the HEK293 kidney cell line to derive the chromatin 
immunoprecipitates. Additionally, the HEK293 template served as a control for IGFBP-1 TSS, since 
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the IGFBP-1 gene was not expressed in HEK293. The result confirmed the prediction that PPARs are 
associated with the promoters of the human IGFBP-1, IGFBP-2, IGFBP-5 and IGFBP -6 genes. 
PPARα associated both in absence and presence of its ligand, whereas modulation was in most cases 
seen for PPARγ and PPARβ/δ association. PPARβ/δ recruitment was most dependent on its ligand 
and in the case, of the PPARγ recruitment to the human IGFBP-6 gene promoter, ligand addition 
abolished the association with the TSS region. None of the PPAR isotypes were detected on the 
IGFBP-3 and IGFBP-4 TSS containing regions. Similarly, neither on the IGFBP-1 gene TSS in 
HEK293 cells, nor on the IGFBP-5 gene TSS PPAR binding was detectable. 
The success of the in silico prediction was also verified by real-time PCR in HEK293 and HepG2 cell 
lines (III, Fig. 6). In HepG2 cells, IGFBP-2 gene expression was induced at 4 h with all PPAR 
isotype selective ligands, whereas IGFBP-6 gene expression was significantly down-regulated at the 
2 h time point with PPARβ/δ ligand (GW501516) stimulation. Very similar effects were seen in 
HEK293: IGFBP-2 induction reached significance at 4 h and in this cell line all PPARs down-
regulated IGFBP-6 gene expression levels, though at different time points. IGFBP-5, the gene that 
was not expressed in HepG2 cells, was regulated significantly, already at 2 h. In neither of the cell 
lines, significant regulation of IGFBP-3 and IGFBP-4 gene expression was detected. 
In summary, these two studies (II and III) identified and characterized three direct VDR targets and 
four PPAR targets, of which direct PPAR-mediated regulation was characterized in detail for IGFBP-
1, amongst the IGFBP gene family. Of these, IGFBP-1 and IGFBP-5 are shared targets of VDR and 
PPAR activation. Moreover, the results indicate a clear correlation with in silico VDRE/PPRE 
predictions and regulations of mRNA levels by the respective receptors. 
 
5.4 Meta-analysis of the binding site composition of human PPAR 
target genes 
The basis of efficient in silico predictions of binding sites and target genes is a detailed understanding 
of target gene properties on sequence level. The characterization of PPREs from regulated gene 
promoters has resulted in a large collection of PPREs that deviate significantly from the consensus 
sequence. The ubiquity of such PPRE-like sequences on a whole genome level is in contrast to the 
number potential PPAR target genes in a physiological context (a few thousand per tissue) and the 
number of receptor molecules (estimates varying from few thousand per cell to values below hundred 
thousand). A recent effort to better model the binding preferences of PPARs used position weight 
matrices to describe all published PPREs (Lemay and Hwang, 2006). However, such an approach has 
limited ability to predict bona fide PPAR binding. In addition to binding strength, a number of 
additional parameters can be named that could influence binding site functionality. One common 
trend in the location of binding sites is a positional bias towards the TSS. This would be apparent 
from the collection of identified PPREs, but as discussed before is in contrast with a multi-genome 
comparison of NR binding site distribution (Xie et al., 2005). Further, a common approach for the 
detection of functional binding sites is to rely on conservation. However, the maintenance of 
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responsiveness may not require conservation of exact binding site composition as exemplified before 
with the Drosophila eve enhancer. The evolutionary models governing the preservation or turnover of 
binding sites have not been studied in detail, however as limits they will influence the design of in 
silico search methods. Therefore, in this study we aimed to explore the binding site composition of 
PPAR target genes and evaluate the contribution of each parameter mentioned, namely binding 
strength, location bias and conservation models. 
At first we addressed the problem of relating binding site predictions with binding strength. This is 
not achieved in weight matrices and also fails when the number of variations increases with the 
affinity matrix approach. Therefore, we created based on experimental data a classification scheme 
that can approximate the binding resulting from the combinations of several variations. Each single 
variation from the consensus sequence had been evaluated earlier (III, Fig. S1) and resulted in a 
classification of variations to three classes (IV, Table S1) subtype specifically. A total of 116 
sequences containing different variations from the AGGTCAaAGGTCA consensus sequence were 
classified according to Table S1 to the variation categories (number of variations from Class I, 
number of variations from Class II and number of variations from Class III) (IV, Table S2). The 
binding of PPARs to these sequences was tested with gelshift. The combinations 1/0/0, 2/0/0 and 
0/1/0 are strong PPREs with 68, 40 and 44% binding respectively. Medium strength PPREs contain 
3/0/0 or 1/1/0 variations resulting in 31 and 25% of binding. In addition, the combinations of 0/0/1, 
0/2/0, 1/2/0, 1/0/1, 3/1/0 and 4/0/0 still resulted in observed binding (on average above 1%). Other 
combinations resulted in less than 1% average binding and were not considered. The standard 
deviations within the categories were between 1 and 15%, which suggest that good accuracy level 
can be reached with the prediction scheme. 
We chose to address the contribution of binding strength, location and conservation with eight known 
PPAR target genes in detail. The selected genes contain the known up-regulated targets ACOX1 
(Varanasi et al., 1996), CPT1B (Mascaro et al., 1998) and PPARα (Pineda et al., 2002). The 
downregulated APOC3 (Hertz et al., 1995) was included for comparison and in addition genes that 
contain unusual location or type of PPRE were selected: sulfotransferase 2A1 (SULT2A1) has a distal 
PPRE (Fang et al., 2005), ANGPLT4 PPRE is inside an intron (Kersten et al., 2000) and RVRα PPRE 
is a DR2-type element (Fontaine et al., 2003). In addition, we included one regulated gene for which 
no PPRE has been described, UCP3 (Son et al., 2001), in order to test whether we could predict and 
verify the regulatory regions of this gene. The regulation of these genes was confirmed in our cellular 
models HEK293 and HepG2 (IV, Fig. S1). Each responded in both cell lines (APOC3 was not 
expressed in HEK293). 
These eight genes were analyzed in silico for PPREs within 10 kB from their TSS (IV, Fig. 1). All 
PPRE categories that included PPREs with 5% or more binding for each subtype are shown. Those 
categories resulting in 1-5% of binding (1/0/1, 3/1/0, 4/0/0) are only indicated if the PPREs were 
conserved in mouse. For each PPRE the height of the bars indicates predicted binding strength, as 
determined based on the experimental binding data set. In total 46 PPREs were found with roughly an 
equal distribution relative to the TSS, ten PPREs were conserved in mouse and further six were inside 
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conserved area (evaluated based on the surrounding sequence 50 bp left and right of the PPRE). The 
published DR1-type PPREs were successfully identified from the other genes, except ACOX1. 
However, the non-functionality of this ACOX PPRE has been reported (Woodyatt et al., 1999). In that 
study it was claimed that the human ACOX1 gene may not be at all a PPAR target, whereas here we 
show that the gene is regulated by PPARs and suggest five alternative binding sites, of which one is 
located in an evolutionary conserved area of intron 1. The in silico prediction of binding strength was 
confirmed for the UCP3 PPREs. This resulted in 16 out of 18 values to match the prediction with a 
deviation of less than 15%. The predictions of PPARγ and PPARβ/δ were all accurate while the two 
deviating values were underestimated for PPARα. 
To evaluate further the functionality parameters we chose PPRE containing regions from these genes 
based on their location. Ten PPREs close to TSS (within one kB), ten further upstream and ten further 
downstream were selected. This resulted in 23 genomic regions that were cloned to luciferase 
reporter constructs (indicated in IV, Fig.1). The activity of the constructs in absence or presence of 
PPAR subtype expression vectors in response to PPAR subtype-specific ligands was tested by 
reporter gene assays in HEK293 and HepG2 cells (IV, Fig. 2). With the exception of the TSS of the 
RVRα gene, containing the DR2-type PPRE, eight of the proximal regions showed in at least one of 
the two cell lines significant inducibility by PPAR ligands. The region of the CPT1B gene region was 
inducible by all three PPAR subtype-specific ligands in both cell lines, whereas the seven other 
regions show a PPAR subtype- and cell type-specific profile. An increase of basal activity compared 
to empty cloning vector and its subsequent loss due to PPAR overexpression was observed with the 
proximal regions of the genes APOC3 and UPC3 in both cell lines and in addition in HepG2 cells 
with the intron 1 region of the ACOX1 gene and the proximal region of the APOA1 gene. A similar 
observation was made with the distal regions of the genes ANGPLT4, APOC3 and PPARα. From the 
upstream regions the region of the SULT2A1 gene was most active. In both cell lines the 
overexpression of PPARs clearly increased its basal activity and in addition a significant inducibility 
by all three PPAR ligands was observed. A similar observation was made in HepG2 cells for the 
distal region of the UCP3 gene, whereas in HEK293 cells response of this region was far more 
modest. In contrast, neither the distal regions of the genes ACOX1 and RVRα nor the region 
containing the published PPRE of the ACOX1 gene displayed any inducibility by PPAR ligands in 
any of the two cells lines. In addition, the distal regions of the genes ANGPTL4 and APOC3 were 
only inducible in HEK293 cells, whereas the PPARα gene responded only in HepG2 cells to 
GW501516 treatment. Within the five downstream regions the intron 2 region of the ACOX1 gene 
and the cluster region of the ANGPTL4 gene (containing four putative PPREs) showed in both cell 
lines a clear response to all three PPAR ligands, whereas the inducibility of the intronic region of the 
APOC3 gene was far more modest. Individual mutagenesis of the ANGPLT4 REs was carried out 
which demonstrated that the other REs in addition to the published RE contribute to the 
responsiveness of this region (data not shown). Finally, the cluster and intronic region of the UCP3 
gene responded only in HEK293 cells to GW501516 treatment. 
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The same 23 genomic regions were investigated by ChIP assays with chromatin extracts from 
HEK293 cells (or from HepG2 cells for regions from the APOC3 gene) that had been treated with 
solvent or for 120 min with the PPARα ligand GW7647 (IV, Fig. 3). We assessed these regions for 
the binding of PPARα, its partner receptor RXRα and p-PolII, i.e. for a sign for a direct link to the 
TSS. Chromatin templates were analyzed by quantitative real-time PCR and the specificity of the 
antibodies for the three proteins was compared with the non-specific background binding to IgG. 
From the 23 tested regions the region of the CPT1B gene, the distal and published region of the 
ACOX1 gene, the distal 1, distal 2 and intronic region of the APOC3 gene and the cluster of the 
UCP3 gene did not show a specific binding of any of the three proteins. For the two regions of the 
ACOX1 gene this result confirmed their failure in the functionality test (IV, Fig. 2). The 16 other 
regions showed a significant association with PPARα in the presence of ligand. However, no 
statistically significant binding of p-PolII, neither in absence nor presence of ligand, was found in the 
published region of the APOC3 gene and in the distal regions of the genes ANGPTL4 and 
RVRα.When comparing the relative association levels of PPARα under this condition, we found most 
prominent binding to the region of the SULT2A1 gene, followed by the regions of the RVRα TSS and 
the proximal region of the PPARα gene (Fig. 3D). The latter two regions as well as the proximal 
regions of the genes APOA1 and UCP3, the distal region of the RVRα gene and the distal and intronic 
region of the UCP3 gene displayed a ligand-independent binding of PPARα.  
In summary, from the 23 investigated genomic regions 17 show in HEK293 cells and 14 in HepG2 
cells a significant inducibility by PPAR ligands. Twelve of these regions also associate in ChIP with 
PPARα, RXRα and p-PolII. Surprisingly, the most responsive regions are located either in far 
upstream or downstream areas of the genes. These results indicate that PPREs do not exhibit a strong 
positional bias towards the TSS. In addition, no preference of evolutionary conserved PPREs was 
found, but each of the genes contains at least one medium or strong PPRE. Three of the 12 fully 
functional regions, the ANGPTL4 cluster region, the proximal region of the PPARα gene and the 
distal region of the SULT2A1 gene, were already known before, but for the genes ACOX1, APOC3, 
RVRα,  and PPARα alternative/additional regulatory regions were identified. Finally, for the the 
UCP3 gene, for which so far no regulatory region was know, we identified three functional regions. 
To extend the conclusions based on these eight genes, we extracted further 30 genes from literature 
that are known to respond to PPARs in humans (the criteria for selection required that regulation was 
shown in mRNA or protein level in humans and the human PPRE was evaluated in gelshift, reporter 
gene assay, or ChIP experiments). Each gene was analyzed in silico the same way as before. The 
orthologous mouse gene was included for comparison in order to identify traces of binding site 
evolutionary patterns. From these gene overview figures the location of the PPREs (x-axis) and their 
respective predicted binding strength (y-axis) is immediately obvious. In order to reveal further 
characteristics of the genes, such as overall similarity of their PPRE pattern and its evolutionary 
conservation, we clustered the genes with the SOM algorithm followed by Sammon’s mapping to 
identify clusters. The input dataset of the SOM consisted of six variables, which are the sum of the 
predicted binding strength (BS), the number of conserved strong and medium binding sites (CS) and 
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the number of weak binding sites (CW) both for the human and the mouse gene (IV, Table S3). An 
initial coarse map resulted in four clusters, which were each separated in the final map in up to five 
subclusters (Fig. 4A). 
In general, clusters I to II contain genes that are well conserved between human and mouse, while the 
genes in cluster III are more divergent and those in cluster IV show no evolutionary conservation of 
PPREs. Cluster IA is formed of the genes ANGPTL4, APOA1, APOC3, CPT1A and 
phosphoenolpyruvate carboxykinase 1 (PEPCK1) (Duplus et al., 2003) that have both in human and 
in mouse multiple conserved regions with strong REs. A subset of genes further expanded this set: 
human CPT1A and mouse APOA1 show significant enrichment of de novo binding sites compared to 
their ortholog. In cluster IB, being represented by the genes LPL (Schoonjans et al., 1996) and LXRα, 
one RE region is conserved, but only the mouse gene contains further REs. UCP3 is found in cluster 
IC together with glycerol kinase (GK) (Patsouris et al., 2004; Lehrke et al., 2005), these both have 
multiple conserved RE regions. The distal UCP3 PPRE is conserved to a strong PPRE in mouse, but 
this element is out of the 10 kB window. On the other hand, the cluster of PPREs in human GK 
promoter seems to have lost significance in the mouse. The lipoprotein receptor-related protein 1 
(LRP1) (Gauthier et al., 2003) gene represents cluster ID, in which multiple conserved REs are strong 
in mouse but weak in human. Together with the genes GK and LRP1, the genes found in cluster IE, 
caveolin 1 (Llaverias et al., 2004) and IGFBP1 (III), exhibit a retain-loss pattern concerning 
conserved PPREs, where only one species retained a cluster of strong PPREs. In case of LRP1, this 
appears to have arisen in the context of several compensating de novo binding sites. In contrast, 
cluster II contains genes with relatively fixed PPRE pattern: only one strong or medium conserved 
RE in human, which is conserved in comparable strength and location in mouse. This cluster is not 
subdivided into subclusters and contains the genes ADRP, CPT1B, CPT2, CYP1A1 (Sérée et al., 
2004), G0S2 (Zandbergen et al., 2005), HMGCS2 (Iida et al., 2002), SR-B1 and spermidine/spermine 
N1-acetyltransferase (SSAT) (Ignatenko et al., 2004). The genes ADRP and CPT2 contain only the 
preserved strong RE. In addition to the conserved promoter cluster, the human CYP1A1 gene contains 
a stronger intronic PPRE, while its orthologs according to both database annotations have expanded 
in number of medium PPREs. Expansion of PPRE set only in one species is observed for mouse 
G0S2 and SSAT. 
Cluster IIIA, which contains the genes cyclooxygenase 2 (COX2) (Pang et al., 2003) and semaphorin 
6B (Collet et al., 2004), extends the pattern observed above (clusters ID and IE) with an opposite 
trend: the human ortholog contains one or two medium/strong REs, which are conserved but only 
weak in the mouse. Possible compensating element appeared only in the mouse ortholog of the latter 
gene. Also cluster IIIB contains one or two conserved REs, but they are weak both in human and in 
mouse. This cluster comprises the genes APOA2, APOA5, fatty acid desaturase 2 (FADS2) (Tang et 
al., 2003), PXR (Aouabdi et al., 2006), RVRα and SLC10A2. Interestingly, these genes each have 
novel binding sites at rather similar locations. The species-specific assembly of PPREs is most 
evident in cluster IV, where none of the PPREs are conserved. The ACOX1 gene represents cluster 
IVA, in which multiple strong, but non-conserved REs are found in both species. The genes resistin 
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(Patel et al., 2003) and SULT2A1 form cluster IVB, these have multiple REs in mouse and strong REs 
in human. The genes APOE (Galetto et al., 2001) and PPARα are in cluster IVC, which is 
characterized by one strong RE in the mouse ortholog and one or more non-conserved REs in the 
human gene. The remaining genes in IVD and E CYP27A1 (Szanto et al., 2004), glutathione S-
transferase A2 (GSTA2) (Park et al., 2004), transferrin (Hertz et al., 1996) and UDP-
glycosyltransferase 1A9 (UGT1A9) (Barbier et al., 2003), carry one or two medium, non-conserved 
REs in both species and the p16 gene (CDKN2A) strong or medium non-conserved REs are found in 
mouse and but only weak REs in human. Taken together, although for some genes a conservation of 
PPRE pattern is evident, also a significant diversification of PPRE composition is visible.  
In order to explore the evolutionary preservation patterns of PPREs further, the genes ACOX1 and 
ANGPLT4 were analyzed also from the genomes of chicken, chimpanzee, dog, rat and zebrafish (IV, 
Fig. 4B). The closest to the human genome is chimpanzee (Pan troglodytes), where four conserved 
PPREs are located in the ACOX1 gene, however the functional intron 2 region is missing. This 
human element was not conserved in any of the species analyzed, suggesting a novel human-specific 
PPRE. Mouse and rat (Rattus norvegicus) share two PPREs, however both also contain a unique set 
of further elements. The analysis of the other species is in accordance with the overall pattern of 
relatively species-specific composition of PPREs. Within mammals, in the ANGPLT4 gene the 
cluster of intronic REs is rather well conserved. The closest PPRE pattern in comparison to the 
human gene is observed in the dog (Canis familiaris). Two intronic PPREs are also present in rat, but 
a significant expansion in PPREs seems to have occurred in this species, including a distal consensus 
RE. The zebrafish ANGPLT4 gene is also profoundly enriched with strong PPREs, whereas the 
chicken gene has a quite poor PPRE content. Interestingly, the loss of the published PPRE is 
observed in the chimpanzee for this gene as well. Therefore, while this gene is an example of a much 
more preserved PPRE pattern, significant diversification is evident in some genomes and not all 
functional PPREs are conserved. 
In conclusion, the SOM analysis and further genome comparisons together suggest that the 
integration of the stabilizing selection model into target gene characterization may more faithfully 
identify PPAR targets. Other common features of these genes include presence of strong PPREs or 
multiple (more than two) medium REs (74% of human genes, 68% of mouse genes). In addition, 
even though location of PPREs clearly does not determine functionality a slight bias to the immediate 
upstream region (500 bp upstream) could be detected (24% of genes). 
In order to evaluate these parameters for the prediction of target genes, the most gene dense human 
chromosome, chr 19 (1445 known genes in Ensembl), was screened for medium and strong PPREs 
(based on PPARγ prediction). In parallel, the syntenic regions in mouse genome were analyzed (956 
ortholog pairs). We identified 109 genes that contain in both species either a strong PPRE, multiple 
medium PPREs, or a proximal medium PPRE (within 500 bp upstream) (IV, Table 3). This approach 
has the ability to detect targets with divergent PPRE composition, at the same time the chance event 
that both species would contain random PPRE occurrences is low. An additional 71 genes were 
predicted using only one species, human (IV, Table S3). This list was limited to genes that show both 
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enrichment (more than two PPREs) and contain at least one strong PPRE (such genes found from 
both species are in bold in Table 3).  
From these lists the six human genes CYP4F8, LASS1, chicken ovalbumin upstream promoter 
transcription factor (COUP-TF) γ, p21-activated kinase 4 (PAK4), SLC27A5 and translocase of inner 
mitochondrial membrane 13 (TIMM13) were selected for the real-time PCR evaluation of their 
response to the PPARα ligand GW7647 in HepG2 cells (IV, Fig. 5A). After a 2 h ligand treatment all 
six genes showed a significant 1.8- to 4.2-fold upregulation of their mRNA. For a more detailed 
analysis we selected the LASS1 gene. The in silico analysis of the gene suggested four non-conserved 
PPREs, of which the two strong REs are in close vicinity (region 2) are the best candidates forming 
the PPAR-responsive region of the LASS1 gene (IV, Fig. 5B). Functional analysis of three genomic 
regions in reporter gene assays and ChIP in HepG2 cells indicated for region 2 a significant 
upregulation by PPARγ and PPARβ/δ ligands and an even more prominent basal activity of PPARα 
(IV, Fig. 5C), confirmed by ChIP (IV, Fig. 5D). A treatment with GW7647 induced significant 
binding of PPARα, RXRα and pPol II to region 2, but not to regions 1 and 3. This suggests that the 
two strong PPREs in region 2 mediate the response of the LASS1 gene to PPAR ligands. 
In summary, the ability to predict binding site strength revealed a clearer picture of the PPRE 
composition of target genes extended over 20 kB of regulatory region. There is relatively weak 
preference for conserved binding sites, or proximal location of PPREs. Instead enrichment of medium 
and strong REs can capture a large majority of these genes. These features when exploited on a 
genomic scale led to the identification of six novel targets in human and the successful identification 
of functional PPREs of the UCP3 and LASS1 genes (in addition to further novel REs shown in the 
panel of seven known targets). 
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6. Discussion 
 
6.1 Ligand-independent CoA association of the PPARs 
The molecular mechanisms of NR activation were originally described for the group of NRs that are 
highly ligand-sensitive. These NRs are unable to interact with CoAs in the absence of a ligand. This 
ligand-dependence was attributed to the exact positioning of the C-terminal H12. Based on apo and 
ligand-bound structures of RARα and RARγ, respectively, an activation model was proposed where 
ligand-binding stabilizes the mobile H12, which then acts as a lid to the LBD (known as the ‘‘mouse-
trap model’’) (Moras and Gronemeyer, 1998). Later on, as more NR structures of the orphan or 
adopted orphan NRs were crystallized, a less prominent movement of H12 was apparent in these 
structures and challenged the status of the previous model as a universal NR activation model (Nolte 
et al., 1998). 
The finding made in this study (I) that PPARs associate, in the absence of a ligand, with CoAs, could 
have two possible explanations: either an endogenous ligand (such as a fatty acid) present in all cells 
leads to a constant active state, or the structural features of the receptor allow the stabilization of H12 
already in the absence of a ligand. This same question applies to other receptors that have been 
described to have constitutive activity, such as CAR, HNF4α, LRH-1, ERRγ, or the ROR isotypes. 
Of these, the crystal structure of HNF4α showed a constitutively bound lipid in its ligand-binding 
pocket (Wisely et al., 2002). Additionally, ROR isotypes were co-crystallized with cholesterol sulfate 
and retinoic acid (Kallen et al., 2002; Stehlin-Gaon et al., 2003).  
Some of these known constitutively active NRs can also be modulated by ligands, as was described 
for LRH-1 and CAR (Krylova et al., 2005; Maglich et al., 2003). The role of the ligand, however, 
seems to be different in these receptors, since those receptors that could be crystallized without a 
ligand do not significantly differ from the ligand-bound structures, with respect to H12 position. This 
situation applies also to PPARγ and PPARβ/δ. The critical distance of the charge clamp residues (one 
of which is located on H12) for efficient CoA interaction was described to be 19 Å for the ligand-
bound VDR (Väisänen et al., 2002). This distance is maintained in the apo-structures of LRH-1 
(19.63 Å), CAR (18.3 Å) and PPAR isotypes (19.9 Å). This suggests a model, where the ligand may 
play a role in the additional stabilization of the active conformation in these receptors, but is not 
absolutely required for it. Furthermore, it could be argued that constitutive versus ligand-dependent 
activity has not diverged completely for the large majority of NRs. A model about NR evolution 
suggests that ligand-binding is an acquired property in the family (or conversely a loss of constitutive 
activity), which has developed most in the endocrine receptors that have lost entirely the property to 
be activated in the absence of a ligand (Bertrand et al., 2004). 
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The explanation of the ligand-independent CoA association is shown here to be based on the 
structural features of PPARs. However, further activation by ligand-binding is not excluded by this 
constitutive activity. Firstly, the structural comparison with constitutively active receptors suggested 
that the apo-forms of the PPAR isotypes represent receptors in active conformations, with respect to 
positioning of H12. In agreement, supershift and transactivation assays support the conclusion that 
the active apo-conformation enables CoA interaction. To further rule out the possibility that this 
effect is due to a natural ligand, present in the cell extracts, the overexpression of a CoR was shown 
to reduce the basal activity. This effect could be overcome by the addition of a synthetic ligand, 
which suggests that a strong natural ligand is not responsible for the high activity level seen in 
untreated cells.  
 
6.2 Structural determinants of H12 stabilization in PPARs 
Four groups of residues were shown by mutagenesis to contribute to the stabilization of H12. They 
modulate the PPAR protein surface at the CoA interface. Part of them do so directly, such as the 
charged surface residues and part indirectly, such as the internal residues that contact and stabilize 
H12 (i.e. without themselves being located at the protein-protein interaction surface). The charge 
clamp residues K329 from H3 and E499 from H12 in the first group are highly conserved and their 
role has been established for a number of NRs. Their exact positioning creates selectivity for the 
otherwise hydrophobic surface. A reversed charge clamp, observed in the NR Nurr1, is not known to 
interact with any known CoAs (Wang et al., 2003b). Our results are in agreement with previous 
studies highlighting their importance: a dramatic loss of both ligand-dependent and -independent 
activity was seen upon mutation of either residue. The interaction between charged residues of the 
second group, K347 and D503, conserved in mouse and human CAR (Frank et al., 2004), forms the 
first direct docking point in H12 stabilization and contributes to CoA stabilization by an additional 
direct contact. In the absence of ligand, mutations severely affected basal activity, reflecting losses in 
H12 stabilization.  
The third group, consisting of the charged residues E352, D424 R425 and R471 and Y505 of H12, 
forms a link between the CoA surface and the other important protein-protein interaction surface, the 
heterodimerization interface. The contact to H12 (via Y505) is unique to PPARs. Finally, residues of 
the fourth group H351, H477, Y355 form a hydrogen-bonding network that encompasses Y501 from 
H12. Y501 was previously described as the ligand-contact point and shown to be crucial for ligand-
dependent activation (Gampe et al., 2000). Here we show that the mutation of this residue does not 
alter ligand-independent activity as dramatically, an observation further against the hypothesis that an 
endogenous ligand would explain the observed constitutive activity of PPARs. Addition of a ligand 
further extends the hydrogen-bond network, yet direct H12 stabilization exists already in absence of a 
ligand. These data show that the inherent structural features of PPARs enable ligand-modulated 
activity as well as contribute to ligand-independent activity. 
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The structural permissivity of PPARs towards ligand-independent CoA association, combined with 
their rather ubiquitous expression pattern, suggests that the activity of these receptors may be more 
dependent on co-regulator protein concentrations or further structural modifications than previously 
thought. The ubiquitously expressed PPARβ/δ is probably the most ligand-sensitive member, having 
the least affinity for CoAs in a comparative panel and exhibiting a stronger affinity for CoRs. 
PPARγ2 expression on the other extreme is mainly differentiation-induced in adipose cells, where a 
ligand may modulate the signaling initiated. However, it could be argued that later the presence of the 
receptor may be sufficient to maintain expression of genes characteristic of adipocyte phenotype. 
Subtle daily changes in energy metabolism in response to food intake may be mediated by the 
modulation of receptor activity by other means, such as covalent modifications (for example through 
insulin/glucagon signaling). The specific responses that enhance their signaling through generation of 
ligands, may reflect an additional ligand-mediated level of the modulation of the gene expression 
profiles. Definite answers are lacking in this respect that encourage further research focusing on the 
comparison of these PPAR activation mechanisms.  
 
6.3 Identification of the direct VDR and PPAR target genes of the 
IGFBP gene family 
IGFs comprise a complex regulatory system that consists of two growth factors (IGF-I and IGF-II), 
two receptors (IGF-I R and IGF-II R), IGFBPs, four low-affinity IGFBPs (IGFBP-7, CTGF, NOV, 
IGFBP-10), proteases that modify the binding proteins and, in addition, several interacting molecules 
(Stewart and Rotwein, 1996). IGF-I and IGF-II are both growth-promoting growth factors, secreted 
by a variety of cells that circulate at concentrations higher than most other peptide hormones (e.g. 
1000-times higher than insulin) (Daughaday and Rotwein, 1989). The initial interpretation of the 
function of the binding proteins was that they would prolong the serum half-life of the IGFs and 
modulate the tissue availability of the growth factors, since IGFBPs bind IGFs with higher affinities 
than the IGF-Rs. Several in vitro experiments and data obtained from transgenic animal models 
indicate that IGFBPs are more than just simple binding proteins (Kelley et al., 1996; Schneider et al., 
2000). These studies show that IGFBPs are secreted in a tissue- and developmental stage-specific 
manner and they can modulate IGF bioactivity either positively or negatively. In addition to their role 
in IGF signaling, the IGFBPs have also been reported to function in some situations IGF-
independently. These effects are to date less well characterized. Both IGFBP-3 and IGFBP-5 contain 
a nuclear localization signal (Radulescu, 1994; Schedlich et al., 1998). In addition, both have been 
also shown to mediate apoptosis, independent of IGFs (Rajah et al., 1997; Thomas et al., 1998). 
Identification of binding sites is a prerequisite for the direct regulation of gene expression. In studies 
II and III, in silico RE detection methods based on in vitro binding strength data were used in the 
characterization of the regulation of IGFBP gene family members by VDR and PPARs.  
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6.3.1 Regulation of the IGFBP gene family by VDR 
Previously, the IGFBP-3 gene had been reported as a direct VDR target gene with a DR3-type VDRE 
(Peng et al., 2004). A substantial body of literature has implicated the induction of the IGFBP-3 gene 
and its protein product by several other growth inhibitory proteins and agents including the tumor 
suppressor protein p53, retinoic acid and TGFβ (Buckbinder et al., 1995; Martin and Baxter, 1991; 
Shang et al., 1999). This suggests that this gene belongs to the set of genes that mediate the anti-
proliferative effects of VDR. The direct regulation of this gene was confirmed here and additionally 
its direct genomic neighbor, IGFBP-1, was found to be a direct VDR target. The analysis of 
translation-independent and early-time scale regulation of IGFBP genes, demonstrated the direct 
regulation of yet a third family member, IGFBP-5. In contrast, IGFBP-2, IGFBP-4 and IGFBP-6 
mRNA levels were unaffected. We observed these effects in bone and prostate cancer cells, but it is 
highly likely that these three genes are direct targets in other 1α,25(OH)2D3 responsive tissues. The 
2- to 4-fold inductions observed are in the order of what was observed for most other 1α,25(OH)2D3  
target genes. 
IGFBP-5 resembles IGFBP-3 in its mechanisms of action. Both a secreted form and a cell surface 
interacting form that promotes IGF signaling due to the lowered affinity to IGFs have been described 
(Mohan et al., 1995; Twigg and Baxter, 1998). In addition, IGF-independent pro-apoptotic effects 
have been reported and the protein contains a nuclear localization signal as mentioned earlier. The 
main physiological roles of IGFBP-5 are in the development of the central nervous system, involution 
of the mammary gland (pro-apoptotic) and bone physiology (mitogenic) (Lee et al., 1995; Richman et 
al., 1999; Tonner et al., 1997). Since VDR plays a major role in bone homeostasis, the regulation of 
this family member fits well its regulatory domain. 
IGFBP-1, on the other hand, has quite a distinct physiological role. It has been linked with several 
nutrition-related diseases. Insulin is known to regulate the synthesis of IGFBP-1 and post-prandial 
increases in serum insulin levels result in a corresponding four- to five-fold decrease in IGFBP-1 
concentration (Busby et al., 1988). A study with non-insulin-dependent diabetes mellitus (NIDDM) 
patients, who do not have reduced insulin secretion, suggested that reduced IGFBP-1 levels 
correlated with risk factors for type II diabetes including impaired glucose tolerance, raised systolic 
and diastolic blood pressure, raised body mass index and raised serum triglyceride level (Heald et al., 
2001). Decreased IGFBP-1 levels have also been added to the list of cardiovascular risk factors and 
have also been shown to predict risk of cardiovascular disease in type-2 diabetes. As discussed 
below, this gene is a shared target with PPARs. Although the role of VDR in the metabolic disorder 
has not been as widely characterized as that of PPARs, some shared target genes exist. For example, 
overlapping roles in the regulation of Insig genes, as described earlier, have been characterized.  
The in silico approach applied here, resulted in the successful identification of multiple functional 
VDREs in the regulatory regions of the IGFBP-1, IGFBP-3 and IGFBP-5 genes, including ER-type 
elements (ER7), for which formerly no natural occurrences had been shown. Additionally, the ER9-
type RE13 is one of the first natural elements of this type characterized. From the, in total, 174 kB 
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genomic sequence, 15 candidate VDREs were identified. ChIP assays indicated that 10 of these 
regions are bound by the VDR in PC-3 cells, which represents a 67% success rate of the in silico 
binding site prediction. Moreover, the non-ligand responsive members IGFBP-4 and IGFBP-6, did 
not contain any VDRE candidates within 24 and 15 kB analyzed, respectively. The correlation of the 
in silico result with the mRNA inductions was not as straightforward in the case of IGFBP-2, where 
two intronic VDREs were identified. The experimental ChIP data was also not conclusive, both 
regions associated with VDR ex vivo. However, no VDR binding was detected on IGFBP-2 TSS by 
ChIP, which indicates that these VDREs may more probably be involved in the regulation of the 
neighboring IGFBP-5 gene. Interestingly, the intronic ER9-type VDRE of IGFBP-5 was found to 
contain a SNP that increases the spacing between the hexamers by 2 nucleotides. This significantly 
decreases its ability to function as a VDRE, as supported by the in vitro data. Unfortunately, the 
frequency of this SNP is very low (3%) and no cellular model was found to evaluate its significance 
in vivo. 
The results concerning VDRE locations are in agreement with the whole genome analysis of 
conserved NR half sites that were found equally distributed around the TSS. Further, the in silico 
screening here was not restricted to cover only a few kB of proximal regulatory sequence (as in a lot 
of other studies), in effect several functional distal VDREs were identified. Based on the present 
understanding of enhancers, where DNA looping can occur free within chromatin units flaked by 
insulators, these distances are no limitations. However, such large distances between RE and TSS 
cannot be assessed by old-fashioned approaches, such as reporter gene assays with truncated 
constructs. Fortunately, more up-to-date ChIP assays allow the analysis of these distal regions. 
The observation that the IGFBP-1/IGFBP-3 gene pair locus contains six functional VDR associated 
regions (2, 3, 4, 5, 6/7 and 8) and the IGFBP-5 gene area four such regions (9, 10, 13 and 14) 
supports the model of multiple REs per primary target genes, established earlier for the genes CYP24 
and cyclin C (Sinkkonen et al., 2005; Väisanen et al., 2004). Furthermore, in a recent report, the 
autoregulation of VDR was mediated by two intronic VDREs (Zella et al., 2006), supporting both the 
lack of proximal bias for functional VDREs and the presence of several functional VDREs per target 
gene. 
6.3.2 Regulation of the IGFBP gene family by PPARs 
In this study, the main focus was on the IGFBP-1 gene, since this gene, from a physiological point of 
view, fits best the niche, where regulation by PPARs has been established in. We could demonstrate 
up-regulation of IGFBP-1 mRNA in human hepatocellular cells and in mouse liver during an early 
induction study (2 to 6 h) by all subtype selective PPAR ligands. This data shows that even though 
the three subtypes had differing expression levels, all of them were equally potent in inducing 
IGFBP-1 expression. Furthermore, even though the induction was not more than 2- to 3-fold and 
further considering the high basal expressed level of this gene, the effect is comparable to or even 
more substantial than that of majority of PPAR target genes, such as CPT1 used as reference here. It 
is also possible that PPARs may participate in the maintenance of the basal expression of this gene, as 
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demonstrated by their presence at the promoter, already in absence of a ligand. Taken together with 
the previous observation that PPAR isotypes possess constitutive activity, it is possible that these 
NRs are acting in a positive way on a number of target genes that are yet to be discovered. The 
development of antagonists (direct or inverse) would be of great benefit for the discovery of these 
genes, by suppressing the constitutive activity of the PPARs. 
In support of the likely direct regulation, putative PPREs were identified from a 20 kB region 
centered around the human IGFBP-1 gene TSS and two were shown to contribute to the regulation in 
transient transfection assays. Of these, the -1.2 kB element was most potent and additionally 
demonstrated a full association panel with the set of regulatory proteins tested in ChIP (PPARα, 
RXRα, p-PolII, TRAP220, NCoR1, RAC3 and PGC-1α). The fact that RE1 showed a more restricted 
association panel in ChIP may reflect weaker association to this element that may not result in 
sufficient signal levels for detection. Alternatively, the role of this region differs from that of RE2 and 
a different set of nuclear proteins are recruited. 
The in silico search method proposed here differs from the alignment-based methods commonly in 
use, such as position-specific WMs, that were also recently applied in a genome-wide PPRE screen 
(Lemay and Hwang, 2006). These methods create mathematical scores over the whole length of the 
binding sequence, which makes them prone to overcompensate for nucleotide combinations that are 
completely unfavorable to TF binding at one position with scores from other positions. This problem 
arises especially in the scoring of larger motifs, such as the NR REs composed of two half sites. 
Therefore, we characterized the binding preferences of the PPARs to individual nucleotide variations 
of the consensus and used this data together with a set of experimentally verified binding results, to 
develop a set of rules how the half site variations can be combined without losing the affinity for the 
PPAR-RXR heterodimers completely. 
This approach resulted in five putative REs in the human IGFBP-1 gene regulatory region, of which 
all were shown to bind in vitro at least one subtype. The binding strength of these elements was weak 
compared to the known CPT1 PPRE, including the functional REs 1 and 2. Regarding the in silico 
method, the successful identification of a set of PPREs that all associate with PPARs in vitro and 
identification of 2 of 5 functional REs demonstrates good selectivity and sensitivity (sequences down 
to the level of 1% binding could be identified). On the other hand, the low affinity of RE2 raises the 
question, whether PPAR binding to this site may require or be supported by the presence of other 
TFs. A sequence alignment of the human and mouse IGFBP-1 genes indicated that the sequence 
around this element showed a much higher conservation than regions of the four other REs. The 
occupancy of the IGFBP-1 gene TSS by PPAR isotypes was shown in HepG2s in presence or 
absence of activating ligands, yet was absent in HEK293 cells that do not express this gene. This 
could suggest that the region around RE1 functions as a selective enhancer module that requires 
presence of more factors than PPARs to get activated and induce basal and PPAR activated 
expression of the IGFBP-1 gene. 
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The approach for detecting PPAR target genes that successfully identified IGFBP-1 as a direct target 
gene i) demonstration of an early induction profile, ii) presence of putative PPREs and iii) detection 
of PPAR binding on the TSS region by ChIP was applied to the other IGFBP family members. Those 
members, IGFBP-2, IGFBP-5 and IGFBP-6 that contain several putative PPREs were found to be 
responsive to PPAR ligands in HepG2 and HEK293 cells in an early time-course (2 to 6 h) and 
PPARs were shown to associate with their TSS regions after 2 h. In contrast, only the IGFBP-6 gene 
PPRE was identified with the alignment-based genome wide PPRE screen. Further analysis of 
candidate PPREs will be needed to fully classify these genes as direct targets, however, the data 
shown here supports this conclusion.  
In addition, further investigations would be required to fully understand the physiological outcome of 
this regulation. IGFBP-1 may mainly have a role in connection to insulin signaling, rather than in 
control of cell growth, though the mechanisms of its action in metabolic control are largely unknown. 
The classical control of IGF signaling was demonstrated for this member in a mouse model, where it 
was shown to reduce hepatic neoplasia. The effect on cell proliferation of the other PPAR responsive 
family members may reflect more the tendency to promote the mitogenic IGF signal. The 
overexpression of IGFBP-2 was shown to be associated with increases in malignant growth and 
metastatic ability in cancer studies (Lee et al., 2005a). In addition, IGFBP-2 has been shown to be 
important as a bone anabolic signal bound to IGF-II. The two molecules form a binary complex that 
can traverse the capillary membrane (Arai et al., 1996) and thus, are available to extra-vascular 
tissues, preferentially skeletal tissue. Patients with the rare syndrome of Hepatitis C Associated 
Osteosclerosis (HCAO), who exhibit remarkable increases in bone mass as adults have been shown to 
have an elevation in IGF-II precursors and IGFBP-2 in their circulation (Khosla et al., 1998). IGFBP-
6, found down-regulated here, is unique in that it predominantly binds IGF-II and inhibits its function 
by blocking its binding to the receptors (Roghani et al., 1989). In accordance, it has been shown to 
function as an autocrine growth inhibitory factor in human keratinocytes (Kato et al., 1995). In effect, 
the regulation pattern observed suggests a potential enhancement in IGF-II signaling. In the context 
of cancer, this effect is not wanted. Such conclusions based on conditions, where normal control 
mechanisms are compromised may not reveal what role this regulation has under normal 
physiological conditions. The dual nature of IGFBP-5 was discussed earlier in connection to repair of 
bone fractures where its role is to promote the mitogenic IGF signal and in the apoptotic process of 
mammary gland involution. The promotion of IGF signaling and the down-regulation of inhibitory 
signals may serve a beneficial functional role under certain physiological conditions, such as in 
injured tissues, which could link these genes to wound healing process that was described in 
connection to PPARβ/δ.  
In conclusion, VDR and PPARs were shown to have both overlapping and diverging roles in the 
regulation of the IGFBP gene family. An interesting link between these two regulatory systems was 
recently shown by Dunlop and colleagues (Dunlop et al., 2005). This study reported an up-regulation 
of the human PPARβ/δ gene transcription by 1α,25(OH)2D3 and it’s receptor, VDR. Principles 
governing target gene regulation of these receptors showed important similarities with respect to 
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correlation between in silico predictions of putative binding sites and regulation that may serve useful 
for the identification of novel target genes, as demonstrated here among IGFBP gene family. 
 
6.4 Meta-analysis of the binding site composition of human PPAR 
target genes 
The pleiotropic actions of PPARs suggest that they regulate a large variety of target genes. This is 
supported by their wide expression pattern (especially that of PPARβ/δ). The acquisition of a full list 
of target genes as a collection of experiments from all these different tissues is challenging and 
further complicated by the possible differences in experimental model organisms and humans. In this 
study, we attempted to reach an understanding of common sequence features, the binding site 
composition, of PPAR target genes to offer an alternative approach to screen for potential targets and 
simultaneously to identify their regulatory elements. At the start of the study a relatively large 
collection of PPAR target genes with characterized REs existed, however with lack of binding 
strength data. The locations of these PPREs also suggested a positional bias towards the proximal 
promoter and many studies relied on conservation of PPREs. 
To assess these parameters in an unbiased manner we started with a method to predict PPAR binding 
strenght. We selected eight PPAR target genes, including both up-regulated and down-regulated 
targets, as well as varying PPRE locations. These genes were screened for PPREs of different binding 
strengths and for the gene UCP3 a very close match of predicted and experimental binding strength 
was shown. This gene had no previously characterized PPRE and in this study we show three 
functional regions, including a strong distal PPRE. Overall, from these eight genes we identified 
several functional regions among the selection of PPREs made initially (we started with a selection of 
10 proximal, 10 distal upstream and 10 distal downstream PPREs), mostly including the published 
PPREs but also suggesting novel regions. However, we could not confirm the functionality of the 
DR2- type RVRα PPRE. We also show that the human ACOX PPRE that was initially suggested as 
the regulatory region of this gene, is not functional, but instead this gene has two intronic PPREs. In 
summary, our data indicates no positional bias or a preferential use of conserved PPREs. Instead, we 
found a strong PPRE in each of these genes. 
The analysis of additional 30 human PPAR targets allowed the extension of these conclusions based 
on the observed PPRE composition of the human gene and its mouse ortholog. A large majority of 
these genes in both human and mouse contained strong PPREs. PPREs could be found upstream and 
downstream of the genes, with only minor bias towards the proximal promoter. Preservation of 
PPREs between mouse and human was evident for some genes, yet even these genes often contained 
additional novel species-specific PPREs. In comparison to the published PPREs of this set of 38 
targets, some genes seem to contain more PPREs, or stronger PPREs, than what was characterized 
earlier. These alternative sites should be validated further, however the high success of validation of 
strong PPREs in the eight genes characterized in detail suggests that these are most likely 
contributing to the responsiveness of the gene. Furthermore, those genes that contain a high 
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enrichment of PPREs that seems to have arisen in only the other species would offer an interesting 
test set to find out how many of these novel sites have acquired functionality. 
There is also one interesting subset of genes that have a poor PPRE content in one species with very 
weak conserved sites that seem to form a stronger cluster in the other species (a retain-loss pattern). 
The IGFBP1 gene is a good example of such an exception where prevalence of medium or strong 
PPREs is only seen in the other species. Among the regions conserved between human and mouse, 
our previous study (III) showed the most proximal region to be functional. The cluster seen in mouse 
further upstream and its conserved human PPREs were not analyzed further, however the detailed 
conservation analysis carried out here suggests that also this region may be of interest for future 
studies. It still remains to be studied how such weak PPREs as seen in the human IGFBP1 can 
compete for the binding of the receptor and achieve transactivation. One likely explanation is that in 
their genomic context these PPREs function in a module of TFs inside which the cooperative binding 
helps attract and stabilize the receptor. The relatively narrow tissue distribution of this gene could be 
seen as an indication that this gene may indeed integrate the signaling of several TFs for its activation 
that may not be present in all tissues. 
The analysis of two genes studied in detail was extended from the two-species comparison to a multi-
species comparison. The genes ACOX1 and ANGPLT4 were selected since they represent two 
extremes, one with a very divergent PPRE composition versus another with a well-preserved one, 
respectively. The two most distant species to human, zebrafish and chicken had little in common (in 
terms of PPRE pattern) with either the human or the mouse gene, except that especially in zebrafish 
an abundance of strong/medium PPREs was seen in both genes. Surprisingly, the closest species to 
human analyzed, the chimpanzee, had also diverged from the human PPRE set. One functional PPRE 
in both ACOX1 and ANGPLT4 had been lost or weakened.  While in mammals the ANGPLT4 gene 
was rather well-preserved, the best match to human seen in the dog gene, also this gene demonstrated 
that turnover of PPREs is occurring and novel sites seem to appear rather often, as seen in the rat 
gene as an example. Taken together, evolutionary constraints to maintain responsiveness do not 
translate to the preservation of an identical PPRE pattern. Instead, the appearance and fixation of 
novel site adds flexibility. Based on the set of human PPAR targets, this appears to manifest as an 
enrichment of strong or medium binding sites. The tracking of this enrichment and turnover from 
multiple species adds power to the in silico approach and enables detection of divergent PPRE 
patterns. Currently the mouse genome that has hardly any gaps serves as the best references, the 
extension to other species awaits the filling of the remaining gaps in their sequences. 
As an example, the most gene dense human chromosome, chr 19, was screened for medium and 
strong PPREs together with its syntenic regions from the mouse genome. We presented the list of 
genes that resemble the known PPAR target set in both species and a more limited list of genes that 
show high enrichment and appearance of strong PPREs in human (to detect also human-specific 
targets). In total 11.2% of genes with orthologs were predicted as targets. The requirement for high 
enrichment and strong PPREs was filled by 8.2% of all known genes on chr 19. Together, these 
numbers suggest that approximately 10% of genes in the whole genome have features typical of 
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PPAR targets, which translates to a few thousand targets in total. This can be considered a relevant 
number based on microarray studies. Among the predicted targets, a number of genes with relevant 
physiology were identified, such as genes involved in lipid metabolism, regulation of cell cycle, 
mitochondrial transport and metabolism and inflammation. We selected six genes from these lists for 
further validation and could show that all responded to PPAR ligands. These included CYP4F8 
involved in ω-oxidation, the NR COUP-TFγ, PAK4 involved in p21-signaling, the inner 
mitochondrial membrane translocase TIMM13, the fatty acid transporter SLC27A5 and LASS1. The 
LASS1 gene that participates in ceramide synthesis was studied in detail, which demonstrated that the 
predicted strong PPREs indeed are functional in reporter gene assay and ChIP. 
In conclusion, this study showed that evaluation of binding strength is useful to discover target genes. 
Combined with the analysis of binding site composition from multiple species, this approach can 
reveal binding site turnover-patterns. In the chr 19 example we focused on predicted target genes that 
show typical features in both species. However, the analysis of multiple species can also suggest the 
regulation of genes where the binding site pattern has weakened in one species. This can be explored 
further as more complete genomes become available. These insights translate to a more efficient 
characterization of PPAR target genes and can be explored in the context of other TFs as well. 
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7. Summary and conclusions 
In conclusion, the four scientific papers, on which this thesis is based on, represent the application of 
in silico methods in the analysis of the gene regulation by NRs, on protein and DNA level. On the 
protein level, a detailed investigation was made about functional properties directing cofactor-LBD 
interactions of PPARs. Whereas at the DNA level, the predictive power of in silico binding site 
search was evaluated for the identification of target genes of both VDR and PPARs.  
Structural explanation for ligand independent CoA interaction in the human PPARs leading to the 
recognition of their constitutive activity (I) 
We demonstrated that structural features of human PPARs allow ligand-independent CoA association 
comparable with the NR CAR. Using PPARγ as an example, we found that four different amino acid 
groups contribute to the ligand-independent stabilization of H12 of the PPAR LBD. These are: (I) 
K329-E499, mediating a charge clamp-type stabilization of H12 via a CoA bridge; (II) K347-D503, 
interacting with each other as well as contacting the CoA; (III) E352, D424, R425, R471 and Y505, 
directly stabilizing the H12 via salt bridges and hydrogen bonds; and (IV) H351, Y355, H477 and 
Y501, forming a hydrogen bond network. These amino acids are conserved within the PPAR 
subfamily, suggesting that the same mechanism applies for all three PPARs. Taking together, the 
ligand-independent contacts to H12 allow its positioning in active conformation allowing the 
interaction with CoA proteins. Further stabilization with a ligand is modest compared to that of VDR 
and similar to that of CAR. Therefore, PPARs more likely should be considered as active NRs in the 
absence of agonist and their functional profile classifies them close to the group of NRs with 
constitutive activity, such as CAR, RORs and LRH-1. The recognition of the constitutive activity of 
PPARs provides an additional view on PPAR signaling.  
Regulation of the IGFBP gene family by VDR (II) 
In this study we aimed to characterize the direct VDR targets of the IGFBP gene family. We found 
that IGFBP-1, its genomic neighbor IGFBP-3 and IGFBP-5 were regulated in a translation-
independent manner in prostate and bone carcinoma cells and identified several functional VDREs in 
their vicinity. The VDRE in silico search based on previous experimental evaluation of published 
VDREs proved to be 67% efficient in predicting functional VDREs. This is a significant 
improvement compared to previous methods. Furthermore, the analysis of putative VDREs revealed a 
correlation between number of found REs and mRNA inductions: IGFBP-4 and IGFBP-6 contained 
no putative VDREs. IGFBP-2 had two distal VDREs in its intron but no inductions were observed in 
mRNA levels and no VDR associated at its TSS region. The results demonstrate that functional 
VDREs could be located distally to the TSS, both up- and downstream. Further, the importance of 
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natural ER-type VDREs was supported. The induction patterns of the IGFBP gene family provide 
insights into the anti-proliferative effects of 1α,25(OH)2D3. 
Regulation of the IGFBP gene family by PPARs (III) 
This study shows that IGFBP-1 is a direct PPAR target in human hepatocarcinoma cells and mouse 
liver and contains two functional PPREs. Variations from the consensus PPRE were generated and 
evaluated by gelshift assays to build a PPRE-search tool. This in silico approach was further applied 
to the other family members and based on putative PPRE content IGFBP-2, IGFBP-5 and IGFBP-6 
were predicted to be responsive. Their regulation was confirmed in human hepatocarcinoma and 
embryonic kidney cells: both mRNA inductions and association of PPARs on their TSS regions were 
observed. The functional IGFBP-1 binding sites are weak-affinity sites for PPARs, which most likely 
associate with other TFs in genomic context for further stabilization. This prompts the inclusion of 
surrounding sequence evaluation for in silico binding site prediction and emphasizes the importance 
of detailed characterization of binding preferences to cover the full set of possible target sequences. 
The existence of shared targets with VDR indicates that additional overlap in the regulomes may 
exist and emphasizes the role of this gene family in NR signaling.  
Meta-analysis of known PPAR target genes 
The initial findings concerning correlation of number of binding sites and mRNA inductions, based 
on the detailed analysis of the IGFBP gene family, were further evaluated, together with other 
parameters governing binding site functionality. An extended in silico analysis of PPAR regulated 
genes in human was performed, together with an experimental analysis of selected regions from eight 
of these genes. These findings resulted in a formulation of target gene prediction method emphasizing 
two of these variables: the binding strength of PPREs and enrichment of target gene regulatory areas 
in medium or strong binding PPREs. An initial test successfully identified both known and novel 
PPAR targets from human chr 19 and its syntenic regions from mouse genome. Furthermore, the 
results support the model of stabilizing selection acting on PPAR binding sites, where appearance of 
de novo PPREs can lead to species-specific binding site composition without the loss of regulation of 
the respective expression levels. These insights translate to a more efficient characterization of PPAR 
target genes and can be explored in the context of other TFs as well. 
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8. Future aspects 
During the last decades bioinformatics has developed into an important research field for studying 
gene regulation. In parallel, molecular biology has advanced in methodology to collect data in a high-
throughput fashion as is evident from the large collection of fully sequenced genomes, diverse 
datasets of genome-wide level expression analysis and more recent efforts to map regulatory proteins 
with ChIP from the unique sequence of the human genome. The impact of both is also seen in the NR 
research field. 
To date many NR crystal structures have been determined. These have provided valuable information 
concerning structural differences that translate into functional diversity within the family. A large 
collection of LBDs exists, with only some orphan NRs lacking. On the other hand, less focus has 
been on the NR DBDs. However, a more diverse collection of DBD structures would allow the 
modeling of NR binding to consensus sequence variants to improve binding strength predictions. 
Moreover, a crystal structure of a whole receptor is still lacking, which will enable the full analysis of 
NR structural dynamics.  
From the in silico analysis of TF binding sites it has become evident that appreciating as much in 
detail as possible the parameters that govern TF binding site functionality has the potential of 
improving search data in silico and will also help in experimental design to study the effects in vivo. 
This requires a good understanding of the binding site sequence variations tolerated by each TF, 
proper alignment methods to detect conservation, means to predict clusters of TF sites where less 
stringent affinity parameters may apply, appreciation of tissue selectivity of regulation and possibly 
means to predict whether predicted targets fit the physiology of the TF. Such analysis will greatly 
benefit from further collection of large datasets of changes in expression levels with a good coverage 
of responses and whole genome binding data for different TFs. 
Equally challenging will be the interpretation of the results in terms of co-regulation patterns and 
higher levels of interactions inherent to complex systems. The dimensionality of this data poses a 
challenge for interpretation. Long lists of regulated genes, listed from hundreds of tissues, even with 
explanation of their biological role, are difficult, or even impossible to digest. This data is readily 
processed by a computer, therefore the development of bioinformatics tools for the visualization and 
interpretation of these datasets promises to simplify the task. Taken together, the combined efforts of 
systems biology modeling, bioinformatics predictions and experimental validations will be seen in 
future regulome research. In effect, each researcher in the bioscience field will also need to integrate 
the use of computational resources together with lab bench work.  
In the NR field regulome level research promises to reveal important aspects of endocrine and 
nutrient signaling that in future hopefully can help prevent and cure such diseases that develop later 
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in life, with continued signaling between the environment and the genome playing a prominent role in 
disease progression. The knowledge of regulatory DNA used by each receptor will enable NR 
signaling to be assessed on an individual level: the detection of variation in these DNA stretches in 
different populations and also within populations, promises to bring a personalized aspect to biology 
and medicine.  
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